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“It’s nice to be important, but it’s more important to be nice” 
Scooter “Move your ass!” (1995)  
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Targeted delivery of a drug to the desired site of action has clear therapeutic 
advantages by maximizing the efficiency of action and minimizing the 
systemic toxicity. Targeting of drugs can be performed by loading a drug 
with a specific molecular carrier.1,2 A molecular carrier can be a ligand 
interacting with a specific receptor at the cell surface. Carbohydrates are key 
ligands in nature and carbohydrate-receptor interactions are involved in 
vitally important processes such as cell-cell communication and immune 
responses.3 For decades naturally occurring and artificial (oligo)saccharides 
have been explored as carriers for drug targeting.4  
This introductory chapter describes selected examples of conjugates bearing 
various mannose ligands, that have been designed and synthesized to enable 









Biesen et al.5 were the first to report on the design of well-defined linear 
mannose clusters. In search for synthetic, high-affinity ligands for the 
mannose receptor (MR) they synthesized a series of oligolysines in which 
the lysine side chains are connected to α-mannosides (Mann+1Lysn) via 
thiourea linkages (Scheme 1, cluster 1). The mannose clusters (1) were 
synthesized by reaction of 4-(-D-mannopyranosyl)phenylisothiocyanate 4 
with the amines in the oligolysines 2 under basic conditions. Mannoside 4 
was obtained by treatment of 4-aminophenyl mannose 3 with thiophosgene 
in quantitative yield (Scheme 1).  
 
Scheme 1: Synthesis of lysine mannose cluster conjugate 1. 
 
Reagents and conditions: a) CSCl2, EtOH/H2O (80:20, v/v), quantitative; b) 0.1 mM NaHCO3 
(aq.), DMF, 12 - 50%. 
 
The obtained mannose clusters 1 were subjected to competition binding 
studies. Isolated human MR was saturated with biotinylated ribonuclease B 
(bio-Rib B) and biotinylated tissue plasminogen activator (bio-t-PA), 
proteins with high mannose-type glycans, for competition with the mannose 
clusters 1. All the clusters (Man2Lys1 – Man6Lys5) showed high affinity 
towards the MR and could completely outcompete both bio-Rib B and bio-t-
PA ligands. Furthermore the number of mannose residues proved to have a 
major influence on the affinity. On average, the introduction of an additional 




was identified to be the most potent ligand with affinity in the nanomolar 
range, and the authors argued that this cluster may find use as a carrier 
device for cell-specific delivery of drugs to macrophages and endothelial 
liver (??) cells.  
Kinzel et al.6 applied the hexavalent lysine mannose cluster 1 (n = 5) for the 
construction of peptide-, polyamide- and peptide nucleic acids (PNA)-
conjugates. They were interested in the selective delivery of these conjugates 
to dendritic cells (DCs) by MR mediated uptake. In the field of regulation of 
gene expression polyamides and PNA oligomers are explored to target a pre-
determined DNA sequence.7 Within this framework bis-PNA 58 and 
polyamide distamycin derivative 69 (Figure 1) were both conjugated to the 
lysine mannose cluster via flexible and water soluble spacers. Furthermore 




Figure 1: Structures of bis-PNA 5, polyamide 6 and peptide 7.  
 
The route of synthesis to the conjugates is shown in Scheme 2 and the key 
conjugation reaction comprises oxime formation by condensation of an 




polyamide 6 and an aldehyde in peptide 7 to give the conjugates 8-10 
respectively (Scheme 2). 
Scheme 2: Synthesis of bis-PNA, polyamide and peptide conjugates 8-10. 
 
Reagents and conditions: (a) TMSCl, Et3N, CH3Cl/MeCN; (b) PS-trityl-Cl, Et3N; (c) 
carbonyldiimidazole, DMF, PEG3-diamine, HOBt; (d) i. Fmoc-Lys(Boc)-OH, PyBOP, HOBt, 
DIPEA; ii. piperidine/DMF (20:80); iii. TFA (87.5%), H2O (5%), phenol (5%), TIPS (2.5%), 
68% from resin 12; (e) triphenylmethanol, BF3·Et2O, AcOH, DCM, 80%; (f) thioisocyanate 
mannoside 4, 0.1M NaHCO3 (aq.), DMF; (g) 3% TFA, 2% TIPS (in DCM), 30% from 15; (h) 
bis-PNA 5 (22%), polyamide 6 (67%), peptide 7 (77), acetate buffer (0.1 M, pH 4.0), DMF. 
 
The assembly of the conjugates starts with the treatment of 
carboxymethoxylamine hemihydrochloride 11 with TMS-chloride and 
subsequent coupling to a 2-chlorotrityl resin to give the aminooxy resin 12. 
Elongation of the resin with a triethylene glycol spacer was followed by five 
consecutive couplings of lysine residues, using standard Fmoc chemistry. 
Removal of the Boc protecting groups and cleavage from the solid support 
under acidic conditions (87.5% TFA) gave peptide 13 in 68% yield. After 
selective tritylation of the aminooxy functionality in 13 the mannose 
moieties were installed by reaction of the free amino functions in 14 with 
isothiocyanide mannoside 4 in the presence of sodium bicarbonate. The 
aminooxy functionality was released by removal of the trityl protective 
group under mild acidic conditions with TIPS as scavenger giving the 
functionalized intermediate 16 in 30% over 3 steps. Bis-PNA 5, polyamide 6 




providing conjugates 8 in 22%, 9 in 67% and 10 in 77%, respectively. Up to 
now the biological activity of conjugates 8-10 has not reported. 
Hillaert et al. reported the design, synthesis and evaluation of a construct in 
which a fluorescent, covalent protease inhibitor is equipped with a mannose 
cluster.10 This study was based on the activity-based cathepsin probe, DCG-
04, a broad spectrum cysteine protease inhibitor, originally developed by the 
group of Bogyo.11 DCG-04 amine derivative 18 was coupled with the 
activated BODIPY acid 19 to give fluorescent inhibitor 20 in 93% yield. The 
synthesis of hexavalent mannose cluster 22 deserves some attention. As 
discussed earlier, previous examples to construct mannosylated lysine 
clusters were performed in solution. Hillaert et al. successfully used the 
copper(I)-catalyzed Huisgen [2+3] azide-alkyne “click” cycloaddition of 
propargyl mannoside 23 and the six azide moieties of immobilized 
hexapeptide 21. Subsequently, Fmoc removal, elongation with pent-4-ynoic 
acid and finally cleavage from the solid support provided mannose cluster 
22. In the second click event compound 20 was connected in solution to 
mannose cluster 22 to give mannosylated BODIPY-DCG-04 construct 17. 
Profiling of the activity of cathepsins with construct 17 using rat liver lysate 
showed a concentration dependent labeling profile similar to that previously 
reported for DCG0412. Importantly, the hexavalent mannoside cluster 
appeared not to interfere with the cathepsin binding. Experiments with 17 
using bone-marrow derived DCs and macrophages revealed uptake and 
intracellular cathepsin labeling in both cell types. Blocking the MR with 
mannan abolished labeling, pointing towards mannose receptor dependent 





Scheme 3: Synthesis of mannosylated BODIPY-DCG-04 construct 17. 
 
Reagents and conditions: (a) DMF, DIPEA, 93%; (b) i. alpha-propargyl-mannopyranoside 23, 
CuSO4, sodium ascorbate, tBuOH/DMF/H2O (2:1:1); c) i. 20% piperidine (in NMP); ii. pent-
4-ynoic acid, BOP, DIPEA, NMP; d) 20% TFA (aq.), 85%; e) CuSO4, sodium ascorbate, 
tBuOH/H2O (1:1.7), 14%. 
 
 
Cyclic scaffolds  
 
Cyclic RAFT peptides 
Regioselectively addressable functionalized templates (RAFTs), are cyclic 
peptide templates that are commonly composed of a backbone-cyclized 
peptide, such as 29 (Scheme 4). This RAFT contains two proline-glycine 
dipeptides as β-turn inducers.13 Renaudet et al. reported the synthesis of 
tetravalent glycoconjugates as a potential tool for cell targeting and cell-




Scheme 4), was evaluated for binding with Concanavalin A (Con A), a 
mannose binding lectin. The mannosylated RAFT conjugate showed a 20-
fold increase in potency relative to α-D-O-methyl mannose.15  
A subsequent study describes the synthesis of biotin and S-3-nitro-2-
pyridinesulfenyl (Npys) functionalized RAFT conjugates 25 and 26 (Scheme 
4) to study the carbohydrate-lectin recognition.16 The assembly of 24-26 
started with the solid phase synthesis of peptide 28, having orthogonally 
protected Boc-lysine and Alloc-lysine residues, using standard Fmoc 
chemistry. After cleavage from the resin, peptide 28 was subjected to an 
intramolecular cyclisation reaction under influence of PyBOP giving key 
cyclic peptide 29 in 87% yield.17 Deprotection of the Boc-protective groups 
in 29 and coupling of the liberated amines with Boc-Ser(tBu)-OH followed 
palladium-mediated deprotection of the alloc group18 and removal of the Boc 
group in the serine residues gave compound 30 in 53% yield over 4 steps.19 
Periodate oxidation of tetravalent serine compound 30 gave the 
corresponding aldehyde 31 which was condensed with aminooxy mannoside 
3220 to give the target tetravalent mannosylated RAFT conjugate 24. The 
free lysine amine in 24 was used to append a biotin moiety giving 
biotinylated tetravalent mannosylated RAFT conjugate 25. To immobilize 
the RAFT on a surface, 24 was functionalized with a cysteine residue 
through coupling of the free lysine with Boc-Cys(Npys)-OSu ester and 
subsequent removal of the Boc-group, to give tetravalent mannosylated 
RAFT conjugate 26. Both 25 and 26 were immobilized on a gold surface at 
various surface densities. The interaction of conjugates 25 and 26 with Con 
A was studied by nanogravimetry and surface plasmon resonance. The 
conjugates show increased affinities towards Con A in comparison with the 
monovalent counterpart. This increase was explained by a clustering effect 
since the mannose ligands in 25 and 26 cannot span the saccharide binding 





Scheme 4: Synthesis of biotin-RAFT mannose conjugate 25 and Cys(Npys)-RAFT mannose 
conjugate 26. 
 
Reagents and conditions: (a) i) 20% piperidine/DMF (3x 20 min); ii) Fmoc-aa-OH, PyBOP, 
DIPEA, DMF; iii) TFA (1%) in DCM, 87%; (b) PyBOP, DIPEA, 86%; (c) i. 50% TFA (in 
DCM); ii. Boc-Ser(tBu)-OH, PyBOP, DIPEA, DMF; iii. Pd(Ph3P)4, PhSiH3, DCM; iiii. 
TFA/TIS/H2O (95:2.5:2.5), 53% over 4 steps; (d) NaIO4, H2O; (e) aminooxy mannoside 32, 
70% AcOH (aq.); (f) biotin sulfone, PyBOP, DIPEA, DMF; (g) i. Boc-Cys(Npys)-OSu ester, 
DMF; ii. TFA/DCM (yields not given) 
 
Several variations in orthogonal protection of the RAFT template and 
conjugation methods have been described in the literature.21 For example, 
cyclic RAFT scaffolds were equipped with an alkyne or azide functionality 
and mannosides were conjugated using Cu(I)-catalyzed click chemistry.22,23 
Two different carbohydrate moieties could be conjugated to one RAFT 
scaffold in a controlled manner by using oxime and triazole formation as two 




tetravalent mannose clusters were conjugated to the scaffold,25 and later on 
second26 and third27 generation “dendri-RAFT” structures were synthesized 
to increase ligand valency. 
 
Cyclodextrins 
Cyclodextrins (CDs) are a family of cyclic oligosaccharides, composed of -
D-glucose moieties, that are biocompatible, non-immunogenic. They can be 
readily functionalized and they are able to encapsulate various hydrophobic 
molecules of appropriate size within their hydrophobic cavity. Therefore 
they have been used in several pharmaceutical applications.28, 
Cyclodextrins have also been exploited for receptor-mediated 
glycotargeting. For instance Fernández and coworkers reported the synthesis 
of heptavalent mannosylated-βCD 33 as a multivalent lectin ligand.29 They 
conjugated the mannose residues to the CD by the formation of a thiourea 
bond using the amines in heptavalent CD derivative 36 and thioisocyanate 
mannoside 42. The route of synthesis starts with the conversion of β-CD 34 
into per-6-(deoxybromo)-cyclodextrin 3530 by selective substitution of the 
primary alcohols using Ph3P/NBS. Next, the bromides in 35 were substituted 
by 2-aminoethanethiol hydrochloride giving amino CD derivative 36 in 86% 
yield. Isothiocyanate mannoside 42, bearing a heptyl spacer, was obtained 
from 1-thio-mannoside 37. Thio-mannoside 37 was elongated with allyl-
ether spacer 38 by a radical reaction using AIBN as initiator providing 39 in 
71% yield. Next the free hydroxyl functionality was transformed into a 
isothiocyanate as follows: Tosylation and substitution with azide to 
proceeded in 65% over two steps to give mannoside 41. Treatment of azide 
41 with Ph3P/CS2 gave thioisocyanate 42 in 67% yield. Isothiocyanate 42 
was then reacted with the amines in cyclodextrin 36 to form thiourea bonds. 
Subsequent saponification of the acetyl groups gave cyclodextrin conjugate 





Scheme 5: Synthesis of mannosylated β-CD conjugate 33. 
 
Reagents and conditions: (a) Ph3P, NBS, DMF, 70 °C, 96%; (b) 2-aminoethanethiol HCl salt, 
TEA, DMF, 86%; (c) 38, AIBN, dioxane, 71%; (d) i. TsCl, DCM, DMAP, 81%; ii. NaN3, 
DMF, 80 °C, 97%; (e) Ph3P, CS2, dioxane, 67%; (f) i. isothiocyanate mannoside 42, NaHCO3, 
H2O/acetone (1:1 v/v), ii. 1M NaOH (aq.), 46%.  
 
The same authors prepared 14- and 21-valent homo- and heteroglycoclusters 
based on CD (Figure x). All glycoclusters were evaluated for their binding 
affinity towards Con A, using an enzyme-linked lectin assay which provides 
information on the intrinsic lectin-ligand affinity and isothermal titration 
microcalorimetry. It turned out that the Con A-binding affinity for 
homogeneous mannose clusters increases when the mannose residues occur 
as triads. Surprisingly hetero-type glycoclusters with not only -mannose 




affinities significantly higher than that of the homogeneous conjugates with 
identical mannose valency. 
Many examples of cyclodextrin based glycoclusters have been reported, 
varying in the nature of the carbohydrate, the valency, and the conjugation 
method and strategy.31,32 For example, Baussanne et al. synthesized a per-
(6→6)-thiourea linked methyl-α-D-mannopyranoside β-CD cluster to study 
the effect of anomeric group on the binding towards Con A.33 Surprisingly 
the binding affinity of this cluster towards Con A was completely abolished 
demonstrating the importance of all hydroxyl groups concerning lectin 
recognition. Carpenter et al. conjugated mono-mannosides and 1,3-1,6-tri-
mannosides by amide bond formation with per-6-amino-β-DC.34  
 
Calixarenes 
Calixarenes are cyclic oligomers, which are obtained by condensation of 
phenols or resorcins with aromatic aldehydes (e.g. 42, Scheme 6). 
Calixarenes are convenient matrices for the development of multivalent 
glycoclusters. The possibility to vary ring size, valency, and conformation of 
calixarenes allows precise control over spatial arrangement of the 
carbohydrate ligands in glycocalixarenes..35 
Gold nanoparticles have found considerable use in tumour targeting 
applications due to their straightforward synthesis and ease of 
functionalization. Recently Avvakumova et al. reported a novel approach for 
non-covalent functionalization of gold nanoparticles (AuNPs) with 
glycocalixarenes bearing four mannose units, resulting in multivalent 





Scheme 6: Synthesis of calix-man 40 and the structure of simplified mono-man 41. 
 
 
Reagents and conditions: a) thioisocyanade mannoside 44, TEA, DCM, 65%; b) NaOMe, 
MeOH, quantitative. 
 
The assembly of these functionalized AuNPs starts with the reaction of the 
amino functions in calix[4]arene 42 and thioisocyanate mannoside 44 
followed by global saponification to give calix-man 40 in 65% overall yield. 
After conversion of Au-nanoparticles into Au-dodecathiol nanoparticles, 
non-covalent functionalization with calix-man 40 was attained by a phase 
transfer procedure where Au-dodecanthiol was mixed with calix-man 40 and 
mono-man 41 in chloroform (Figure 2).  
 
Figure 2: Schematic representation of the gold nanoparticle functionalization using a phase 
transfer procedure. Formation of Au-calix-Man 40. 
After removal of the solvent the calixarene-AuNPs were redispersed in 




functionalized with mono-man 41 were tested for cell uptake in HeLa cells. 
The results showed that the uptake of AuNPs functionalized with calix-man 
40 was increased three-fold relative to the simplified AuNPs functionalized 
with mono-man 41 and an eight-fold increase compared to the untreated gold 
particles. However uptake of the untreated gold particles was also observed. 
Competition with dextran abolished the uptake of AuNPs functionalized 
with both 40 and 41, indicating a mannose dependent uptake. Furthermore, 
the uptake of untreated gold particles was scarcely influenced by the 




Dendrimers and dendrons 
 
Dendrimers are structurally defined, highly branched, symmetrical 
macromolecules that adopt a globular-type structure. The iterative synthesis 
of dendrimers permits for the introduction of multiple glycoconjugation sites 
to give glycodendrimers.38,2 Two main strategies can be discerned for 
constructing glycodendrimers, namely a divergent or a convergent synthesis 
strategy.39 In the divergent approach, the dendrimer is constructed in a 
stepwise manner starting from a core molecule and growing outwards with 
typically doubling of the number of reactive functionalities being introduced 
with each new generation. When the desired number of reactive 
functionalities has been reached carbohydrates can be introduced to form a 
glycodendrimer. A disadvantage of this method is the increasing number of 
reactions that has to be performed during each extension to a next 
generation. Incomplete transformation and/or side reactions give rise to the 
formation of mixtures of closely related compounds and separation can 
become impractical.40  
In the convergent approach a glycodendrimer is constructed inwards from 
the periphery to the core. Dendritic segments or dendrons of selected size are 




molecule to obtain the desired dendrimer.41 In comparison to the divergent 
strategy, the convergent method avoids many of the synthetic problems 
inherent in the divergent strategy, and it affords dendritic polymers with on 
average higher structural homogeneity. However, a convergent strategie 
requires large quantities of carbohydrate-derived materials, which typically 
need to be protected during dendrimer assembly (necessitating a global 
deprotection step at the end of the synthesis). Protecting groups can lead to 
steric crowding, which in turn may influence coupling efficiencies.42 
Many studies described in the literature use commercially available dendrons 




Figure 3: Structure of PAMAM dendron and dendrimer. 
Mannosylated PAMAM dendrimer conjugates have been synthesized to 
study protein-carbohydrate interaction. Based on the X-ray structure of a 
complex of Con A and methyl -D-mannopyranoside Cloninger and co-
workers reasoned that a large dendrimer should be able to bind 
simultaneously to two binding sites in ConA, located about 65 Å apart on 
one side of the protein.43,44 They synthesized 1st to 6th generations of 
PAMAM dendrimers in which the mannose residues are linked via thiourea 




dependent on the density of the sugars on the dendrimer with the largest 
dendrimer binding best. In a subsequent study by the same group the degree 
of mannose functionalization was controlled by stoichiometric addition and 
this agreed with the lectin binding activity and the number of lectins 
clustered around the dendrimer.45,46 Many other conjugation techniques has 
been applied to decorate the dendrimer scaffold with carbohydrates.47,48 
Fernández and co-workers described the synthesis of a row of mannose-
coated β-cyclodextrin-dendrimers, such as construct 45 (Scheme 7).49 
Mannosylated dendron 51 was obtained by a convergent methodology in 
which isothiocyanate and amine functionalized building blocks repeatedly 
react to give thiourea linkages. Boc-protected triaminopropane 46 was first 
elongated with azidohexanoyl chloride to give 47 in 96% yield. Boc removal 
followed by reaction of the released amines with isothiocyanate mannoside 
44 gave divalent conjugate 49. Azide 49 was converted to isothiocyanate 50 
in 72% yield using Ph3P and CS2. Thioisocyanate 50 was then coupled with 
diamine 48 giving dendron 51.  
 
Scheme 7: Synthesis of mannosyl-coated β-cyclodextrin-dendron construct 45. 
 
Reagents and conditions: a) azidohexanoylchloride, DMF/collidine (1:1), 96%; b) TFA/H2O 
(1:1); c) thioisocyanade mannoside 44, pyridine, 82% (over two steps); d) (Ph)3P, CS2, 
dioxane, 72%; e) diamine 48, NaHCO3 (aq.) pH 8, acetone, 55%; f) (Ph)3P, CS2, dioxane, 





A second conversion of the azide to the corresponding thioisocyanate gave 
dendron 52 which was coupled to β-cyclodextrin-mono-amine 5450 in 60% 
yield. Global deprotection provided mannosyl-coated β-cyclodextrin-
dendrimer 45 in 89% yield. Evaluation of the mannose-functionalized β-
cyclodextrin-dendrimers towards Con A with the aid of an enzyme-linked 
lectin assay showed that the strength of the lectin binding increased with 
increasing valency of the constructs. For instance, dendrimer 45 showed a 
14-fold increase in binding affinity towards Con A relative to mono-
mannosylated-βCD. In a following study of the same group, a hexavalent 
dendron was conjugated to βCD as drug carrier for the drug docetaxal (DTX, 
Taxotere®).51 Complexation of the mannosylated-βCD with DTX showed a 
1000-fold increase in water solubility and a 20-fold increase in uptake by 
peritoneal mouse macrophages compared to the unmannosylated-βCD/DTX 
complex. In another study, Fernández and co-workers used trivalent 
mannosylated β-cyclodextrin (βCD) conjugates for the targeted delivery of 
pharmacological chaperones for Gaucher disease to macrophages.46 
Complexes of mannosylated βCD conjugates and two nojirimicin based 
chaperones were tested for chaperone activity and targeted delivery to 
macrophages. No difference in chaperone activity was observed for the 
nojirimicin derivatives and its mannosylated βCD complex and uptake of the 
complexes by macrophage-like cells was clearly visualized by fluorescence 
microscopy.  
Wong and co-workers studied the effect of neighbouring glycans on 
antibody-carbohydrate recognition using microarrays.52 With the aim to 
mimic the HIV envelope glycoprotein gp120 surface using heterogeneous 
glycans, they hoped to find an optimal presentation of the carbohydrate 
epitope. In order to achieve this, high-mannose dendron conjugate 57, 
having Man9 and/or Man4 glycans was synthesized by a convergent approach 
(Scheme 8), in which oligo-mannosides 55 (Man4) and 56 (Man9) (Scheme 
8) containing an azide were coupled in different ratios to nona-valent alkyn 




removed to give 59. The released amino group enabled the installation of a 
glycol spacer by a double elongation with acid 60 giving triester 61 which 
was subsequently hydrolyzed to the corresponding tri-acid 62 in 94% overall 
yield.  
 
Scheme 8: Synthesis of high mannose dendron conjugate 69. 
 
Reagents and conditions: (a) 50% TFA (in DCM), DCM, 99%; (b) i. carboxylic acid 60, 
EDC, HOBt, DIPEA, DMF; ii. 50% TFA (in DCM), DCM; iii. carboxylic acid 60, EDC, 
HOBt, DIPEA, DMF, 96%; (c) 1M NaOH (aq.), MeOH (62: 99%, 64: quantitative); (d) 
propargyl amine, EDC, HOBt, DIPEA, DMF, 75%; (e) TFA (50% in DCM), DCM, 96%; (f) 
tri-alkyn 66, EDC, HOBt, DIPEA, DMF, 69%; (g) TFA (50% in DCM), DCM; (h) Man4-N3 





Tri-alkyn amide 65 was also obtained from tri-ester 58. Hydrolysis of 58 to 
tri-acid 63, followed by coupling with propargylamine provided Boc-
protected tri-alkyn 64. Removal of the Boc-protective group, gave tri-alkyn 
amine 6553 in 72% yield starting from 58. Next, the obtained tri-alkyn amine 
65 was coupled to tri-acid 62 giving nona-alkyn dendron 66 in 69% yield. 
After Boc-deprotection, nona-alkyn 67 was subjected to coupling with 
oligomannosides Man4-N3 55 and Man9-N3 56 under Cu(I) catalysed “click” 
conditions. By varying the concentration of oligomannosides 55 and 56 
Wong and co-workers could successfully control the average Man4/Man9 
ratio conjugated to the dendron. With this method they synthesized five 
constructs with a Man4/Man9 ratio of 9:0, 0:9, 6:3, 3:6 and 5:4.  
The obtained constructs were printed on N-hydroxysuccinimide (NHS) 
activated glass slides to form an array of conjugates with varying densities. 
Binding studies were performed with 2G12 antibodies that recognize a 
mannose containing epitope on the gp120 surface protein.54 The results 
showed an increase of binding affinity with increasing glycan density of the 
constructs. Furthermore, the conjugate, having a Man4/Man9 5:4 ratio 
showed the highest relative binding towards the 2G12 antibody. This study 
showed that the use of heterogeneous glycans is a useful tool to mimic 






N-linked glycans play a pivotal role in a number of vital processes such as 
protein folding, quality control and transportation.55 All N-linked glycans 
contain a core pentasaccharide featuring an 1,3-1,6-α-linked trimannoside 
1,4-β-linked to a GlcNAc dimer. The high mannose N-glycan consists of 
three 1,2-α-linked mannose dimers attached to the mannose trimer core 
(Figure 4), to give three mannose arms, termed the D1, D2 and D3 arms. 




oligosaccharides rely on the synthesis of modified or truncated fragments 
and their multivalent presentation.  
 
 
Figure 4: Structure of the high-mannose N-glycan. 
 
Seeberger synthesized a set of oligomannosides derived from the natural 
high-mannose N-glycan (Figure 5) to investigate their targeting ability to DC 
surface receptors.56 Oligomannoside Man9 70 resembles the full mannose 
cluster of the high mannose N-glycan, Man6 69 is truncated with three 
mannose units at the D1, D2 and D3 arm, respectively. Further truncation 
gives the branched Man3 68. Mannosides 68, 69 and 70 have a β-linked 
polyethylene glycol thiol spacer for further functionalization.57  
 
 
Figure 5: Structures of a set of high-mannose oligomannosides 68-70. 
 
The synthesis of oligomannosides 68-70 is shown in Scheme 9. 
Condensation of spacer containing acceptor 71,58 and donor 80 under 




silylether, the obtained dimer 73 was coupled with donor 81 yielding core 
trisaccharide 74 in 85% over two steps. Deacylation of 74 provided 75 and 
subsequent removal of all benzyl ethers by Pd/C catalysed hydrogenation 
gave target compound 68 in 59% yield starting from monomer 71. Coupling 
of the three hydroxyl functions in trimer acceptor 75 with donor 80 using 
TMSOTf as activator gave fully protected hexasaccharide 76 in 94% yield. 
Target hexasaccharide 69 was obtained by saponification of the acetyl esters 
followed by hydrogenolysis of the benzyl ethers in 77 to provide 
hexasaccharide 69 in 64% overall yield. Finally, nonasaccharide 70 was 
synthesized by coupling of triol acceptor 77 with donor 80 to give fully 
protected nonamer 78 in 80% yield. Global deprotection provided the target 
nonasaccharide 70 in 53% overall yield. 
Scheme 9: Synthesis of High mannose oligomannosides 68-70. 
 
Reagents and conditions (a) TBDMSOTf, donor 80, DCM, -20 °C, 99%; (b) TFA/THF/H2O 
(1:3:3), 91%; (c) TBDMSOTf, donor 81, DCM, -20 °C, 93%; (d) NaOMe, MeOH/DCE (1:1) 
(75: 89%, 77: quantitative, 79: 90%; (e) TMSOTf, donor 80, DCM, -20 °C (76: 94%, 78: 
80%); (f) Pd/C, H2, EtOH/EtOAc, (68: 79%, 69: 81%, 70; 88%). 
 
In a subsequent study, mannosides 68-70 were conjugated to a maleimide 




were treated with mannosylated-OVA and antigen presentation was 
monitored by CD4+ and CD8+ response. In vitro data demonstrated that 
mannose modified-OVA conjugates all showed an increase in antigen 
presentation to CD4+ T cells up to a 50-fold enhancement for the Man9-OVA 
conjugate. A 10-fold enhancement was observed for CD8+ T cells, indicating 
that the appendage of the oligomannosides can lead to enhanced cross-
presentation of antigens on MHC class I. 
 
 
Outline of this Thesis 
 
The research described in this Thesis is mainly focussed on the design and 
synthesis of glycoconjugates provided with oligomannoside structures or 
mannose clusters that can be recognized by the mannose receptor (MR) or 
other mannose binding lectins. Chapter 2 describes the synthesis and 
biological evaluation of high-mannose conjugated cathepsin probes. 
Mannosides varying in size were conjugated to the probe and tested for 
uptake and activity in DCs. Chapter 3 describes the synthesis and biological 
evaluation of two mannose conjugated cyclophellitol probes. A synthesis 
route is presented towards 6-azido cyclophellitol with the necessary 
modifications to allow for site selective conjugation at the C-4 OH. The 
probes were tested on macrophages to label the enzyme Glucocerebrosidase. 
Chapter 4 describes the synthesis of a library of mannosylated oligopeptide 
epitopes. A set of propargyl mannosides were synthesized and used for 
conjugation to the epitope bearing various azidolysine residues to form 
multivalent mannosyl-clusters. To investigate how the nature and amount of 
mannose residues influence antigen presentation, DCs were subjected to the 
conjugates, and the antigen presentation measured. Chapter 5 describes the 
synthesis of a number of imidate based glucosidase, galactosidase and 
mannosidase probes. The compounds were synthesized using a single 
general procedure. Both α- and β-isomers were synthesized. Chapter 6 




aziridine cyclophellitol. Chapter 7 summarizes the research described in 
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The targeted delivery of chemotherapeutics through the intermediacy of cell 
surface receptors represents an attractive means to selectively deliver cargo 
to target cells or subcellular compartments
2
. Conceptually distinct 
approaches have been developed over the years to selectively deliver 
therapeutics and diagnostics to specific cell types through receptor-mediated 
uptake. Various ligands have been used as a homing device, including 
antibodies
3,4







 Lectins are carbohydrate-binding receptors involved in a 
wide variety of cellular recognition and communication processes.
10
 They 
are abundantly expressed on dendritic cells and macrophages, the guardians 
of our innate immune system, to survey their surroundings and detect 
pathogens and danger signals.
11,12
 Many of the lectins found on these cells 
are members of the C-type lectin family and these include the mannose 
receptor (MR),
12






binding receptors have been exploited in various antigen-targeting strategies 
to enable both the efficient uptake of antigens (as described in chapter 4) and 
simultaneous stimulation of the immune cells. Proteases play a key role in 
the generation of peptide antigens and as such in antigen presentation. To 
probe the activity of cathepsins in living DCs Hoogendoorn et al. reported 
the adaptation of the broad-spectrum cathepsin inhibitor, DCG-04 to obtain 
targeted activity-based cathepsin probes.
14
 DCG-04 was originally reported 
by Bogyo and co-workers, in a seminal paper,
15
 which, together with the first 
paper by Cravatt and co-workers on serine hydrolase probes,
16
 shaped the 
field of activity-based protein profiling. Taking the natural product and 
broad-spectrum cysteine protease inhibitor, E-64, as a basis, Bogyo and co-
workers appended both a biotin and – in a later contribution – a set of 
different fluorophores and showed that all these structures retain potency and 
(broad-spectrum) specificity against numerous mammalian cathepsin 
cysteine proteases.
17
 From these studies, which yielded activity-based probes 
currently widely used by the chemical biology community, it became 
apparent that cathepsin cysteine proteases tolerate a wide variety of 
functional groups appended to the dipeptide epoxysuccinate core.  
Functionalization of the irreversible cathepsin inhibitor, DCG-04 with a 
BODIPY dye and a mannose cluster gave activity-based probe (ABP) 1 
(UHG392
18
 as depicted in Figure 1), which was used probe the activity of 
cathepsins in living DCs. ABP 1 contains an artificial mannose cluster built 
up from mono-mannosides covalently attached through a triazole linker to a 
hexalysine scaffold. The nature of the mannose ligand may influence 
recognition by the cell surface lectins and consequently uptake and routing 
of the conjugates. For example, it is known that the prevalent carbohydrate 
binding lectins on DCs, DC-SIGN and the MR, bind oligomannosides better 
than monomannosides.
19,20
 Glycan microarray studies have revealed that 
DC-SIGN strongly binds high mannose type structures
21
 and available 
crystal structures of DC-SIGN bound to natural ligands show that a terminal 
branched trimannose structure, featuring -(1,3) and -(1,6) mannose 
branches on a core mannose residue, fits well in the carbohydrate binding 
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site of this signaling receptor.
22
 The MR also binds oligomannosides and a 
preference for the same type of branching has been reported.
23
 Because the 
nature of the carbohydrate ligand(s) is important for the recognition by the 
cell surface lectins and consequently for the uptake and routing of the 
molecules, a set of BODIPY-DCG-04-oligomannose conjugates, bearing 
oligomannosides that feature natural glycosidic connections (i.e. -(13) 
and -(16) linkages) were designed and synthesized. In this chapter the 
assembly of three BODIPY-DCG-04-mannose clusters (2, 3 and 4, Figure 
1), bearing either a mono-, tri- or heptamannoside targeting entity and their 




Figure 1: Structures of the known DCG-04 mannose conjugate 1 and the new DCG-04 






Results and discussion 
 
Synthesis 
The projected BODIPY-DCG-04 mannose conjugates 2, 3 and 4 were 
assembled by conjugation of the corresponding propargyl mono-, tri- or 
heptamannosides 7, 19 and 27 with azide functionalized BODIPY-
epoxysuccinate 5 (Scheme 3). The synthesis of monomannoside 7 together 
with building block 12 and the glycosylation reactions toward propargyl tri- 
and heptamannoside 19 and 27 are shown in schemes 1 and 2.  
Treatment of peracetylated mannose 6 with propargyl alcohol and BF3·Et2O 
gave monomannoside 7 (Scheme 1).
24
 Starting from peracetylated mannose 
6, orthoester 8 was obtained via the intermediate formation of a mannosyl 
iodide, as reported by Adinolfi et al.
25
 The iodide was intramolecularly 
substituted to give orthoester 8, which was deacetylated and subsequently 
benzylated to give orthoester 10. Acidic hydrolysis of 10 then yielded 
hemiacetal 11
26,27
 in 82% over 4 steps. Treatment of this lactol with (N-
phenyl)trifluoroacetamidoyl chloride in the presence of Cs2CO3 afforded (N-
phenyl)trifluoroimidate donor 12 in 90% yield. 
 
Scheme 1: Syntesis of propargyl mannoside 7 and donor mannoside 12. 
 
Reagents and conditions (a) i) I2, Et3SiH, CH2Cl2, reflux; ii) MeOH, 2,6-lutidine, rt; (b) 
K2CO3, MeOH, rt; (c) NaH, BnBr, DMF, 0 °C to rt; (d) DME/H2O (10:1), pTsOH, 82% over 
4 steps; (e) Cs2CO3, acetone, (CF3)C(NPh)Cl, 90%; (f) propargyl alcohol, BF3·Et2O, DCM, rt, 
61%. 
 
The construction of key trisaccharide 14, which was used as a precursor for 
both the propargyl trimannoside 19 and heptasaccharide 27, was 
accomplished by a double glycosylation of known diol 13
24 
using donor 12 
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and a catalytic amount of TfOH (Scheme 2). Next trimer 14 was converted 
into the corresponding anomeric acetate 15 using NIS and AcOH. Removal 
of all benzyl groups from this trimer required a two-step sequence. The fully 
protected trisaccharide was first treated with Pd/C and H2 in a mixture of 
EtOAc/tBuOH/H2O (1:3:4) and subsequently with Pd/C and H2 in water to 
effect removal of all benzyl groups. Peracetylation of the crude trimer 16 
yielded 17 in 76% over the two steps. Propargyl alcohol was then condensed 
with trimannosyl acetate 17 under the agency of BF3·Et2O to provide the 
fully protected trimer 18. Global deacetylation under Zemplén conditions 
yielded the propargyl trimannoside Man3 19. 
The heptasaccharide 21 was assembled using trisaccharide donor 14 and 
acceptor 20. The latter building block was obtained by treatment of thio 
mannoside 13
28
 with NIS and AcOH (Scheme 2).
29
 This led to the formation 
of the -acetate 20 in 40% yield, alongside the generation of its -anomeric 
counterpart (37%) and a minor by-product that was characterized as 1,6-
anhydro-2,4-di-O-benzyl--D-mannose (11%). Condensation of both 
alcohols in acceptor 20 with trisaccharide donor 14 was achieved using the 
NIS/TfOH promotor couple to yield heptamer 21 as a single product in 62% 
yield. Hydrogenation of 21 with Pd/C and H2 in EtOAc/MeOH/H2O (5:4:1) 
was followed by a second hydrogenation in MeOH/H2O (1:1) to give the 
debenzylated heptamer 22, which was subjected without further purification 
to global acetylation. Attempts to introduce the propargyl moiety onto the 
peracetylated heptamer using BF3·Et2O did not lead to the desired product 
and therefore a more potent glycosylating agent was used. To this end the 
anomeric acetyl was chemoselectively deblocked using hydrazine acetate 





Scheme 2: Synthesis of the propargyl trimannoside Man3 19 and propargyl heptamannoside 
Man7 27. 
 
Reagents and conditions: (a) 12, DCM, TfOH, act. Mol. Siev, -40 °C to rt, 84%; (b) NIS, 
AcOH, DCE/Et2O (1:1), 94%; (c) i) Pd/C, H2, EtOAc/tBuOH/H2O (1:3:4), ii) Pd/C, H2, H2O; 
(d) Ac2O, pyridine, 0 °C to rt, 76% over 2 steps; (e) propargyl alcohol, BF3·Et2O, DCM, rt, 
61%; (f) MeOH, NaOMe, 68%; (g) NIS, DCM/AcOH (1:1), rt, 40%; (h) 14, NIS, TfOH, act. 
Mol. Siev., DCM, -40 °C to rt, 62%; (i) Pd/C, H2, EtOAc/MeOH/H2O (5:4:1); ii) Pd/C, H2, 
MeOH/H2O (1:1); (j) Ac2O, pyridine, 0 °C to rt, quantitative yield over two steps; (k) 
H2NNH2·AcOH, DMF, 0 °C, 79%; (l) ClC(=NPh)CF3, Cs2CO3, acetone, quantitative; (m) 
propargyl alcohol, TfOH, DCM, act. Mol. Siev., -40 °C to 0 °C, 40%; (n) i) NaOMe/MeOH; 
ii) 0.1M NaOH (aq.), quantitative. 
 
Glycosylation of propargyl alcohol with donor 25 under mild acid catalysis 
yielded the peracetylated heptamannoside 26 in 40% yield. Deacetylation 
under standard Zemplén conditions led to the partial removal of the acetyl 
groups, necessitating an extra saponification step with aqueous 0.1M NaOH 
to provide the target heptamer Man7 27. 
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The BODIPY-DCG-04-mannose conjugates were obtained through a Cu(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition
30
 of azido BODIPY-DCG-04 
(5) and the propargyl mannosides 7, 19 and 27 (Scheme 3). After HPLC 
purification the three target constructs were obtained in 42% (2), 24% (3) 
and 32% (4) yield respectively. 
 
Scheme 3: Assembly of the mannose-BODIPY-DCG-04 conjugates 2, 3 and 4 and structures 
of cathepsin binding probes 5 (BODIPY-DCG-04), 28 (AS44), 29 (azido-DCG-04) and 30 
(BODIPY(FL)-DCG-04). 
 
Reagents and conditions: (a) sodium ascorbate, CuSO4, DMF/H2O (1:1), Man1-BODIPY-
DCG-04 (2) 42%, Man3-BODIPY-DCG-04 (3) 24%, Man7-BODIPY-DCG-04 (4) 32%. 
 
Biological evaluation 
To investigate labeling of cathepsins by activity-based probes 2, 3 and 4 
their activities were first evaluated in cell lysates. To this end mouse liver 
lysate was incubated with increasing concentrations of Man1-BODIPY-
DCG-04 (2), Man3-BODIPY-DCG-04 (3) and Man7-BODIPY-DCG-04 (4) 
after which the proteins in the lysates were resolved on SDS-PAGE (Figure 
2A). All three mannosyl DCG-04 probes label cathepsins in a concentration-
dependent manner, as is evident from Figure 2A. A small difference in gel-
shift is apparent for the three different constructs and correlates to their 
varying molecular weight. A decrease in binding capacity was observed with 
increasing cluster size suggesting that the steric bulk of the heptamannosyl 




efficacy of the larger mannosyl clusters, together with the difference in gel-
shift of the labeled proteins indicates that mannosidases present in the cell 
lysate do not (effectively) trim the probes when bound to the cathepsins or 
when unbound in the cell extract. Incubation of immature mouse dendritic 
cell (DC) lysate with the probes showed a similar concentration-dependent 




Figure 2. Cathepsin labeling experiments in mouse liver and dendritic cell lysate. Mouse liver 
lysate (10 µg total protein, A) or immature mouse dendritic cell (DC) lysate (8 µg total 
protein, B) was incubated (1 h, 37 °C) with increasing concentration of probe 2, 3 or 4 at pH 
5.5 or 1 µM at pH 7. Alternatively, lysates were incubated (1 h, 37 °C) with azido-DCG-04 (1 
or 10 µM), AS44 (10 µM) or BODIPY(FL)-DCG-04 (1 or 10 µM), before treatment with 
probe 2, 3 or 4 (1 µM, 1 h, 37 °C). Proteins were resolved on 12.5% SDS-PAGE, followed by 
fluorescence scanning (Cy2 (green): BODIPY(FL), Cy3 (red): BODIPY(TMR) and total 
protein staining with coomassie brilliant blue (CBB). M: dual color protein molecular weight 
marker. 
 
In line with the previous findings, changing the pH of the buffer from pH 5.5 
(the optimal pH for most cathepsin activity)
18
 to pH 7 led to abrogation of 
cathepsin binding showing that active enzymes are required for labeling. 
Next a set of competition experiments was performed. The lysates were pre-
incubated with different DCG-04 competitors, namely, AS44 28
14
, azido-
DCG-04 29 and BODIPY(FL)-DCG-04 30
18
 (See Scheme 3 for the 
structures of the competitors), followed by incubation with the probes. As 
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seen in Figure 2B labeling of the cathepsins with the red mannosyl 
BODIPY-DCG-04 conjugates was effectively prevented leading to either 
disappearance of the fluorescent bands in the competition experiment with 
non-fluorescent azido-DCG-04 and AS44, or the appearance of green 
fluorescent bands in the experiment with the green DCG-04 probe 30. These 
competition experiments corroborate that probes 2, 3 and 4 label active 
cathepsins. 
Next the probes were tested for uptake and binding of cathepsins in living 
DCs (Figure 3). In line with the results obtained with the cell lysates, a 
concentration-dependent labeling pattern was observed (Figure 3A, left 
panel). The most efficient and selective labeling was achieved with the 
trimannosyl probe 3, where the monomannosyl compound 2 showed most 
background fluorescence. Also in these experiments the heptamannoside 
probe 4 labeled the target cathepsins somewhat less efficient than its 
trimannoside counterpart 3. Competition experiments with non-fluorescent 
cell-permeable azido-DCG-04 probe AS 8 indicated that also in living DCs 
active cathepsins are labeled by the probes. To test whether uptake of the 
probes was carbohydrate receptor mediated the DCs were pre-incubated with 
mannan, a mixture of mannose polysaccharides prior to exposure to the 
probes. Mannan, the natural substrate, binds to the mannose receptor and 
thus the uptake is prevented. In doing so, labeling by the tri- and 
heptamannosyl probes was effectively blocked showing that uptake of these 
ABPs is receptor dependent. The receptor-mediated uptake and labeling was 
confirmed by confocal microscopy. Figure 3B shows a clear uptake of Man3-
BODIPY-DCG-04 3 and Man7-BODIPY-DCG-04 4 in DCs but little uptake 
of Man1-BODIPY-DCG04 2 (Figure 3B, left panels). Pre-incubation of the 
cells with mannan prevented uptake of probes 3 and 4. Combined, the results 
indicate that Man3-BODIPY-DCG-04 3 and Man7-BODIPY-DCG-04 4 are 
taken up through the intermediacy of a carbohydrate binding receptor, where 
Man1-BODIPY-DCG04 2 can be internalized (at least in part) through a 
receptor-independent pathway. Receptor mediated internalization is clearly 




receptor can bind monomannosides, in the case at hand it appears that this is 




Figure 3. Uptake and cathepsin binding of the probes in live dendritic cells. A) DCs were 
treated with varying concentrations of 2, 3 or 4 (2 h, 37 oC) or pre-incubated (1 h, 37 oC) with 
azido-DCG-04 (20 µM) or mannan (3 mg/mL), followed by addition of 2, 3 or 4 (1 µM, 2 h, 
37 oC), washed with PBS, lysed and resolved on 12.5% SDS-PAGE. In-gel fluorescence of 
BODIPY (Cy3) and total protein stain (CBB) are shown. B) Representative confocal 
microscope images of DCs treated with 1 µM of probes 1, 2 or 3 (left panels) or with mannan 
(right panels) for 1 h, followed by treatment with the probes. After treatment, cells were 
washed with PBS, fixed with 4% formaldehyde, nuclei stained with Draq5 and imaged using 
the Cy3 (λex 532 nm) settings for BODIPY (red) and Cy5 (λex 635 nm) settings for Draq5 as a 
nuclear stain (blue). 
 
With respect to our first generation probe (1) it appears that DCG-04 
labeling with the trimannoside probe is equally efficient. We have however 
observed a difference in processing of the probes. Where probe 1 seems to 
be processed by mannosidases in living cells (as judged from the minimal 
difference in gel-shift for the labeled cathepsins, indicating only a small shift 
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in molecular size), the current probes are more resistant to the 





The assembly of three fluorescent cathepsin probes functionalized with 
different mannosides to investigate the role of these carbohydrate 
appendages on inhibition efficacy and internalization efficiency has been 
achieved. The size of the mannose oligosaccharides proved to influence the 
rate of inhibition, with the largest heptamannoside showing least effective 
cathepsin labeling in cell lysates at low inhibitor concentrations. The tri- and 
heptamannoside outcompete the monomannoside probe where it comes to 
effective uptake in live cells, and the trimannoside-modified DCG04 






General: Traces of water in the starting materials were removed by co-
evaporation with toluene for all moisture and oxygen sensitive reactions and 
the reactions were performed under an argon atmosphere. Dichloromethane 
was distilled over P2O5 and stored over activated 3 Å molecular sieves under 
an argon atmosphere. Propargyl alcohol was distilled over K2CO3 prior to 
use. All other solvents and chemicals (Acros, Fluca, Merck) were of 
analytical grade and used as received. Column chromatography was 
performed on Screening Device silica gel 60 (0.040-0.063 mm). Size 
exclusion was performed on Sephadex LH20 (eluent DCM/MeOH, 1:1). 
TLC analysis was conducted on HPTLC aluminium sheet (Merck, TLC 
silica gel 60, F254). Compounds were visualized by UV absorption (λ = 254 




(NH4)6Mo7O24·4H2O (25g/l) in 10% H2SO4 in H2O followed by charring at 




C NMR spectra were recorded on a Bruker DPX 300 
(300 and 75 MHz respectively), Bruker AV 400 (400 and 100 MHz 
respectively), Bruker DMX 400 (400 and 100 MHz respectively), or Bruker 
DMX 600 (600 and 125 MHz respectively). Chemical shifts are given in 
ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal 
standard. J couplings are given in Hz. Optical rotations were measured on a 
Propol automatic polarimeter. IR spectra (thin film) were conducted on a 
Perkin Elmer FTIR Spectrum Two UATR (Single reflection diamond). LC-
MS measurements were conducted on a Thermo Finnigan LCQ Advantage 
MAX ion-trap mass spectrometer (ESI+) coupled to a Thermo Finnigan 
Surveyor HPLC system equipped with a standard C18 (Gemini, 4.6 mm x 50 
mm, 5µm particle size, Phenomenex) analytical column and buffers A: H2O, 
B: MeCN, C: 0.1% TFA (aq.). High-resolution mass spectra were recorded 
on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer.  
 
2-O-Acetyl-3,4,6-tri-O-benzyl-D-mannopyranoside (11): 
To a solution of peracetylated mannose 6 (114.5 g, 293.2 
mmol) in DCM (750 mL) was added iodine (104.2 g, 410.5 mmol) and 
triethylsilane (66.3 mL, 410.5 mmol). The reaction mixture was heated till 
reflux. After 4 h TLC showed complete conversion of the starting material 
and mixture was cooled to rt. To the reaction mixture was added 2,6-lutidine 
(140 mL), MeOH (71.2 mL) and the reaction mixture was stirred overnight 
at rt. The reaction mixture was concentrated in vacuo, dissolved in EtOAc, 
washed with water (1x), 10% Na2S2O3 (aq.) (2x), H2O (3x), brine (2x), dried 
over Mg2SO4, filtered and concentrated in vacuo. The residue was dissolved 
in MeOH (500 mL), and to the solution was added K2CO3 (6.6 g, 48 mmol) 
and stirred for 4 h at rt. The reaction mixture was concentrated in vacuo and 
co-evaporated with toluene (3x). The product was dissolved in DMF (1.0 L) 
and to the solution was added BnBr (158 mL, 1.32 mol). The reaction 
mixture was cooled to 0 °C and to the cooled solution was added NaH (60% 
m/m) (31.7 g, 1.32 mol) in small portions over 6 h. The reaction mixture was 
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gradually warmed to rt and was stirred overnight at rt. The reaction mixture 
was cooled to 0 °C and quenched with MeOH. The solvent was removed in 
vacuo and the concentrate was dissolved in Et2O, washed with H2O (4x), 
brine (2x), dried over MgSO4, filtered and concentrated in vacuo. The crude 
was dissolved in DME/H2O (10:1) (1.5 L) and the solution was cooled to 0 
°C. To the cooled solution was added pTsOH (75 mmol, 14.3 g), after 3 h at 
0 °C the reaction was quenched with sat. NaHCO3 (aq.). Brine was added 
and the organic layer was separated. The product was extracted with DCM 
(3x) and the combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography yielded 
mannose 11 as a colourless oil (118.4 g, 240.4 mmol, 82% over 4 steps as an 
α/β mixture 10:1). Spectroscopic data were in accordance with known 
literature.
31
 Spectroscopic data are reported for the major (α) isomer: 
1
H 
NMR (400 MHz, CDCl3) δ 7.36 – 7.23 (m, 13H), 7.18 – 7.12 (m, 2H), 5.36 
(dd, J = 3.3, 1.9 Hz, 1H), 5.19 (s, 1H), 4.85 (d, J = 10.8 Hz, 1H), 4.69 (d, J = 
11.2 Hz, 1H), 4.59 (d, J = 12.1 Hz, 1H), 4.52 (d, J = 8.2 Hz, 1H), 4.49 (d, J 
= 9.1 Hz, 1H), 4.45 (d, J = 10.9 Hz, 1H), 4.09 – 4.05 (m, 1H), 4.03 (dd, J = 
9.3, 3.2 Hz, 1H), 3.74 (d, J = 9.6 Hz, 1H), 3.69 – 3.66 (m, 2H), 2.14 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ 170.6, 138.4, 138.0, 137.9, 128.5, 128.4, 
128.4, 128.3, 128.3, 128.2, 128.1, 128.1, 128.0, 127.9, 127.8, 92.5, 77.8, 
77.5, 77.1, 76.8, 75.2, 74.7, 73.5, 71.9, 71.2, 69.4, 69.2, 29.8, 21.3. 
 
2-O-Acetyl-3,4,6-tri-O-benzyl-1-O-(N-phenyl-trifluoroacetimidoyl)-α/β-
D-mannopyranoside (12): To a solution of mannose 11 
(24.6 g, 50 mmol) in acetone (200 mL) was added N-(p-
anisyl)-2,2,2-trifluoroacetimidoyl chloride (10.4 mL, 68.8 mmol) and cooled 
to 0 °C. To the cooled solution was added Cs2CO3 (20.7 g, 55 mmol) and the 
reaction mixture was allowed to warm to rt. After 6 h the solids were filtered 
over celite and the filtrate was concentrated in vacuo. Purification by column 
chromatography yielded trifluoro imidate donor 12 as a yellow oil (29.8 g, 
44.9 mmol, 90% as α/β mixture 5:0.2). [α]D
22
 + 26.4° (c = 1.0, DCM). FT-IR: 
vmax (neat)/cm
-1 




1489.32, 1597.42, 1716.21, 1749.15, 2867.10, 3031.71. Spectroscopic data 
are reported for the major (α) isomer: 
1
H NMR (400 MHz, CDCl3, T = 328 
°K) δ 7.38 – 7.01 (m, 18H), 6.79 (d, J = 7.4 Hz, 2H), 6.20 (s, 1H), 5.47 (dd, 
J = 3.2, 2.0 Hz, 1H), 4.87 (d, J = 10.9 Hz, 1H), 4.72 (d, J = 11.2 Hz, 1H), 
4.64 (d, J = 12.0 Hz, 1H), 4.57 (dd, J = 11.3 Hz, 2H), 4.51 (d, J = 12.0 Hz, 
1H), 4.01 (ddd, J = 8.3, 3.1, 1.3 Hz, 1H), 3.99 – 3.89 (m, 2H), 3.78 (dd, J = 
7.8, 3.7 Hz, 1H), 3.72 (dd, J = 11.2, 1.7 Hz, 1H), 2.11 (s, 3H). 
13
C NMR 
(100 MHz, CDCl3) δ 169.9, 143.4, 138.5, 138.4, 137.8, 128.9, 128.5, 128.5, 
128.3, 128.0, 127.8, 127.8, 127.7, 124.6, 119.6, 77.7, 75.4, 74.5, 74.0, 73.6, 





mannopyranoside (14): Trifluoro imidate 
donor 12 (19.9 g, 30 mmol) and acceptor 13 
(4.5 g, 10 mmol) were dissolved in DCM (200 
mL) and stirred over activated molecular 
sieves (3Å) at rt for 30 minutes. The solution was cooled to -40 °C and to the 
cooled solution was added Tf2O (0.18 mL, 2.0 mmol) and the reaction 
mixture was gradually allowed to warm to 0 °C. At 0 °C the reaction was 
quenched with TEA and the mixture was filtered over celite and rinsed with 
DCM. The organic phase was washed with H2O and the aqueous phase was 
extracted with DCM (4x). The combined organic layers were dried over 
MgSO4, filtered, concentrated in vacuo. Purification by column 
chromatography yielded trimer 14 as a colorless oil (11.76 g, 8.4 mmol, 
84%). [α]D
22
 + 64.6° (c = 1.0, DCM). FT-IR: vmax (neat)/cm
-1
 978.54, 
1026.58, 1049.14, 1078.97, 1232.74, 1367.72, 1453.88, 1742.59, 2866.77, 
3030.51. 
1
H NMR (400 MHz, CDCl3) δ 7.40 – 7.08 (m, 52H), 5.54 (s, 1H), 
5.51 (dd, J = 3.4, 1.8 Hz, 1H), 5.44 (dd, J = 3.0, 1.9 Hz, 1H), 5.22 (d, J = 1.9 
Hz, 1H), 4.92 (d, J = 1.8 Hz, 1H), 4.88 (d, J = 8.8 Hz, 1H), 4.85 (d, J = 8.5 
Hz, 1H), 4.76 (d, J = 11.1 Hz, 1H), 4.67 (d, J = 2.9 Hz, 1H), 4.64 (s, 1H), 
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4.63 (d, J = 11.8 Hz, 1H), 4.62 (d, J = 7.8 Hz, 1H), 4.60 (d, J = 9.7 Hz, 1H), 
4.56 – 4.40 (m, 9H), 4.38 (d, J = 11.2 Hz, 1H), 4.22 (dd, J = 9.8, 3.4 Hz, 
1H), 4.13 (s, 1H), 4.09 (dd, J = 9.3, 3.0 Hz, 1H), 4.02 (dd, J = 9.1, 3.3 Hz, 
1H), 3.96 – 3.86 (m, 5H), 3.83 (d, J = 9.4 Hz, 1H), 3.80 – 3.73 (m, 2H), 3.72 
– 3.66 (m, 3H), 3.64 (dd, J = 11.2, 1.9 Hz, 1H), 3.60 (dd, J = 10.7, 1.7 Hz, 
1H), 2.13 (s, 3H), 2.09 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ 170.4, 170.2, 
138.7, 138.6, 138.3, 138.0, 137.9, 137.9, 134.8, 131.0, 129.2, 128.6, 128.6, 
128.5, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 
127.6, 127.6, 127.3, 100.0, 98.3, 85.0, 79.2, 78.2, 77.9, 77.5, 77.2, 76.8, 
75.3, 75.1, 75.0, 74.5, 74.2, 73.7, 73.4, 73.4, 72.4, 72.3, 72.1, 72.0, 71.6, 
71.6, 71.6, 69.3, 68.9, 68.8, 68.5, 66.7, 21.3, 21.1. HRMS: [M+H]
+
 





mannopyranoside (15) To a suspension of 
NIS (1.25 g, 5.55 mmol) in DCE/THF (1:1) 
(27 mL) was added acetic acid (21.2 mL, 
370 mmol). To the NIS mixture was added 
a solution of trimer 14 (5.17 g, 3.7 mmol) in DCE/THF (1:1) (5 mL) and the 
reaction mixture was stirred overnight at rt. The reaction mixture was diluted 
with EtOAc, washed with 10% Na2S2O3 sol. (aq.) (2x), H2O, 3x sat (1x). 
NaHCO3 sol. (aq.) (1x), H2O (3x), brine (2X), dried over MgSO4, filtered 
and concentrated in vacuo. Purification by column chromatography yielded 
trimer 15 as a colorless oil (4.67 g, 3.5 mmol, 94%). [α]D
22
 + 50.0° (c = 1.0, 
DCM). FT-IR: vmax (neat)/cm
-1
 975.53, 1026.80, 1048.27, 1090.94, 1231.12, 
1368.81, 1453.91, 1496.72, 1743.42, 2870.34, 3031.12. 
1
H NMR (400 MHz, 
CDCl3) (α/β mixture, 1:0.4) δ 7.41 – 7.08 (m, 56H), 6.18 (d, J = 2.0 Hz, 1H), 
5.59 (s, 0.4H), 5.50 (ddd, J = 8.3, 3.3, 1.9 Hz, 2.8H), 5.20 (d, J = 1.8 Hz, 
1.4H), 4.96 (d, J = 1.9 Hz, 1H), 4.94 (d, J = 1.8 Hz, 0.4H), 4.89 (s, 1H), 4.86 




= 1.7 Hz, 1H), 4.70 (d, J = 2.0 Hz, 0.4H), 4.67 (s, 0.4H), 4.66 – 4.63 (m, 
2.4H), 4.62-4.60 (m, J = 1.9 Hz, 2H), 4.57 (d, J = 2.3 Hz, 0.4H), 4.54 (s, 
0.4H), 4.51 (s, 0.4H), 4.50 – 4.38 (m, 10H), 4.12 (dd, J = 9.6, 3.1 Hz, 1H), 
4.02 (ddd, J = 8.1, 5.2, 2.7 Hz, 2H), 4.00 – 3.83 (m, 8.4H), 3.84 – 3.78 (m, 
1H), 3.78 – 3.65 (m, 6H), 3.64 (s, 0.4H), 3.62 (t, J = 2.0 Hz, 0.8H), 3.59 (s, 
0.4H), 3.57 (s, 0.4H), 3.51 (ddd, J = 8.8, 4.4, 2.0 Hz, 0.4H), 2.35 (s, 1H), 





 MHz, CDCl3) δ 170.3, 170.3, 170.2, 170.1, 169.0, 
168.9, 138.6, 138.6, 138.5, 138.3, 138.1, 137.9, 137.8, 137.8, 137.6, 129.1, 
128.6, 128.5, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 127.9, 
127.9, 127.9, 127.9, 127.8, 127.7, 127.7, 127.7, 127.6, 127.6, 125.4, 100.1, 
99.7, 98.5, 98.3, 92.8, 90.8, 79.7, 78.1, 78.0, 77.7, 76.5, 76.3, 75.3, 75.2, 
75.1, 75.0, 74.7, 74.4, 74.3, 74.2, 74.1, 74.1, 74.0, 73.6, 73.5, 73.5, 73.4, 
72.4, 72.2, 72.1, 72.0, 72.0, 71.7, 71.6, 71.5, 71.3, 69.2, 69.0, 68.8, 68.7, 
68.6, 68.6, 68.4, 68.3, 66.4, 66.3, 21.3, 21.1, 21.0. HRMS: [M+H]
+
 




mannopyranoside (17): Trimer 15 (2.5 
mmol, 3.38 g) was dissolved in an 
EtOAc/tBuOH/H2O (1:3:4) mixture (50 mL) 
and the solution was purged with argon. To 
the solution was added cat. Pd/C (10%) and stirred at rt under H2 (g) 
atmosphere. After TLC showed complete conversion to a single spot the 
Pd/C was filtered over a pad of celite, rinsed with MeOH and the filtrate was 
concentrated in vacuo. Proton NMR of the crude showed the presence of 
aromatic signals. The crude was taken up in H2O (50 mL) and purged with 
argon. To the solution was added cat. Pd/C (10%) and stirred at rt under H2 
(g) atmosphere overnight. The Pd/C was filtered over a pad of celite, rinsed 
with H2O and the filtrate was concentrated in vacuo. Proton NMR of the 
crude showed complete removal of aromatic signals and the crude was co-
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evaporated with 1,4-dioxane (3x). The crude was dissolved in pyridine (25 
mL) and the solution was cooled to 0 °C. To the cooled solution was added 
acetic anhydride (2.5 mL) and the reaction mixture was gradually allowed to 
warm to rt. After complete conversion, the reaction mixture was cooled to 0 
°C, quenched with MeOH and concentrated in vacuo. The crude product was 
dissolved in EtOAc and washed with 1M HCl (aq.) (1x), sat. NaHCO3 (aq.) 
(1x), H2O (3x), brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded per-O-acetylated 
trimer 17 as a colorless oil (1.81 g, 1.9 mmol, 76%). [α]D
22
 + 40.4° (c = 1.0, 
DCM). FT-IR: vmax (neat)/cm
-1
 975.27, 1039.52, 1139.46, 1212.30, 1368.79, 
1433.73, 1741.84, 2925.08. 
1
H NMR (300 MHz, CDCl3) (α/β mixture, 
1:0.25) δ 6.05 (d, J = 1.9 Hz, 1H), 5.81 (s, 0.25H), 5.48 (d, J = 3.2 Hz, 
0.25H), 5.27 (dd, J = 8.8, 2.7 Hz, 4.4H), 5.04 (d, J = 2.6 Hz, 2H), 5.02 (s, 
0.4H), 4.80 (s, 1.2H), 4.35 – 4.20 (m, 3.4H), 4.19 – 4.00 (m, 7.2H), 3.90 (dq, 
J = 10.0, 3.1 Hz, 1H), 3.75 (dd, J = 11.0, 5.5 Hz, 1H), 3.57 (dd, J = 10.9, 3.2 
Hz, 1H), 2.27 (s, 0.8H), 2.25 (s, 2.6H), 2.18 (s, 4H), 2.16 (d, J = 2.1 Hz, 
12H), 2.11 (s, 7H), 2.07 (s, 5.5H), 2.05 (s, 3H), 2.00 (s, 4H), 1.99 (s, 4.5H). 
13
C NMR (75 MHz, CDCl3) δ 170.7, 170.6, 170.3, 170.1, 170.0, 170.0, 
169.9, 169.8, 169.6, 99.2, 97.6, 90.4, 74.7, 71.5, 69.9, 69.6, 69.5, 69.3, 69.1, 
68.5, 68.2, 67.9, 66.9, 65.8, 62.4, 62.3, 60.4, 20.9, 20.9, 20.8, 20.7, 20.7. 
HRMS: [M+H]
+




mannopyranoside (18): To a solution 
of per-O-acetylated trimer 17 (29 mg, 30 
µmol) in DCM ( 300 µL) was added a 
0.6M propargyl alcohol solution (150 
µL, 90 µmol) in DCM and a 0.3M 
BF3·Et2O solution (150 µl, 45 µmol) in DCM. The mixture was heated to 50 
°C for 6 h after which the reaction mixture was cooled to rt, diluted with 




organic phase was transferred to the top phase. The organic phase was 
washed with sat. NaHCO3 (2x), H2O (3x), brine (2x), dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography 
yielded per-O-acetylated propargyl trimer 18 as a white milky oil (17.6 mg, 
18.3 µmol, 61%). [α]D
22
 + 80.4° (c = 1.0, DCM). FT-IR: vmax (neat)/cm
-1 
978.00, 1038.64, 1136.67, 1214.43, 1368.90, 1433.77, 1741.73, 2926.85. 
1
H 
NMR (400 MHz, CDCl3) δ 5.35 – 5.17 (m, 7H), 5.04 – 4.98 (m, 3H), 4.82 
(d, J = 1.8 Hz, 1H), 4.29 – 4.25 (m, 3H), 4.24 (s, 1H), 4.21 (dd, J = 9.9, 3.5 
Hz, 1H), 4.16 (t, J = 2.6 Hz, 1H), 4.13 (d, J = 2.4 Hz, 1H), 4.11 (d, J = 1.9 
Hz, 1H), 4.10 – 4.06 (m, 1H), 3.88 (ddd, J = 9.7, 6.6, 2.5 Hz, 1H), 3.78 (dd, 
J = 10.8, 6.6 Hz, 1H), 3.53 (dd, J = 10.8, 2.5 Hz, 1H), 2.50 (t, J = 2.4 Hz, 
1H), 2.23 (s, 3H), 2.16 (s, 3H), 2.14 – 2.13 (m, 9H), 2.12 (s, 3H), 2.06 (s, 
3H), 2.05 (d, J = 1.1 Hz, 3H), 1.99 (s, 3H), 1.98 (s, 3H). 
13
C NMR (100 
MHz, CDCl3) δ 170.9, 170.8, 170.6, 170.3, 170.2, 170.2, 170.1, 169.9, 
169.74, 99.0, 97.4, 96.0, 78.1, 75.7, 74.1, 70.8, 70.2, 70.1, 69.6, 69.5, 69.2, 
68.8, 68.4, 68.4, 67.0, 66.1, 66.1, 62.6, 62.5, 54.8, 21.0, 21.0, 20.9, 20.9, 
20.9, 20.8, 20.8. HRMS: [M+H]
+




mannopyranoside (19): To a solution of 
per-O-acetylated propargyl trimer 18 (18.3 
mg, 17.6 µmol) in MeOH (370 µL) was 
added a 5 mM sol. NaOMe (370 µL, 
m1.83 µmol) in MeOH. After complete 





The solids were filtered and the filtrate was concentrated in vacuo. 
Purification by column chromatography followed by lyophilisation yielded 
propargyl trimer 19 as a white powder (6.2 mg, 11.3 µmol, 61%). [α]D
22
 + 
114.0° (c = 1.0, MeOH). FT-IR: vmax (neat)/cm
-1
 981.81, 1042.80, 1131.53, 
1363.00, 2490.41, 2929.08, 3285.13. 
1
H NMR (400 MHz, MeOD) δ 5.06 (s, 
1H), 4.91 (d, J = 1.8 Hz, 1H), 4.84 (d, J = 1.8 Hz, 1H), 4.26 (t, J = 2.3 Hz, 
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2H), 4.04 (dd, J = 3.1, 1.8 Hz, 1H), 3.98 (dd, J = 3.3, 1.7 Hz, 1H), 3.94 (dd, 
J = 11.1, 5.2 Hz, 1H), 3.89 – 3.84 (m, 3H), 3.84 – 3.81 (m, 2H), 3.81 – 3.78 
(m, 2H), 3.78 – 3.65 (m, 5H), 3.65 – 3.58 (m, 3H), 2.88 (t, J = 2.5 Hz, 1H). 
13
C NMR (100 MHz, MeOD) δ 104.0, 101.5, 100.2, 80.7, 79.9, 76.2, 74.9, 
74.4, 73.8, 72.6, 72.4, 72.1, 72.0, 71.2, 68.7, 68.5, 67.3, 67.1, 62.8, 55.0. 
HRMS: [M+H]
+
 calculated for C21H35O16 543.19196, found 543.19224.  
 
Acetyl 2,4-O-Benzyl-α-D-mannopyranoside (20a): To a 0 °C cooled 
solution of NIS (0.25 g, 1.1 mmol) in DCM/AcOH (1:1) (20 
mL) was added dropwise a 0.1M solution of thio mannose 13 
(10 mL, 1.0 mmol) in DCM. The reaction mixture was stirred at 0 °C for 1 h 
and allowed to warm to rt. After complete consumption of the starting 
material the reaction was quenched with 10% Na2S2O3 (aq.) and the product 
was extracted with EtOAc (4x). The combined organic phases were washed 
with H2O (2x), sat. NaHCO3 (aq.) (3x), H2O (3x), brine (2x), dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography yielded α-O-acetyl mannose 20a as a colourless amorphous 
solid (0.15 g, 0.4 mmol, 40%). [α]D
22
 + 14.6° (c = 1.0, DCM). FT-IR: vmax 
(neat)/cm
-1
 1026.60, 1071.89, 1239.98, 1366.52, 1454.28, 1496.96, 1720.48, 
2930.75, 3031.24, 3420.07. 
1
H NMR (400 MHz, CDCl3) δ 7.40 – 7.25 (m, 
10H), 6.20 (d, J = 1.8 Hz, 1H), 4.90 (d, J = 11.1 Hz, 1H), 4.76 (d, J = 11.7 
Hz, 1H), 4.66 (d, J = 11.0 Hz, 1H), 4.59 (d, J = 11.7 Hz, 1H), 3.99 (d, J = 
7.0 Hz, 1H), 3.83 (dd, J = 12.1, 2.6 Hz, 1H), 3.80 – 3.73 (m, 2H), 3.72 – 
3.65 (m, 2H), 2.52 (s, 1H), 2.32 (s, 1H), 2.05 (s, 3H). 
13
C NMR (100 MHz, 
CDCl3) δ 169.3, 138.2, 137.25, 128.7, 128.7, 128.3, 128.1, 128.1, 128.0, 
91.0, 77.0, 75.6, 75.2, 74.0, 73.1, 71.4, 61.8, 21.0. HRMS: [M+H]
+
 












(21): Trimer donor 
14 (4.2 g, 3 mmol) 
and acceptor 20a 
(402 mg, 1 mmol) 
were dissolved in 
DCM (20 mL) and stirred over activated molecular sieves (3Å) at rt for 30 
minutes. To the solution was added NIS (0.74 g, 3.3 mmol) and stirred at rt. 
After 15 minutes the reaction mixture was cooled to -40 °C and TfOH (0.3 
mmol, 27 µL) was added to the mixture. The reaction mixture was gradually 
warmed to rt and quenched with Et3N. The mixture was filtered over celite 
and diluted with DCM. The organic phase was washed with 10% Na2S2O3 
(aq.) and the aqueous phase was extracted with DCM (5x). The combined 
organic layers were washed with H2O (1x), brine (1x), dried over MgSO4, 
filtered and concentrated in vacuo. Purification by size exclusion 
(DCM/MeOH, 1:1) yielded benzylated heptamer 21 as a colourless oil 
(1.835 g, 0.62 mmol, 62%). [α]D
22
 + 43.6 (c = 1.0, DCM). FT-IR: vmax 
(neat)/cm
-1
 977.68, 1026.77, 1051.75, 1232.44, 1368.31, 1453.93, 1496.62, 
1742.78, 2868.56, 3032.00. 
1
H NMR (400 MHz, CDCl3) δ 7.36 – 7.07 (m, 
90H), 6.17 (d, J = 1.8 Hz, 1H), 5.54 – 5.46 (m, 4H), 5.21 (s, 3H), 4.97 (d, J = 
1.8 Hz, 1H), 4.93 (s, 1H), 4.90 (s, 1H), 4.84 (dt, J = 10.5, 5.2 Hz, 5H), 4.75 – 
4.69 (m, 3H), 4.64 (d, J = 3.8 Hz, 1H), 4.63 – 4.46 (m, 12H), 4.46 – 4.35 (m, 
14H), 4.34 (d, J = 2.2 Hz, 2H), 4.24 (d, J = 12.1 Hz, 1H), 4.15 (ddd, J = 
18.1, 9.2, 3.0 Hz, 2H), 4.05 (dd, J = 9.2, 3.2 Hz, 2H), 3.95 (d, J = 8.9 Hz, 
2H), 3.93 – 3.82 (m, 10H), 3.83 – 3.71 (m, 3H), 3.71 – 3.46 (m, 15H), 3.39 
(dd, J = 10.8, 5.9 Hz, 2H), 2.12 (s, 6H), 2.06 (s, 3H), 2.04 (s, 3H), 2.02 (s, 
3H). 
13
C NMR (100 MHz, CDCl3) δ 170.3, 170.2, 170.1, 170.1, 169.0, 
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138.8, 138.7, 138.6, 138.5, 138.3, 138.3, 138.2, 138.2, 138.2, 138.0, 138.0, 
137.9, 137.9, 137.9, 137.8, 137.2, 128.7, 128.6, 128.6, 128.5, 128.4, 128.4, 
128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 
127.8, 127.8, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 127.6, 127.5, 127.5, 
127.4, 127.4, 127.2, 127.1, 99.7, 98.5, 98.3, 97.2, 90.7, 78.3, 78.2, 78.0, 
77.5, 77.2, 76.8, 76.4, 75.2, 75.1, 74.9, 74.9, 74.6, 74.5, 74.2, 74.1, 74.1, 
73.8, 73.45, 73.4, 73.4, 72.3, 72.1, 72.0, 72.0, 71.9, 71.8, 71.8, 71.6, 71.6, 







α-D-mannopyranosyl)-α-D-mannopyranoside (23): Benzylated heptamer 
21 (896 mg, 0.3 
mmol) was dissolved 
in EtOAc/MeOH/H2O 
(5:4:1) (6 mL) and the 
solution was purged 
with argon. To the 
solution was added cat. Pd/C (10%) and the mixture was stirred overnight at 
rt under H2 (g) atmosphere. The Pd/C was filtered over celite, rinsed with 
methanol and concentrated in vacuo. Proton NMR of the crude showed the 
presence of aromatic signals. The crude was taken up in MeOH/H2O (1:1) (6 
mL) and purged with argon. To the solution was added cat. Pd/C (10%) and 
stirred at rt under H2 (g) atmosphere overnight. the Pd/C was filtered over a 
pad of celite, rinsed with MeOH and the filtrate was concentrated in vacuo. 
Proton NMR of the crude showed complete removal of aromatic signals. The 
debenzylated intermediate was co-evaporated with pyridine (3x), dissolved 
in pyridine (10 mL) and the solution was cooled to 0 °C. To the cooled 




allowed to warm to rt. After complete conversion of the starting material the 
mixture was cooled to 0 °C and the reaction was quenched with MeOH. The 
reaction mixture was concentrated in vacuo and the crude was dissolved in 
EtOAc. The organic phase was washed with 1M HCl (aq.) (1x), sat. 
NaHCO3 (aq.) (2x), H2O (3x), brine (3x), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography yielded per-
acetylated heptamer 23 as a colourless amorphous solid (635.2 mg, 0.3 
mmol, quantitative yield). FT-IR: vmax (neat)/cm
-1
 976.88, 1038.56, 1084.01, 
1138.17, 1213.21, 1369.06, 1432.60, 1742.41, 2935.07. 
1
H NMR (400 MHz, 
CDCl3) δ 5.98 (d, J = 1.9 Hz, 1H), 5.37 – 5.17 (m, 13H), 5.15 (s, 1H), 5.10 – 
5.04 (m, 2H), 5.01 (s, 2H), 4.99 (s, 2H), 4.93 (s, 1H), 4.88 – 4.78 (m, 2H), 
4.28 (dtd, J = 18.4, 10.1, 8.2, 4.0 Hz, 4H), 4.20 – 3.86 (m, 13H), 3.85 – 3.65 




 MHz, CDCl3) δ 170.7, 170.6, 170.6, 170.6, 170.5, 170.5, 
170.4, 170.4, 170.3, 170.2, 170.0, 170.0, 169.9, 169.9, 169.8, 169.8, 169.8, 
169.7, 169.7, 169.6, 169.6, 169.6, 169.5, 169.5, 168.4, 168.0, 99.6, 99.2, 
99.0, 98.7, 97.4, 97.3, 90.5, 90.5, 77.5, 76.0, 75.6, 75.3, 75.2, 75.0, 74.7, 
73.4, 71.4, 70.9, 70.8, 70.7, 70.6, 70.1, 70.0, 69.8, 69.8, 69.6, 69.5, 69.4, 
69.4, 69.3, 69.1, 69.0, 69.0, 68.8, 68.7, 68.5, 68.5, 68.4, 67.7, 67.5, 67.5, 
67.2, 66.9, 66.3, 66.0, 65.9, 65.8, 65.7, 65.6, 62.3, 62.2, 62.1, 62.0, 20.8, 
20.8, 20.8, 20.8, 20.7, 20.7, 20.6, 20.6, 20.6, 20.5. MALDI: [M+H]
+
 








(24): To a 0 °C cooled 
solution of per-acetylated 
heptamer 23 (0.498 g, 
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0.235 mmol) in DMF (2.8 mL) was added hydrazine acetate (23.3 mg, 0.259 
mmol). The reaction was stirred at 0 °C for 1 h and 30 minutes at rt. After 
TLC showed complete conversion the reaction was quenched with acetone 
and the reaction mixture was concentrated in vacuo. The crude was 
dissolved in Et2O and the organic phase was washed with brine (3x), dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography yielded 1-OH acetylated heptamer 24 as a white amorphous 
solid (0.384 g, 0.186 mmol, 79%). FT-IR: vmax (neat)/cm
-1 
978.58, 1038.62, 
1081.66, 1137.06, 1215.09, 1369.26, 1433.38, 1741.35, 2926.28. 
1
H NMR 
(400 MHz, CDCl3) δ 5.37 (dd, J = 3.4, 1.6 Hz, 1H), 5.33 – 5.24 (m, 8H), 
5.21 (dd, J = 10.4, 3.2 Hz, 2H), 5.17 (d, J = 3.0 Hz, 2H), 5.11 (t, J = 10.1 Hz, 
1H), 5.07 – 5.02 (m, 3H), 4.99 (dd, J = 4.8, 1.8 Hz, 2H), 4.95 (s, 1H), 4.86 – 
4.82 (m, 3H), 4.76 (d, J = 5.0 Hz, 1H), 4.37 – 4.22 (m, 4H), 4.18 (dd, J = 
9.8, 3.4 Hz, 1H), 4.15 – 3.96 (m, 12H), 3.94 (ddd, J = 9.7, 5.0, 2.2 Hz, 1H), 
3.86 (ddd, J = 10.2, 6.0, 2.5 Hz, 1H), 3.76 (tt, J = 7.6, 2.7 Hz, 3H), 3.55 (dd, 
J = 11.4, 3.2 Hz, 1H), 3.51 (dd, J = 11.4, 3.2 Hz, 1H), 3.47 (d, J = 9.5 Hz, 
1H), 2.21 (s, 3H), 2.18 (s, 3H), 2.17 – 2.13 (m, 24H), 2.13 – 2.11 (m, 12H), 
2.06 (s, 3H), 2.05 – 2.03 (m, 9H), 2.00 – 1.97 (m, 12H). 
13
C NMR (100 
MHz, CDCl3) δ 171.1, 170.9, 170.8, 170.8, 170.7, 170.5, 170.5, 170.5, 
170.4, 170.3, 170.2, 170.2, 170.1, 170.1, 167.0, 169.9, 169.9, 169.8, 169.7, 
169.7, 99.5, 99.2, 99.0, 97.9, 97.6, 97.4, 91.4, 77.5, 77.2, 76.8, 75.3, 75.0, 
74.5, 72.7, 70.9, 70.8, 70.1, 70.0, 69.9, 69.7, 69.6, 69.6, 69.5, 69.4, 69.3, 
69.2, 68.6, 68.5, 68.5, 68.4, 68.2, 68.1, 67.7, 67.3, 66.8, 66.7, 66.3, 66.0, 
65.7, 62.4, 62.3, 62.2, 62.1, 21.2, 21.1, 21.0, 21.0, 20.9, 20.8, 20.8, 20.7. 
HRMS: [M+H]
+











(25): To a solution of 
1-OH acetylated 
heptamer 24 (56.9 
mg, 27.4 µmol) in 
acetone (274 µL) 
was added a 0.15M N-phenyl trifluoroacetimidoyl chloride solution (274 µL, 
41.1 µmol) in acetone. To the reaction mixture was added Cs2CO3 (15.5 mg, 
41.1 µmol) and the mixture was stirred at rt till TLC showed complete 
conversion of the starting material. The reaction mixture was concentrated in 
vacuo and directly purified without further work up. Purification by column 
chromatography yielded heptamer imidate donor 25 as a slightly yellow oil 
(61.6 mg, quantitative yield). FT-IR: vmax (neat)/cm
-1 
1040.72, 1084.61, 
1138.28, 1215.66, 1370.23, 1435.52, 1674.33, 1743.57, 2854.33, 2924.27. 
1
H NMR (400 MHz, CDCl3) δ 7.28 (t, J = 7.5 Hz, 2H), 7.09 (t, J = 7.5 Hz, 
1H), 6.85 (d, J = 7.7 Hz, 2H), 5.40 – 5.16 (m, 16H), 5.10 – 5.05 (m, 2H), 
5.04 – 4.95 (m, 4H), 4.91 (s, 1H), 4.84 (d, J = 1.7 Hz, 1H), 4.81 (s, 1H), 4.36 
– 4.22 (m, 4H), 4.22 – 3.88 (m, 13H), 3.87 – 3.79 (m, 1H), 3.79 – 3.70 (m, 
3H), 3.60 – 3.46 (m, 3H), 2.25 – 2.01 (m, 54H), 2.01 – 1.95 (m, 9H), 1.92 (s, 
3H). 
13
C NMR (100 MHz, CDCl3) δ 170.8, 170.7, 170.7, 170.7, 170.5, 
170.2, 170.1, 170.1, 170.1, 167, 167.0, 169.9, 169.8, 169.8, 169.7, 169.7, 
169.5, 143.2, 128.9, 124.7, 119.5, 99.6, 99.4, 99.1, 97.6, 97.6, 75.5, 75.2, 
71.9, 70.8, 70.8, 70.0, 69.9, 69.9, 69.8, 69.6, 69.5, 69.5, 69.4, 69.1, 68.7, 
68.7, 68.6, 68.6, 67.8, 67.4, 66.8, 66.4, 66.1, 66.0, 65.9, 65.7, 62.5, 62.2, 
62.1, 29.8, 21.0, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7, 20.6.  
 









imidate donor 25 
(43.9 mg, 19.5 
µmol) was 
dissolved in a 
0.274M propargyl 
alcohol solution (356 µL, 97.5 µmol) in DCM and the mixture was stirred 
over activated molecular sieves (3Å) for 30 min. at rt. After 30 min. the 
mixture was cooled to -40 °C and to the cooled mixture was added a 0.1M 
TfOH solution (36 µL, 3.9 µmol) in DCM and the reaction mixture was 
gradually warmed to 0 °C. The reaction was quenched with a 0.1M Et3N 
solution (0.1 mL) in DCM and the solution was filtered over celite and 
concentrated in vacuo. Purification by column chromatography yielded per-
acetylated propagyl mannose heptamer 25 as a white milky oil (16.5 mg, 7.8 
µmol, 40%). FT-IR: vmax (neat)/cm
-1
 1037.06, 1136.93, 1214.09, 1369.36, 
1433.95, 1740.68, 2926.41. 
1
H NMR (600 MHz, CDCl3) δ 5.35 (dd, J = 9.9, 
3.5 Hz, 1H), 5.33 – 5.32 (m, 1H), 5.29 – 5.22 (m, 7H), 5.21 (dd, J = 10.0, 3.4 
Hz, 2H), 5.19 – 5.16 (m, 1H), 5.07 (dd, J = 3.0, 1.9 Hz, 1H), 5.05 (dd, J = 
3.4, 1.8 Hz, 1H), 5.00 – 4.97 (m, 3H), 4.97 – 4.94 (m, 3H), 4.92 – 4.89 (m, 
1H), 4.85 (d, J = 1.8 Hz, 1H), 4.84 (d, J = 1.9 Hz, 1H), 4.32 – 4.23 (m, 6H), 
4.17 (td, J = 10.0, 3.4 Hz, 2H), 4.14 – 4.09 (m, 2H), 4.08 (s, 1H), 4.07 – 3.99 
(m, 4H), 3.97 (dd, J = 9.9, 3.4 Hz, 2H), 3.97 – 3.88 (m, 3H), 3.87 (ddd, J = 
10.3, 5.2, 2.7 Hz, 1H), 3.75 (dq, J = 10.8, 5.5 Hz, 3H), 3.71 (d, J = 5.6 Hz, 
1H), 3.56 (dd, J = 11.4, 2.2 Hz, 1H), 3.53 (d, J = 2.6 Hz, 1H), 3.52 (d, J = 
2.6 Hz, 1H), 2.52 (t, J = 2.4 Hz, 1H), 2.21 (s, 3H), 2.19 (s, 3H), 2.17 (s, 3H), 
2.16 – 2.13 (m, 21H), 2.12 – 2.11 (m, 12H), 2.06 (s, 3H), 2.06 (s, 3H), 2.04 






NMR (150 MHz, CDCl3) δ 171.1, 171.0, 170.9, 170.8, 170.8, 170.8, 170.8, 
170.8, 170.6, 170.6, 170.6, 170.5, 170.4, 170.3, 170.3, 170.2, 170.2, 170.2, 
170.2, 170.1, 170.1, 170.1, 170.0, 170.0, 170.0, 170.0, 169.9, 169.9, 169.8, 
169.8, 169.8, 169.7, 99.4, 99.2, 97.8, 97.7, 97.3, 96.6, 78.8, 75.6, 75.5, 75.3, 
75.0, 71.2, 71.0, 70.9, 70.3, 70.0, 70.0, 69.8, 69.6, 69.6, 69.5, 69.5, 69.5, 
69.3, 69.2, 68.8, 68.7, 68.6, 68.6, 68.0, 67.8, 67.6, 66.8, 66.8, 66.4, 66.1, 
66.1, 66.0, 66.0, 65.8, 62.5, 62.3, 62.2, 55.0, 21.0, 21.0, 21.0, 21.0, 20.9, 
20.9, 20.9, 20.9, 20.8, 20.8, 20.8, 20.8. HRMS: [M+H]
+
 calculated for 




mannopyranosyl)-α-D-mannopyranosyl)-α-D-mannopyranoside (27): To 
a solution of per-O-
acetylated propargyl 
mannose heptamer 26 
(16.5 mg, 7.8 µmol) 
in MeOH (156 µL) 
was added a 125mM 
NaOMe (156 µL, 3.9 µmol) solution in MeOH and the reaction was stirred 
overnight at rt. TLC-MS analysis showed incomplete deacetylation of the 





(pH≤7). The crude was taken up in H2O (0.5 mL) and a 0.2M NaOH (aq.) 
(0.5 mL) solution was added to the solution. The reaction was followed on 





 (pH≤7). Solids were filtered and the filtrate was concentrated in 
vacuo. The product was lyophilized from H2O without further purification 
yielding propargyl mannose heptamer 27 as a white powder (9.3 mg, 7.8 
µmol, quantitative yield). 
1
H NMR (600 MHz, D2O) δ 5.17 (d, J = 1.8 Hz, 
1H), 5.14 (d, J = 1.8 Hz, 1H), 5.07 (d, J = 1.8 Hz, 1H), 5.02 (d, J = 1.8 Hz, 
1H), 4.92 (d, J = 1.8 Hz, 1H), 4.91 (d, J = 1.8 Hz, 1H), 4.88 (d, J = 1.9 Hz, 
1H), δ 4.36 (s, 2H), 4.26 (dd, J = 3.3, 1.8 Hz, 1H), 4.16 (dd, J = 3.3, 1.8 Hz, 
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1H), 4.11 (dd, J = 3.2, 1.7 Hz, 1H), 4.08 (dt, J = 3.6, 1.9 Hz, 2H), 4.03 (dd, J 
= 9.6, 3.5 Hz, 1H), 4.01 – 3.97 (m, 5H), 3.96 – 3.92 (m, 2H), 3.92 – 3.87 (m, 
11H), 3.87 – 3.83 (m, 2H), 3.80 – 3.72 (m, 8H), 3.70 (ddd, J = 12.6, 7.3, 2.1 
Hz, 4H), 3.67 (s, 2H), 3.65 (s, 1H). 
13
C NMR (150 MHz, D2O) δ 103.8, 
103.7, 103.5, 100.8, 100.7, 100.6, 100.3, 80.1, 79.7, 79.7, 74.70, 74.6, 74.0, 
73.9, 73.1, 72.7, 72.2, 71.9, 71.9, 71.7, 71.4, 71.3, 71.3, 71.2, 70.9, 70.9, 
70.8, 68.1, 68.1, 68.0, 67.1, 67.1, 66.8, 66.7, 66.6, 66.4, 62.4, 62.2, 56.2. 
HRMS: [M+H]
+
 calculated for C45H75O36 1191.40325, found 1191.40308. 
 
Man1-BODIPY-DCG-
04 (2): To a solution of 
propargyl mannose 7 
(1.75 mg, 8 µmol) and 
BODIPY-DCG-04 (5) 
(8.6 mg, 7.6 µmol) in 
DMF/H2O (1:1) (3 mL) 
was added 0.1 M sodium 
ascorbate (aq.) (160 µL, 
16 µmol) and 0.1M CuSO4 (aq.) (16 µL, 1.6 µmol). The resulting mixture 
was stirred for 2 h at room temperature, before being concentrated and co-
evaporated with toluene. Purification by HPLC-MS (A: 25 mM NH4OAc, B: 
linear gradient 20 35% ACN in12’) followed by lyophilization from H2O 
yielded Man1-BODIPY-DCG-04 (2) (4.3 mg, 3.2 μmol, 42%). 
1
H NMR (600 
MHz, CDCl3/MeOD): δ 8.02 (s, 1H), 7.92 (t, J = 5.6 Hz, 1H), 7.86 (d, J = 
7.5 Hz, 2H), 7.83 (d, J = 7.6 Hz, 1H), 7.76 (t, J = 5.6 Hz, 1H), 7.40 (s, 1H), 
7.06 (d, J = 4.1 Hz, 1H), 7.01 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H,), 
6.69 (d, J = 8.5 Hz, 2H, 2), 6.59 (d, J = 4.1 Hz, 1H), 4.80 (d, J = 12.4 Hz, 
1H), 4.67 - 4.60 (m, 3H, CH2), 4.45 (t, J = 7.5 Hz, 1H), 4.40 - 4.36 (m, 1H), 
4.30 - 4.19 (m, 3H), 4.08 (t, J = 5.8 Hz, 2H), 3.85 (dd, J = 11.8, 2.1 Hz, 1H), 
3.82 - 3.77 (m, 1H), 3.74 - 3.65 (m, 3H), 3.64 - 3.55 (m, 3H), 3.15 - 3.11 (m, 
3H), 3.06 - 3.01 (m, 1H), 2.99 - 2.93 (m, 1H), 2.86 - 2.80 (m, 1H), 2.75 (t, J 




2H), 2.25 (s, 3H), 2.21 - 2.16 (m, 2H), 1.78 - 1.69 (m, 1H), 1.62 - 1.48 (m, 
6H), 1.46 - 1.41 (m, 2H), 1.41 - 1.35 (m, 2H), 1.31 - 1.29 (m, 5H), 1.22 - 
1.15 (m, 2H), 0.92 (d, J = 6.4 Hz, 3H), 0.88 (d, J = 6.4 Hz, 3H,). 
13
C NMR 
(150 MHz, CDCl3/MeOD): δ 177.02, 176.02, 174.68, 173.56, 172.96, 
168.66, 168.31, 160.68, 160.59, 157.16, 156.37, 145.22, 141.69, 136.49, 
135.67, 131.84, 131.81, 131.78, 131.68, 131.30, 129.27, 128.81, 127.14, 
125.60, 124.63, 119.12, 116.19, 115.14, 100.70, 74.84, 72.42, 71.93, 68.54, 
65.67, 63.19, 62.90, 60.64, 56.36, 54.34, 54.11, 53.33, 53.14, 48.49, 41.56, 
40.15, 40.12, 38.14, 36.86, 36.58, 32.64, 30.93, 29.87, 29.74, 27.32, 26.39, 
25.80, 24.17, 23.29, 22.02, 21.29, 14.35, 13.28, 9.62. HRMS: [M+H]
+
 
calculated for C65H89BF2N11O17 1344.64935, found 1344.65139. 
 
 
Man3-BODIPY-DCG-04 (3): To a solution of propargyl mannoside 19 (2.4 
mg, 4.5 µmol) and BODIPY-DCG-04 (5) (5.12 mg, 4.5 µmol) in DMF/H2O 
(1:1) (2 mL) was added 0.1M sodium ascorbate (aq.) (90 µl, 9 µmol) and 
0.1M CuSO4 (aq.) (2.2 µL, 0.22 µmol). The resulting mixture was stirred for 
1 h at room temperature, before being concentrated and co-evaporated with 
toluene. Purification by HPLC-MS (A: 25 mM NH4OAc, B: linear gradient 
20  35% ACN in 12’) followed by lyophilization from H2O yielded Man3-
BODIPY-DCG-04 (3) (1.8 mg, 1.1 μmol, 24 %) 
1
H NMR (600 MHz, 
MeOD): δ 8.08 (s, 1H), 7.88 (d, J = 8.9 Hz, 2H,), 7.43 (s, 1H), 7.07 (d, J = 
4.0 Hz, 1H), 7.01 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.9 Hz, 2H), 6.69 (d, J = 
8.5 Hz, 2H), 6.62 (d, J = 4.1 Hz, 1H), 5.05 (s, 1H), 4.85 - 4.77 (m, 3H), 4.69 
- 4.61 (m, 3H), 4.45 (t, J = 7.6 Hz, 1H), 4.38 (dd, J = 9.3, 5.7 Hz, 1H), 4.29 - 
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4.23 (m, 3H), 4.09 (t, J = 5.9 Hz, 2H), 4.05 (d, J = 2.5 Hz, 1H), 3.98 - 3.90 
(m, 2H), 3.88 - 3.54 (m, 17H), 3.16 - 3.09 (m, 3H), 3.07 - 2.99 (m, 1H), 2.99 
- 2.93 (m, 1H), 2.86 - 2.80 (m, 1H), 2.76 (t, J = 7.3 Hz, 2H), 2.51 (s, 3H), 
2.42 (p, J = 6.5 Hz, 2H), 2.33 (t, J = 7.3 Hz, 2H), 2.26 (s, 3H), 2.20 - 2.14 
(m, 2H), 1.77 - 1.70 (m, 1H), 1.64 - 1.47 (m, 6H), 1.47 - 1.41 (m, 2H), 1.41 - 
1.35 (m, 2H), 1.32 - 1.29 (m, 5H), 1.20 - 1.15 (m, 2H), 0.92 (d, J = 6.4 Hz, 
3H), 0.88 (d, J = 6.4 Hz, 3H). 
13
C NMR (150 MHz, MeOD): δ 177.14, 
176.13, 174.79, 173.69, 173.08, 168.74, 168.43, 165.61, 163.01, 160.81, 
160.67, 157.29, 156.48, 150.29, 145.18, 142.19, 136.59, 135.75, 131.90, 
131.77, 131.36, 129.35, 128.91, 127.23, 125.71, 124.73, 119.16, 116.24, 
115.22, 103.97, 101.33, 100.79, 80.67, 74.96, 74.39, 73.70, 72.66, 72.46, 
72.10, 71.27, 68.80, 68.64, 67.48, 67.14, 65.75, 63.23, 62.91, 60.71, 56.47, 
54.38, 54.21, 53.42, 53.19, 41.62, 40.20, 38.19, 36.91, 36.63, 32.71, 31.05, 
29.95, 29.82, 27.40, 26.48, 25.88, 24.25, 23.30, 22.02, 21.34, 14.35, 9.59. 
LC/MS analysis (linear gradient 10%  90% ACN) tR: 6.53 min, ESI-MS 
(m/z): [M + H]+: 1668.40. 
 
 
Man7-BDP-DCG-04 (4): To a solution of propargyl mannoside 27 (4 mg, 
3.4 µmol) and BODIPY-DCG-04 (5) (3.8 mg, 3.4 µmol) in DMF/H2O (1:1) 
(2 mL) was added 0.1M sodium ascorbate (aq.) (68 µL, 6.8 µmol) and 0.1M 
CuSO4 (aq.) (6.8 µL, 0.68 µmol). The resulting mixture was stirred for 8 h at 
room temperature, before being concentrated and co-evaporated with 
toluene. Purification by HPLC-MS (A: 25 mM NH4OAc, B: linear gradient 




BDP-DCG-04 (4) (2.5 mg, 1.1 μmol, 32%). 
1
H NMR (600 MHz, MeOD): δ 
8.28 (s, 1H), 8.09 (d, J = 8.1 Hz, 1H), 7.95 (s, 1H), 7.90 - 7.85 (m, 2H), 7.79 
(t, J = 5.6 Hz, 1H), 7.42 (s, 1H), 7.07 (d, J = 4.1 Hz, 1H), 7.01 (d, J = 8.5 
Hz, 2H), 6.98 (d, J = 8.9 Hz, 2H), 6.69 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 4.1 
Hz, 1H), 5.11 (s, 1H), 5.07 (s, 1H), 4.99 (s, 1H), 4.81 - 4.64 (m, 8H), 4.50 - 
4.43 (m, 1H), 4.41 - 4.36 (m, 1H), 4.31 - 4.23 (m, 3H), 4.19 (d, J = 2.8 Hz, 
1H), 4.12 - 4.07 (m, 4H), 4.03 - 3.53 (m, 41H), 3.16 - 3.10 (m, 3H), 3.07 - 
3.02 (m, 1H), 3.00 - 2.94 (m, 1H), 2.88 - 2.80 (m, 1H), 2.76 (t, J = 7.3 Hz, 
2H), 2.51 (s, 3H), 2.44 (q, J = 6.4 Hz, 2H), 2.34 (t, J = 7.2 Hz, 2H), 2.26 (s, 
3H), 2.21 - 2.17 (m, 2H), 1.78 - 1.71 (m, 1H), 1.66 - 1.47 (m, 6H), 1.47 - 
1.41 (m, 2H), 1.41 - 1.36 (m, 2H), 1.33 - 1.28 (m, 5H), 1.23 - 1.17 (m, 2H), 
0.92 (d, J = 6.4 Hz, 3H), 0.88 (d, J = 6.4 Hz, 3H). HRMS: [M+H]
+
 
calculated for C101H149BF2N11O47 2317.96965, found 2317.97256. 
 
Cell culture of primary cells. Immature dendritic cells were obtained from 
the bone marrow of C75BL/6 mice and were a gift from the 
Biopharmaceutical Department (Leiden University). The use of animals was 
approved by the ethics committee of Leiden University. Mice were sedated, 
bone marrow of tibiae and femurs was flushed out and washed with PBS. 
Cells were grown in dendritic cell selection medium (IMDM containing 
granulocyte-macrophage colony stimulating factor (GM-CSF) (2:1 v/v) 
containing 8% FCS, penicillin/streptomycin (100 units/mL), glutamax (2 
mM) and β-mercaptoethanol (20 μM). Cells were selected for 10 days (37 
°C; 5% CO2) and subcultured every 2-3 days before use in the assays. 
 
Labeling of cathepsins in mouse liver and immature dendritic cell lysate. 
Lysates (~8-10 μg total protein, determined on a Qubit 2.0 fluorometer, Life 
Technologies-Invitrogen) in 50 mM sodium citrate pH 5.5 or pH 7 (as 
indicated), 5 mM DTT, 0.2% CHAPS, and 0.1% Triton X-100, were 
incubated with the indicated concentration of probe (total volume: 10 μL) for 
1 h at 37 °C. For competition experiments, lysates were first incubated with 
N3-DCG-04 (1 or 10 μM), AS44 (10 μM) or BODIPY(FL)-DCG-04 (1 or 10 
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μM) for 1 h, 37 °C, before addition of the probe and continued incubation 
for 1 h. After treatment, 5x Laemli’s sample buffer (including β-
mercaptoethanol) was added and the samples were boiled (100 °C, 5 min) 
and resolved on 12.5% SDS-PAGE. Gels were scanned on a Typhoon 2000 
imager (GE Healthcare) using the Cy2 (λex 532 nm; λem 526 nm) and Cy3 (λex 
532 nm; λem 580 nm) settings. Total protein loading was determined by 
staining with Coomassie brilliant blue and subsequent scanning on a BioRad 
GS800 calibrated densitometer. Image processing was done with ImageJ, 
representative gels from at least three independent experiments are shown. 
 
Labeling of cathepsins in live immature mouse dendritic cells. Cells were 
seeded onto tissue-culture coated 24-wells plates (200.000 cells/well, 250 μL 
medium) and allowed to attach for 2 h (37 °C; 5% CO2), before addition of 
inhibitor or probe to the medium. Pre-incubations with N3-DCG-04 (20 μM) 
or mannan (3 mg/mL) were conducted for 1 h, followed by addition of 
compound 2, 3 or 4 (1 μM) and continued incubation for 2 h. For direct 
labeling experiments, cells were cultured for 2 h (37 °C; 5% CO2) in the 
presence of probes 2, 3 or 4 (0.1, 0.25, 0.5, 0.75 or 1 μM). After incubation, 
cells were washed with PBS (2x), lysed (35 μL Invitrogen complete cell 
extraction buffer) and proteins resolved on 12.5% SDS-PAGE, followed by 
fluorescence scanning (Cy3 settings) and CBB staining. Image processing 
was done with ImageJ, representative gels from at least three independent 
experiments are shown. 
 
Confocal fluorescence microscopy. Experiments were conducted on a 
Leica TCS SPE confocal microscope, using dsRed filter settings for 
BODIPY (λex 532 nm) and Cy5 settings for Draq5 (λex 635 nm). Cells (30-75 
x 10
4
 cells/well) were seeded onto sterile Labtek II 4- or 8-chamber 
borosilicate coverglass systems (Fisher Emergo). Dendritic cells were 
allowed to attach for 2 h before pre-incubation with mannan (3 mg/mL) (1 h, 
37 °C, 5% CO2) and subsequent probe incubation (1 μM, 2 h). Cells were 




again with PBS, nuclei stained with Draq5 (Thermo Scientific) and imaged. 
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Glucocerebrosidase (GBA) catalyses the hydrolysis of β-glucosylceramide 
into glucose and ceramide.2 Impaired functioning of GBA leads to the 
accumulation of glucosylceramide causing Gaucher disease, the most 
prevalent lysosomal storage disorder.3 The severity of Gaucher disease is 
related to the degree of activity of GBA in lysosomes. Monitoring GBA levels 
would give insight in the extent of Gaucher disease, allow for tailor-made 
personalized treatment of patients and be useful for the development of new 
therapies. The development of activity-based probes (ABPs) is a new and 
effective approach to detect, identify and monitor enzymes. The most sensitive 
ABPs for GBA to date have been developed by Witte et al.4 These probes are 
characterized by the covalent attachment of a fluorescent BODIPY label at the 
C7 (cyclophellitol numbering) of cyclophellitol, an efficient mechanism-
based β-glucosidase inhibitor (1 and 2, see Figure 1a).5,6 GBA is a retaining 
glycosidase and processes β-glucosylceramide with retention of the anomeric 
configuration.7 Hydrolysis proceeds via a double displacement mechanism as 




glucoside can be hydrolysed, cyclophellitol lacks the pyranose ring oxygen. 
Upon binding of cyclophellitol to the enzyme a double replacement event is 
blocked (Figure 1c). 
 
 
Figure 1: a) Structures of ABPs 1 and 2. b) Double replacement mechanism of retaining 
glycosidase GBA. c) β-glucosidase inhibition mechanism of cyclophellitol. 
 
In Gaucher patients storage of glucosylceramide mainly occurs in 
macrophages and therefore these cells are termed Gaucher cells. With the 
objective to transform ABP 1 into an ABP capable of specifically targeting 
Gaucher cells, it was envisioned that the mannose receptor, ubiquitously 
expressed at the cell surface of macrophages, could be exploited. A relevant 
example of drug targeting to Gaucher cells is presented by studies with 
cerezyme, a recombinant version of GBA. In the enzyme replacement therapy 
to treat Gaucher disease, cerezyme is chronically administered to patients and 
studies have shown an increased uptake and targeting to Gaucher cells of 
cerezyme when mannose residues were appended to the enzyme.8,9 Apart from 
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this there are various reports that illustrate the decoration of specific cargo 
molecules with mannosides to induce targeting and internalization into 
macrophages. These examples of cargo molecules vary from small 
molecules,10,11 peptide fragments,12,13 macrocycles,14,15 proteins16,17,18 to 
nanoparticles,19,20 as discussed in chapter 1. 
 
 
Figure 2: a-c) Design of the (tri)mannose cyclophellitol probes 3 and 4.  
 
Guided by these examples probes 3 and 4 were designed in which a 
monomannoside and trimannoside (part a, Figure 2) were selected as a homing 
device to target the fluorescent cyclophellitol based inhibitor (part c, Figure 
2) via the mannose receptor to Gaucher cells. To liberate the BODIPY-
cyclophellitol probe in the lysosome, a self-immolative linker system (part b, 
Figure 2) was introduced between the (tri)mannoside and the cyclophellitol. 
This linker system, first described by Engelhardt and co-workers,21 has 
previously been used in various carbohydrate based prodrug approaches, 
including a strategy to selectively deliver paclitaxel (Taxol®) to necrotic 
tumors22,23 and an approach described by Boons and co-workers who 
developed a mannostatin prodrug.24 The projected fragmentation of the 
cyclophellitol prodrug-probes is depicted in Figure 3a. Following mannose 
mediated targeting and internalization the probe is delivered to lysosomes,25 
where the mannosidic linkages are projected to be cleaved by lysosomal α-
mannosidase, setting the stage for the fragmentation of the linker and 
concomitant release of the probe. This chapter describes the synthesis and 






Figure 3: a) Degradation reaction of the linker liberating Inhibody GREEN 3. b) Covalent 
inhibition of GBA by IG. 
 
 
Results and discussion 
 
The route of synthesis to target probes 3 and 4 is divided in four parts, namely, 
1) synthesis of the mono- and trimannosides; 2) installation of the linker to the 
anomeric center of peracetylated (tri)mannoside; 3) construction of the 
conjugation ready cyclophellitol; and 4) assembly and global deprotection of 
the caged probe. Protected mannose trimer 7 was synthesized by condensing 
both alcohols in the known diol acceptor 526
,27 with trifluoroacetimidate 6 
followed by further processing of the obtained trimer as described in chapter 
2 (Scheme 1). The anomeric acetyl in 7 was selectively removed by treatment 
with hydrazine acetate yielding completely α-configured trimer 8 in 87%. 
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Scheme 1: trimer 8 synthesis. 
 
Reagents and conditions: (a) Hydrazine acetate, DMF, 0 °C, 87% α-product. 
 
The first step towards installment of the linker comprises the introduction of 
a phenolic -mannosyl linkage. Acetylated mannose monomers 9-11 with 
different groups at the anomeric position and aldehydes 12-13 were selected 
to find a productive coupling to phenolic mannoside 14. The results are 
summarized in Table 1. 
 




Entry R1 R2 Reaction conditions Yielda 
α/β 
ratiob 
1 I (9) 
OH 
(12) 
Ag2O, MeCN, reflux 24 1:0 
2 Br (10) 
OH 
(12) 
Ag2O, MeCN, reflux 42 1:0 
3 Br (10) 
OH 
(12) 




















F (13) NaH, DMF n.i. 1:1c 
a) Isolated yield. b) α/β ratio determined by 1H-NMR of the crude. c) Not isolated. 
 
Coupling of anomeric iodine 9 with nitrophenol 12, using silver oxide as 
activator, gave 14 with high α-selectivity but in a low yield (24%, Entry 1). 
After replacing the anomeric iodide in 9 by bromine and subjecting 12 to 
similar conditions 14 was obtained in an improved yield (42%, Entry 2). In 
contrast, phase transfer conditions using 1.25M NaOH (aq.)/CHCl3 and 
Bn(Et)3NCl
28 gave hardly any product (2%) and inversion of stereoselectivity 
(α/β, 1:3, Entry 3). Next, nucleophilic aromatic substitution reactions were 
explored. Reaction of 4-fluoro-3-nitro-benzaldehyde 13 with hemiacetal 11 in 
DCM under influence of Li2CO3, a catalytic amount of DMAP
29 and 
molecular sieves gave, after column chromatography, the required α-product 
14 in 82% yield alongside 5% of the β product (Entry 4). In this reaction 
DMAP functions as a shuttle base between the organic solvent and the solid 
lithium carbonate. Using DMF and DABCO not only reduced the yield (64 %, 
Entry 5) but also led to diminished stereoselectivity (α/β = 3:1). The use of 
sodium hydride as a base in DMF30 gave a complex mixture of products, from 
which the required compound could not be isolated. Proton NMR of the crude 
reaction mixture showed a 1:1 mixture of α/β-anomers (Entry 6). The 
conditions described in Entry 4 were applied on mannotriose 8 to give α-
linked Man3-nitrobenzaldehyde 15 in 93 % yield (Scheme 2).  
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Scheme 2: Linker installation and elongation. 
 
Reagents and conditions: (a) Li2CO3, DMAP, 13, Mol. Siev. (Man1 14: 88%, Man3 15: 93%); 
(b) NaBH4, CHCl3/i-PrOH (4:1), silica, 0 °C (Man1 16: 87%, Man3 17: 59%); (c) i. para-
nitrophenyl chloroformate, pyridine, DCM, 0 °C; ii. Mono-Boc diamine 22, DMAP, 0 °C to rt. 
(Man1 18: 93%, Man3 19: 97%); (d) 4M HCl in EtOAc, 0 °C to rt (Man1 20: quantitative, Man3 
21: quantitative). 
 
Next the linker on the anomeric centre was extended by reduction of the 
benzaldehyde moiety in Man1-nitrobenzaldehyde 14 and Man3-
nitrobenzaldehyde 15 to the corresponding benzyl alcohols 16 and 17, 
respectively (Scheme 2). To this end NaBH4 in the presence of silica was used 
and after complete conversion of the starting material more silica was added 
and the solvents were removed in vacuo.31 Subsequently the adsorbed product 
was purified by column chromatography to yield Man1-nitrobenzylalcohol 18 
and Man3-nitrobenzylalcohol 19 in 87% and 59% yield respectively. 
Treatment of 18 and 19 with 4-nitrophenyl chloroformate in DCM in the 
presence of 1.5 eq. pyridine gave the corresponding 4-nitrophenyl carbonates 
and subsequent in situ elongation with mono-Boc diamine 2221 in the presence 
of DMAP led to the isolation of Man1-Boc-diamine 18 in 93% yield and Man3-
Boc-diamine 19 in 97% yield. The final step in the installation of the linker 
comprises the removal of the Boc-protective group by treatment of 18 and 19 
with 4M dry HCl in EtOAc. Ensuing removal of the solvents provided 20 and 
21 in quantitative yield. 
The required 6-azido cyclophellitol derivative 40 was assembled as depicted 
in Scheme 3, following essentially the procedure of Madsen et al.32 but with 
some optimizations to allow for synthesis on larger scale.33 Methyl 
xylofuranose was obtained by treatment of xylose in MeOH with HCl. 
Selective tritylation of the primary hydroxyl of 23 was followed by 
benzylation of the remaining hydroxyls to give fully protected 25. Acid 




over four steps. Using Ph3P and I2 the primary alcohol in 26 was converted to 
the corresponding iodide 27 (92% yield) and subsequent elimination with 
activated zinc gave aldehyde 28 in 75% yield. 
 
Scheme 3: Synthesis of 7-azido-2,3-O-acetyl-cyclophellitol derivative 40. 
 
Reagents and conditions: (a) MeOH, AcCl, 0 ° to rt. quantitative; (b) trityl chloride, pyridine; 
(c) BnBr, NaH, DMF, 0 °C to rt.; (d) MeOH/DCM (1:1), pTsOH (72% over 4 steps); (e) i. Ph3P, 
imidazole, THF, 70 °C; ii. I2, THF, 70 °C, 92%; (f) activated Zn, THF/H2O (9:1), sonicate, 50 
°C, 75%; (g) Indium, La(OTf)3, H2O, 61%; (h) Grubbs 2nd, DCM, reflux, 85%; (i) DIBAL-H, 
NaBH4, THF, 95%; (j) mCPBA, DCM 59%; (k) Pd/C, H2, MeOH, 85%; (l) i. (tBu)2Si(OTf)2, 
pyridine, DMF, -40 °C to 0 °C; (m) Ac2O, pyridine 0 °C to rt., 60% over two steps; (n) 
HF·pyridine, THF/pyridine (2:1), 0 °C, quantitative; (o) i. Tf2O, pyridine, THF, -25 °C; ii. 
NaN3, 15-crown-5, THF, -25 °C, 90%. 
 
Key step in the cyclophellitol synthesis entails the indium/La(OTf)3 mediated 
stereoselective Barbier reaction of aldehyde 28 with ethyl 4-bromocrotonate. 
This reaction gave target diene 29 and its L-idose configured C-5 epimer in a 
4:1 ratio. After column purification the desired diene 29 was isolated in 61%. 
Ring-closing metathesis of the obtained diene 29 was accomplished by the use 
of Grubbs 2nd generation catalyst in boiling DCM. As gauged by TLC-MS 
analysis, formation of the target cyclohexene 30 ([M+Na]+ 405.6) was 
accompanied by the formation of a side product ([M+Na]+ 387.6), which 
likely originates from condensation of the 4-OH. Careful monitoring of the 
reaction progress and adjusting the amount of Grubbs catalyst led to the 
isolation of the desired cyclohexene 30 in 85% yield. Reduction of the ethyl 
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ester 30 to the corresponding alcohol proceeded uneventfully to afford 
partially protected cyclohexene 31. The ensuing epoxidation of 31 using 
mCPBA proved to be difficult to monitor. Staining of the reaction TLC with 
anisaldehyde, in combination with TLC-MS analysis proved to be the best 
way to monitor the progress of the reaction, hydrogenolysis of the benzyl 
ethers with Pd/C, H2 (g) provided β-cyclophellitol (33) in 85% yield (Scheme 
3). Next, cyclophellitol 33 was further processed towards 7-azido-2,3-O-
acetyl-cyclophellitol 40, to enables the attachment to the (tri)mannoside. 
Regioselective introduction of 4,7-di-O-tbutylsilylidene by treatment of 33 
with (tBu)2Si(OTf)2 in DMF and pyridine
34 was accompanied by the formation 
of an unidentified side product. Acetylation of the crude mixture and ensuing 
purification led to the isolation of fully protected cyclophellitol 35 in 60% 
over two steps. The silylidene protective group in 35 was removed with 
HF·pyridine in THF.35 Because the product 36 proved to be soluble in water, 
aqueous work-up conditions had to be avoided and therefore the reaction was 
quenched with solid NaHCO3, after which the mixture was filtered, 
concentrated, co-evaporated with toluene and purified by column 
chromatography to yield the partially acetylated cyclophellitol 36 in 
quantitative yield. 
To regioselectively introduce the azide function at the primary hydroxyl of 
diol 36 a number of procedures were explored, the results of which are 
summarized in Table 2. Selective mesylation of 36 in DCM with Et3N as base 
proceeded quantitatively but the subsequent substitution with sodium azide in 
DMF at 60 °C gave a mixture of products, from which the desired azide could 
not be obtained (Entry 1). The selective tosylation of 36 with tosyl chloride in 
the presence of pyridine36 proceeded in low yield (14%, Entry 2), and the use 
of Et3N and tosyl chloride was accompanied by migration of the acetyl groups. 
From this latter reaction compound 38 could be obtained in 59% yield, but the 
ensuing azide substitution failed (Entry 3). Therefore a more potent leaving 
group was explored. A first attempt to form 39 in situ in THF in the presence 
of pyridine was unsuccessful (Entry 4). In the next attempt to synthesize 40, 




triflate 39. After work-up, the crude 39 was subjected to substitution with 
sodium azide in DMF at -25 °C to 0 °C to give 40 in 11% yield (Entry 5). The 
low yield in this reaction could be partially accounted for by the water 
solubility of the product 40. Avoiding the aqueous work-up procedure and the 
use of 18-crown-637,38 in the substitution reaction yielded 6-azido-
cyclophellitol 40 in 78% yield (Entry 6). The yield was further improved with 
the aid of 15-crown-5, giving product 40 in 90% yield (Entry 7).  
 
Table 2: Azide installation, synthesis azido-cyclophellitol 40. 
 
 




MsCl, Et3N, DCM,  
0 °C. 
NaN3, DMF, 60 °C, 
overnight 
n.i.a 
2 Ts (38) 
TsCl, pyridine, DCM,  
0 °C to rt. 
--- b --- 
3 Ts (38) 
TsCl, Et3N, DCM,  
0 °C to rt. 
NaN3, DMF, 60 °C, 
overnight. 
n.i.a 
4 Tf (39) 
THF, pyridine, Tf2O,  
-25 °C to rt. 
--- c --- 
5 Tf (39) 
DCM, pyridine, Tf2O,  
-25 °C. 
NaN3, DMF, -25 to  
0 °C 
11 
6 Tf (39) 
DCM, pyridine, Tf2O,  
-25 °C. 
NaN3, 18-crown-6, 
THF, -25 to 0 °C 
78 
7 Tf (39) 
DCM, pyridine, Tf2O,  
-25 °C. 
NaN3, 15-crown-5, 
THF, -25 to 0 °C 
90 
a) Product not isolated, ladder of products on TLC. b) Little intermediate formation observed. c) 
No intermediate formation observed. 
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With the two mannosyl linkers and cyclophellitol alcohol in hand the 
assembly of the caged probes was undertaken (Scheme 4). Thus, azido-
cylophellitol 40 was functionalized with a p-nitrophenyl carbonate moiety and 
the obtained 41 was coupled to monomannosyl linker system 21 and 
trimannoside 22 to give fully protected Man1-cyclophellitol 42 (73%) and 
Man3-cyclophellitol 43 (51%), respectively. Both constructs were 
deacetylated under standard Zémplen conditions providing Man1- 
cyclophellitol 44 and Man3-cyclophellitol 45 in 79% and 69% respectively. 
No degradation of the linker system and no hydrolysis of the epoxide were 
observed during this reaction. 
 
Scheme 4: Assembly of final compounds 3 and 4. 
 
Reagents and conditions: (a) p-nitrophenyl chloroformate, pyridine, DCM, 0 °C to rt, 
quantitative; (b) 47, Et3N, DMF, 0 °C to rt. (Man1-OAc-cyclophellitol 42: 73%, Man3-OAc-
cyclophellitol 43: 51%); (c) NaOMe, MeOH, rt. (Man1-OH-cyclophellitol 44: 79%, Man3-OH-
cyclophellitol 45: 69%); (d) BODIPY-alkyne 46, 75 mM sodium ascorbate (aq.), 50 mM CuSO4 
(aq.), DMF (Man1-BODIPY-cyclophellitol 3: 64%, Man3-BODIPY-cyclophellitol 4: 30%). 
 
Finally BODIPY-alkyne 4639 was conjugated to azides 44 and 45 by means of 
Cu(I)-catalyzed azide alkyne cycloaddition providing Man1-BODIPY-
cyclophellitol 3 and Man3-BODIPY-cyclophellitol 4, which were purified by 




degradation of the BODIPY moiety (LC-MS showed the formation of a side 
product having lost a BF2 group ([M-BF2+H]
+ 953.40) it proved necessary to 
directly lyophilize the product containing fractions. This led to Man1-
BODIPY-cyclophellitol 3 in 64% yield and Man3-BODIPY-cyclophellitol 4 





The inhibitory potencies of 3 and 4 towards recombinant β-glucocerebrosidase 
(imiglucerase, GBA)40 were determined using the green BODIPY-
cyclophellitol inhibitor 1 (See Figure 1) as reference. The enzyme was 
incubated with varying concentrations of compounds 1, 3 and 4, after which 
residual enzyme activity was measured with the fluorogenic substrate 4-
methylumbelliferyl-β-D-glucopyranoside (4MUGlc). The residual activity 
was plotted against the probe concentration and these curves were used to 
calculate the IC50 values (Figure 3). Caged cyclophellitol 3 showed an IC50 
value of 33.4 µM, which is 2,000 fold higher compared to cyclophellitol 
derivative 1, having an IC50 of 17.1 nM. At a concentration of 100 µM 
compound 1 did not completely inhibit the enzyme. Probe 4 showed hardly 
any inhibition of the enzyme and an IC50 value could therefore not be 
determined. 
 




Figure 4: Inhibition of recombinant GBA by 1, 3 and 4. Imiglucerase was treated with the 
probes for 30 min at 37 °C after which residual activity was determined using 4MUGlc. 
 
Next the detection limit of both probes was tested by pre-incubation of 2 pmol 
of imiglucerase with different concentrations of 3 and 4. The residual enzyme 
activity was probed with the red BODIPY-cyclophellitol 2 and resolved on 
SDS-page (Figure 4). 
For probe 3 (Figure 5a) a band was visible at probe concentrations ranging 
from 100 µmol to 5 µmol and clear yellow bands were formed in the overlay. 
Probe 4 (Figure 5b) showed hardly any labelling. Only faint bands were 
observed at high concentration (100 and 50 µmol) and no labeling was 








Figure 5: Detection limit of 3 and 4 for GBA. Imiglucerase (2 pmol) was incubated with 3 (a) 
or 4 (b) in different concentrations (nm) for 60 min at 37 °C. Residual enzyme activity was 
determined by incubation with IR for 30 min at 37 °C. All gels are 10% SDS-PAGE with 
fluorescent readout. 
 
Next it was investigated whether mannosidases present in Gaucher cell lysate 
were capable of liberating the cyclophellitol probes. To this end 3 and 4 were 
incubated with varying concentrations of Gaucher spleen lysate. Subsequently 
imiglucerase was added and allowed to react for 60 min. Residual 
imiglucerase activity was then determined by treatment of the mixtures with 
red-BODIPY cyclophellitol 2. Figure 6 depicts the SDS-PAGE gels of the 
cyclophellitol-lysate-imiglucerase mixtures. As can be seen in Figure 6a, no 
imiglucerase binding of probe 3 could be detected, regardless of the amount 
of Gaucher cell lysate added as only red-BODIPY labeling of the enzyme was 
seen. The faintly labelled band running above imiglucerase was assigned as 
ovalbumine, present in the used cell lysate. For probe 4 an identical picture is 









Figure 6: 3 (a) and 4 (b) processing with α-mannosidase present in Gaucher spleen lysate prior 
to labelling with recombinant GBA. a-b) 10µmol of 3 and 4 were incubated with different 
amount of spleen lysate and incubated for 60 min at 37 °C. Recombinant GBA was incubated 
with the lysate mixture for 60 min at 37 °C and the residual enzymes were incubated with IR 
for 30 min at 37 °C. All gels are 10% SDS-PAGE with fluorescent readout. 
 
To improve α-mannosidase activity of the Gaucher spleen lysate, the ZnCl2 
and ZnSO4 concentrations as well as the pH were optimized. After having 
established that these conditions did not adversely affect the activity of 
imiglucerase, the probes 3 and 4 were subjected to the optimal mannosidase 
conditions (1 or 10 M ZnCl2 or ZnSO4, pH 3.5) as depicted in Figure 7. In line 
with the above-described experiments, the probes were first subjected to 
Gaucher spleen lysate before the addition of imiglucerase and finally red 
BODIPY-probe 2. This time very faint bands were observed in the Gaucher 
spleen lysate, indicative of residual GBA activity. The intensity of the band 
did not change with different concentrations of zinc salts. They did become 
more intense upon addition of red-BODIPY probe 2. Adding imiglucerase to 
the mixtures led to more intense bands, but again no dependence on the 
concentration of zinc salts was observed. With trimannoside probe 4 no 







Figure 7: 3 (a) and 4 (b) processing with α-mannosidase (with- or without different zinc salts) 
present in Gaucher spleen lysate prior to labelling of imiglucerase. a-b) 3 and 4 were treated 
with Gaucher spleen lysate (with or without different zinc salts) and incubated for 60 min at 37 
°C in a pH 3.5 buffer. The mixture was incubated with imiglucerase for 60 min at 37 °C and 
the residual enzymes were labelled by incubation with IR for 30 min at 37 °C. All gels are 10% 
SDS-PAGE with fluorescent readout. 
 
Finally an in situ labelling was performed on human monocyte-derived 
macrophages. The macrophages were incubated with green-BODIPY probes 
1, 3 and 4 and chased over a period of time (Figure 8).  
 
 
Figure 8: in situ labelling of GBA in human monocyte-derived macrophages. a-c) Human 
monocyte-derived macrophages, matured for 7 d, were incubated with IG (a), 3 (b) and 4 (c) in 
the presence or absence of mannan for 2 h at 37 °C. Cells were washed with PBS and chased 
in fresh medium over 96 h. The cells were lysed and the residual enzymes were labelled by 
incubation with IR for 60 min at 37 °C. All gels are 10% SDS-PAGE with fluorescent readout. 
 
After incubation the cells were lysed and the unbound enzymes were probed 
with red-BODIPY probe 2. The experiments were performed in the absence 
or presence of mannan to block the mannose receptor, thereby prohibiting the 
uptake of the mannose conjugates. As can be seen in Figure 8a green-BODIPY 
probe 1 labels endogenous GBA almost immediately after addition to the 
tissue culture, with no red-BODIPY labelling observed. The intensity 
a b
a b c
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decreases over time due to production of new GBA, which is labelled by the 






The successful synthesis of Man1-BODIPY-cyclophellitol 3 and Man3-
BODIPY-cyclophellitol 4 as caged activity based probes for 
glucocerebrosidase, the key enzyme in Gaucher disease, was accomplished. 
In a convergent synthetic route the mannose building blocks were fused with 
a suitably protected azido cyclophellitol through a degradable linker system. 
Global deprotection and instalment of a BODIPY fluorophore completed the 
synthesis of the porbes. The obtained Man1-BODIPY-cyclophellitol 3 and 
Man3-BODIPY-cyclophellitol 4 were designed for specific targeting to 
Gaucher cells. After uptake via the mannose receptor, the probes have to be 
trimmed by intracellular mannosidases to allow for labelling of 
glucocerebrosidase. However, no effective labelling of (recombinant) 
glucocerebrosidase by 3 and 4 was achieved, which most likely is due to 
ineffective cleavage of the mannosyl residues from the probes. Hydrolysis of 
the mannose moieties from probes 3 and 4 is an essential prerequisite for their 
inhibitory action, as judged from the minimal inhibition of imiglucerase by 





General: Traces of water in the starting materials were removed by co-
evaporation with toluene for all moisture and oxygen sensitive reactions and 
the reactions were performed under an argon atmosphere. Dichloromethane 
was distilled over P2O5 and stored over activated 3 Å molecular sieves under 




were of analytical grade and used as received. Column chromatography was 
performed on Screening Device silica gel 60 (0.040-0.063 mm). Size 
exclusion was performed on Sepadex LH20 (eluent DCM/MeOH, 1:1). TLC 
analysis was conducted on HPTLC aluminium sheet (Merck, TLC silica gel 
60, F254). Compounds were visualized by UV absorption (λ = 254 nm), 
staining with p-anisaldehyde (3.7 mL in 135 mL EtOH, 1.5 mL AcOH and 5 
mL H2SO4), 20% H2SO4 in EtOH or with a solution of (NH4)6Mo7O24·4H2O 
(25g/l) in 10% H2SO4 in H2O followed by charring at +/- 140 °C. 
1H and 13C 
NMR were recorded on a Bruker DPX 300 (300 and 75 MHz respectively), 
Bruker AV 400 (400 and 100 MHz respectively), Bruker DMX 400 (400 and 
100 MHz respectively), or Bruker DMX 600 (600 and 125 MHz respectively). 
Chemical shifts are given in ppm (δ) relative to the residual solvent peak or 
TMS (0 ppm) as internal standard. J couplings are given in Hz. Optical 
rotations were measured on a Propol automatic polarimeter. IR spectra (thin 
film) were conducted on a Perkin Elmer FTIR Spectrum Two UATR (Single 
reflection diamond). LC-MS measurements were conducted on a Thermo 
Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) coupled 
to a Thermo Finnigan Surveyor HPLC system equipped with a standard C18 
(Gemini, 4.6 mm x 50 mm, 5µm particle size, Phenomenex) analytical column 
and buffers A: H2O, B: MeCN, C: 0.1% TFA (aq.). High-resolution mass 
spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) mass 
spectrometer. 
 
 2-Nitro-4-benzaldehyde 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
(14): To a solution of mannose 11 (2.61 g, 7.5 mmol) in 
DCM (50 mL) was added Li2CO3 (1.11 g, 15.0 mmol) 
and 4-fluoro-3-nitrobenzaldehyde 13 (1.52 g, 9 mmol) 
under argon atmosphere. To the solution was added activated mol. siev. (3 Å) 
and DMAP solution 0.27 g, 2.25 mmol). The reaction mixture was stirred for 
4 hours at rt and solids were formed. The solids were filtered over a pad of 
celite and the filtrate was concentrated in vacuo. Purification by column 
chromatography yielded benzaldehyde mannose 14 as a slightly yellow 
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amorphous solid (3.25 g, 6.5 mmol, 87 %). 1H NMR (400 MHz, CDCl3) δ 
9.99 (s, 1H), 8.44 (d, J = 2.0 Hz, 1H), 8.11 (dd, J = 8.7, 2.1 Hz, 1H), 7.50 (d, 
J = 8.7 Hz, 1H), 5.82 (d, J = 1.9 Hz, 1H), 5.56 (dd, J = 10.0, 3.4 Hz, 1H), 5.50 
(dd, J = 3.5, 1.9 Hz, 1H), 5.43 (t, J = 10.0 Hz, 1H), 4.29 (dd, J = 12.3, 5.0 Hz, 
1H), 4.16 – 4.11 (m, 1H), 4.08 (dd, J = 12.3, 2.3 Hz, 1H), 2.23 (s, 3H), 2.08 
(s, 3H), 2.05 (s, 3H), 2.04 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 188.7, 170.5, 
170.0, 169.8, 169.6, 152.7, 140.6, 134.5, 131.1, 127.8, 117.2, 96.3, 70.7, 68.9, 
68.4, 65.4, 61.9, 20.9, 20.8, 20.8, 20.7. HRMS: [M+H]+ calculated for 
C21H24NO13 498.12422, found 498.12421.  
 
2-Nitro-4-benzaldehyde 2,3,4,6-tetra-O-acetyl-β-D-mannopyranoside (β-
by-product): 1H NMR (400 MHz, CDCl3) δ 9.98 (s, 1H), 
8.38 (d, J = 2.0 Hz, 1H), 8.09 (dd, J = 8.6, 2.0 Hz, 1H), 
7.38 (d, J = 8.7 Hz, 1H), 5.71 (dd, J = 3.5, 1.7 Hz, 1H), 
5.55 (d, J = 1.7 Hz, 1H), 5.32 (t, J = 8.8 Hz, 1H), 5.23 
(dd, J = 9.2, 3.4 Hz, 1H), 4.34 (dd, J = 12.2, 6.4 Hz, 1H), 4.25 (dd, J = 12.2, 
3.2 Hz, 1H), 3.95 (ddd, J = 8.3, 6.4, 3.2 Hz, 1H), 2.25 (s, 3H), 2.10 (s, 3H), 
2.08 (s, 3H), 2.06 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 188.7, 170.5, 170.1, 
170.1, 169.6, 153.4, 140.7, 134.1, 131.1, 127.6, 117.5, 96.0, 73.2, 69.5, 67.4, 
66.0, 62.4, 20.8, 20.8, 20.7, 20.7. HRMS: [M+H]+ calculated for C21H24NO13 
498.12422, found 498.12422.  
 
2-Nitro-4-(hydroxymethyl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-
mannopyranoside (16): To a solution of benzaldehyde 
mannose 14 (0.124 g, 0.25 mmol) in CHCl3/i-PrOH 4:1 
(2.5 mL) was added silica (0.19 g, 0.75g/mmol) under 
argon atmosphere. The reaction mixture was cooled to 0 
°C and NaBH4 (113 mg, 3 mmol) was added in small portions. The mixture 
was allowed to warm to rt, after complete conversion of the startingmaterial 
more silica was added (0.5 g). The solvent was removed in vacuo and the 
immobilized product was purified by column chromatography yielding 




88 %). 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 2.4 Hz, 1H), 7.55 (dd, J = 
8.5, 2.2 Hz, 1H), 7.29 (d, J = 8.6 Hz, 1H), 5.66 (d, J = 2.1 Hz, 1H), 5.55 (dd, 
J = 10.0, 3.4 Hz, 1H), 5.50 (dd, J = 3.5, 1.9 Hz, 1H), 5.40 (t, J = 10.0 Hz, 1H), 
4.73 (s, 2H), 4.28 (dd, J = 12.3, 5.1 Hz, 1H), 4.18 (ddd, J = 10.2, 5.1, 2.2 Hz, 
1H), 4.08 (dd, J = 12.4, 2.3 Hz, 1H), 2.21 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 
2.03 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.6, 170.1, 169.9, 169.8, 147.8, 
140.6, 136.6, 132.4, 124.1, 117.9, 96.8, 70.3, 69.2, 68.7, 65.7, 63.5, 62.1, 21.0, 
20.8, 20.8, 20.8. HRMS: [M+H]+ calculated for C21H26NO13 500.13987, found 
500,1986.  
 
Mono-Boc-diamine 23: To an ice cooled solution of N,N’-
dimethylethylenediamine (3.7 mL, 34 mmol) in DCM (40 mL) 
was added a Boc2O solution (2.35 mL, 11 mmol ) in DCM (20 
mL) dropwise by a mechanical syringe (3 mL/h). After addition of the Boc2O 
the reationmixture was allowed to warm to rt and stirred overnight. The 
reaction mixture was diluted with DCM, washed with brine (1x), dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (EtOAc/MeOH, 80:20, 1% Et3N) yielded mono-Boc-
diamine 20 as a slightly yellow oil (1.65 g, 8.5 mmol, 26 %). Spectroscopic 
data were in accordance with published data.21 1H NMR (400 MHz, CDCl3) δ 
3.36 (t, J = 6.1 Hz, 2H), 3.23 (s, 1H), 2.88 (s, 3H), 2.76 (t, J = 6.6 Hz, 2H), 
2.47 (s, 3H), 1.46 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 177.3, 156.0, 100.1, 




(18): To a solution of benzylalcohol mannose 
16 (0.25 g, 1 mmol) in DCM (18 mL) was 
added dry pyridine (0.12 mL, 1.5 mmol) under 
argon atmosphere and the mixture was cooled 
to 0 °C. To the cooled solution was added p-nitrophenyl chloroformate (0.302 
g, 1.5 mmol) and the reaction was stirred for 30 min at 0 °C and 1.5 h at rt. 
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The reaction mixture was cooled back to 0 °C and a mono-Boc-diamine 
solution (0.320 g, 1.7 mmol) in DCM (2 mL) and DMAP (208 mg, 1.7 mmol) 
were added to the reaction mixture. The mixture was allowed to warm to rt 
and was stirred overnight. The reaction mixture was diluted with DCM and 
washed with H2O. The aquaeous phase was extracted with DCM (3x) and the 
combined organic layers were washed with H2O (3x), brine (3x), dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography yielded mannose-Boc-diamine 18 as a yellow amorphous 
solid (0.666 g, 0.93 mmol, 93 %). FT-IR: vmax (neat)/cm
-1 975.14, 1218.86, 
1365.49, 1535.22, 1693.00, 1747.76, 2974.90. 1H NMR (400 MHz, CDCl3) δ 
7.92 (s, 1H), 7.55 (d, J = 7.3 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 5.67 (s, 1H), 
5.56 (dd, J = 10.1, 3.4 Hz, 1H), 5.49 (d, J = 2.6 Hz, 1H), 5.41 (t, J = 10.0 Hz, 
1H), 5.11 (s, 2H), 4.29 (dd, J = 12.3, 5.0 Hz, 1H), 4.17 (ddd, J = 10.1, 5.0, 2.2 
Hz, 1H), 4.08 (d, J = 13.2 Hz, 1H), 3.50 – 3.27 (m, 4H), 2.96 (s, 3H), 2.88 (s, 
1.6H rotamer), 2.82 (s, 1.4H rotamer), 2.21 (d, J = 0.9 Hz, 3H), 2.07 (s, 3H), 
2.05 (s, 3H), 2.03 (d, J = 0.9 Hz, 3H), 1.44 (s, 9H). 13C NMR (100 MHz, 
CDCl3) δ 170.5, 170.0, 169.8, 169.6, 155.7, 148.3, 140.5, 140.5, 134.0, 133.8, 
132.6, 132.5, 132.4, 125.6, 125.4, 117.7, 96.7, 79.8, 70.3, 69.2, 68.6, 65.6, 
65.5, 65.3, 62.1, 47.4, 47.2, 46.9, 46.6, 46.0, 35.5, 34.9, 34.6, 28.5, 20.9, 20.8, 
20.8, 20.7. HRMS: [M+NH4]




(nitrobenzyloxycarbonyl)-ethylendiamine HCl salt (20): A freshly 
prepared 4M HCl solution in EtOAc (37.5 mL) 
was cooled to 0 °C and to the cooled solution 
was added dropwise a Mannose-Boc-diamine 
18 (357 mg, 0.5 mmol) solution in EtOAc (12.5 
mL). After 15 min at 0 °C the solution was gradually warmed to rt and stirred 
for 1 h. The reaction mixture was concentrated in vacuo and co-evaporated 
with toluene (3x) and Et2O (1x) yielding mannose-diamine HCl salt 20 as a 




8.24 – 7.83 (m, 1H), 7.66 (d, J = 8.7 Hz, 1H), 7.34 (d, J = 8.7 Hz, 1H), 7.13 
(s, 3H), 6.87 – 6.58 (m, 1H), 5.84 (s, 1H), 5.45 (d, J = 8.4 Hz, 2H), 5.29 (t, J 
= 9.9 Hz, 1H), 5.09 (d, J = 7.1 Hz, 2H), 4.25 (dd, J = 12.0, 4.2 Hz, 1H), 4.15 
(d, J = 10.3 Hz, 0H), 4.03 (d, J = 12.3 Hz, 1H), 3.58 (dd, J = 13.7, 7.6 Hz, 
2H), 3.27 – 3.22 (m, 1H), 3.18 (t, J = 5.7 Hz, 2H), 2.89 (d, J = 18.2 Hz, 3H), 





To a 0 °C cooled solution of peracetylated mannose 
trimer 7 (1.45 g, 1.5 mmol) in DMF (7.5 mL) was added hydrazine acetate 
(0.145 g, 1.65 mmol) and stirred till complete conversion. The reaction was 
quenched with acetone and concentrated in vacuo. The crude was dissolved in 
Et2O and washed with H2O (2x), brine (2x), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography yielded 
mannose trimer 8 as a white amorphous solid (1.20 g, 1.30 mmol, 87 %). 1H 
NMR (600 MHz, CDCl3) δ 5.32 (dd, J = 10.1, 3.5 Hz, 1H), 5.30 – 5.17 (m, 
4H), 5.04 (dd, J = 3.2, 1.8 Hz, 1H), 5.01 (d, J = 1.9 Hz, 1H), 4.84 – 4.80 (m, 
2H), 4.77 (d, J = 4.0 Hz, 1H), 4.30 (dd, J = 6.8, 3.3 Hz, 2H), 4.28 (t, J = 6.1 
Hz, 1H), 4.25 (dd, J = 12.3, 5.2 Hz, 1H), 4.14 (dd, J = 10.1, 2.1 Hz, 2H), 4.13 
– 4.05 (m, 4H), 3.76 (dd, J = 11.2, 6.2 Hz, 1H), 3.56 (dd, J = 11.2, 2.9 Hz, 
1H), 2.21 (s, 3H), 2.15 (s, 3H), 2.14 (d, J = 2.1 Hz, 6H), 2.12 (s, 3H), 2.11 (s, 
3H), 2.06 (d, J = 1.8 Hz, 6H), 1.99 (s, 3H), 1.98 (s, 3H). 13C NMR (150 MHz, 
CDCl3) δ 170.9, 170.8, 170.6, 170.2, 170.1, 170.0, 169.9, 169.9, 169.8, 169.6, 
98.8, 97.6, 91.9, 74.1, 71.5, 70.0, 69.4, 69.3, 69.1, 69.1, 68.6, 68.5, 68.3, 67.5, 
66.2, 66.0, 62.4, 62.4, 20.9, 20.8, 20.8, 20.8, 20.7, 20.7, 20.7, 20.6. HRMS: 
[M+H]+ calculated for C38H53O26 925.28196, found 925.28199. 
 





mannopyranoside (15): To a solution of 
mannose trimer 8 (0.783 g, 0.725 mmol) in 
DCM (7.25 mL) was added Li2CO3 (0.112 g, 
1.52 mmol) and 4-fluoro-3-
nitrobenzaldehyde 13 (0.147 mg, 0.87 
mmol) under argon atmosphere. To the solution was added activated 
molecular sieves (3 Å) and a 0.25M DMAP solution (1 mL, 0.25 mmol) in 
DCM. The reaction mixture was stirred for 4 hours at rt and solids were 
formed. The solids were filtered over a pad of celite and the filtrate was 
concentrated in vacuo. Purification by size exclusion (DCM/MeOH, 1:1) 
yielded benzaldehyde mannose trimer 15 as a slightly yellow amorphous solid 
(0.296 g, 0.134 mmol, 93%). 1H NMR (400 MHz, CDCl3) δ 9.94 (s, 1H), 8.44 
(s, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 5.87 (s, 1H), 5.52 
(dd, J = 3.1, 1.4 Hz, 1H), 5.35 – 5.17 (m, 4H), 5.12 (s, 1H), 5.08 (dd, J = 3.2, 
1.6 Hz, 1H), 5.02 – 4.96 (m, 1H), 4.85 (dd, J = 10.2, 3.6 Hz, 1H), 4.69 (s, 1H), 
4.48 (dd, J = 9.8, 3.4 Hz, 1H), 4.38 – 4.31 (m, 1H), 4.26 (d, J = 11.7 Hz, 1H), 
4.16 (dd, J = 6.5, 5.1 Hz, 1H), 4.14 – 4.01 (m, 3H), 3.97 (t, J = 9.4, 8.3 Hz, 
1H), 3.77 (dd, J = 10.8, 7.8 Hz, 1H), 3.43 (d, J = 10.4 Hz, 1H), 2.27 (d, J = 
1.3 Hz, 3H), 2.22 (d, J = 1.3 Hz, 3H), 2.17 (d, J = 1.6 Hz, 3H), 2.17 (s, 3H), 
2.14 (d, J = 1.2 Hz, 3H), 2.11 (d, J = 1.3 Hz, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 
2.01 (d, J = 1.3 Hz, 3H), 1.94 (d, J = 1.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) 
δ 188.9, 170.8, 170.6, 170.1, 170.1, 170.0, 169.9, 169.8, 169.7, 169.7, 169.5, 
151.9, 140.0, 134.4, 131.0, 128.2, 117.2, 99.1, 96.9, 95.3, 73.7, 71.4, 69.9, 
69.7, 69.6, 69.1, 68.6, 68.2, 66.2, 62.6, 62.3, 20.8, 20.8, 20.8, 20.7, 20.7, 20.6, 











(17): To a solution of benzaldehyde 
mannose trimer 15 (0.537 g, 0.5 mmol) in 
CHCl3/i-PrOH 4:1 (5 mL) was added silica 
(0.375 g, 0.75g/mmol) under argon 
atmosphere. The reaction mixture was cooled to 0 °C and NaBH4 (0.227 g, 6 
mmol) was added in small portions. The mixture was allowed to warm to rt, 
after complete conversion of the startingmaterial more silica was added (1 g). 
The solvent was removed in vacuo and the immobilized product was purified 
by column chromatography yielding benzylalcohol mannose trimer 17 as a 
yellow amorphous solid (0.306 g, 2.9 mmol, 59%). 1H NMR (400 MHz, 
CDCl3) δ 7.91 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 8.6, 2.2 Hz, 1H), 7.34 (d, J = 
8.6 Hz, 1H), 5.77 – 5.73 (m, 1H), 5.50 (dd, J = 3.5, 1.8 Hz, 1H), 5.29 (t, J = 
10.0, 9.6 Hz, 1H), 5.27 – 5.21 (m, 2H), 5.19 (dd, J = 10.2, 4.4 Hz, 2H), 5.10 
(d, J = 1.8 Hz, 1H), 5.07 (dd, J = 3.2, 1.8 Hz, 1H), 5.03 (dd, J = 10.0, 3.6 Hz, 
1H), 4.96 (dd, J = 3.7, 1.6 Hz, 1H), 4.70 – 4.60 (m, 2H), 4.48 (dd, J = 9.9, 3.5 
Hz, 1H), 4.34 (dd, J = 12.3, 5.5 Hz, 1H), 4.22 – 4.18 (m, 2H), 4.14 – 4.01 (m, 
4H), 3.96 (ddd, J = 10.4, 8.6, 1.8 Hz, 1H), 3.76 (dd, J = 10.9, 8.4 Hz, 1H), 
3.42 (dd, J = 11.0, 1.9 Hz, 1H), 2.26 (s, 3H), 2.17 (s, 3H), 2.16 (s, 3H), 2.13 
(d, J = 1.9 Hz, 9H), 2.07 (s, 3H), 2.06 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 170.9, 170.9, 170.4, 170.3, 170.2, 170.2, 169.9, 
169.8, 169.8, 146.8, 139.9, 136.8, 132.9, 124.4, 116.6, 99.1, 97.1, 94.9, 73.9, 
70.9, 70.3, 69.9, 69.6, 69.2, 69.1, 68.5, 68.4, 67.7, 66.6, 66.4, 65.9, 63.8, 62.5, 
62.5, 21.0, 20.9, 20.9, 20.9, 20.8, 20.7. HRMS: [M+H]+ calculated for 
C45H58NO29 1076.30890, found 1076.30891. 
 
  






ethylendiamine (19): To a 
solution of benzylalcohol 
mannose trimer 17 (0.251 g, 
0.233 mmol) in DCM (2.3 mL) 
was added dry pyridine (28.3 µl, 
0.35 mmol) under argon 
atmosphere and the mixture was cooled to 0 °C. To the cooled solution was 
added p-nitrophenyl chloroformate (70.5 mg, 0.35 mmol) and the reaction was 
sitrred for 30 min at 0 °C and 1.5 h at rt. The reaction mixture was cooled back 
to 0 °C and a mono-Boc-diamine solution (74.6 mg, 0.4 mmol) in DCM (0.4 
mL) and DMAP (48.9 mg, 0.40 mmol) were added to the reaction mixture. 
The mixture was allowed to warm to rt and was stirred for 1h. The reaction 
mixture was diluted with EtOAc and washed with sat. NaHCO3 (aq.) (7x), 
H2O (5x), brine (2x), dried over MgSO4, filtered and concentrated in vacuo. 
Purification by size exclusion chormatography (DCM/MeOH, 1:1) yielded 
mannose trimer-Boc-diamine 19 as a slightly yellow amorphous solid (0.293 
g, 0.227 mmol, 97%). FT-IR: vmax (neat)/cm
-1 1043.26, 1219.78, 1367.97, 
1536.33, 1700.42, 1745.90, 2938.17. 1H NMR (400 MHz, CDCl3) δ 7.93 (s, 
1H), 7.69 – 7.61 (m, 1H), 7.35 (d, J = 8.6 Hz, 1H), 5.70 (d, J = 1.9 Hz, 1H), 
5.47 (dd, J = 3.3, 1.9 Hz, 1H), 5.35 (t, J = 9.9 Hz, 1H), 5.30 (d, J = 3.1 Hz, 
1H), 5.25 (ddd, J = 10.1, 6.6, 2.9 Hz, 1H), 5.21 – 5.11 (m, 2H), 5.09 (d, J = 
2.5 Hz, 2H), 4.76 (s, 1H), 4.45 (dd, J = 9.8, 3.4 Hz, 1H), 4.35 (dd, J = 12.2, 
5.3 Hz, 1H), 4.25 (dd, J = 12.3, 5.5 Hz, 1H), 4.16 (d, J = 2.4 Hz, 1H), 4.14 – 
4.03 (m, 3H), 4.00 (t, J = 7.3 Hz, 1H), 3.77 (dd, J = 11.1, 6.5 Hz, 1H), 3.46 
(d, J = 10.7 Hz, 1H), 3.44-3.33 (m, 4H), 2.97 (s, 3H), 2.88 (s, 1.6H rotamer), 
2.83 (s, 1.4H rotamer), 2.27 (s, 3H), 2.17 (s, 3H), 2.16 (s, 3H), 2.14 (s, 3H), 
2.12 (s, 3H), 2.11 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 
1.44 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 170.8, 170.8, 170.8, 170.8, 




169.6, 155.7, 155.7, 148.1, 148.1, 140.1, 140.1, 134.3, 134.3, 132.4, 132.4, 
125.5, 125.5, 125.3, 125.3, 117.5, 117.5, 99.2, 99.2, 97.6, 97.6, 96.1, 96.1, 
74.3, 74.3, 71.0, 71.0, 70.3, 70.3, 69.8, 69.8, 69.6, 69.6, 69.3, 69.3, 68.9, 68.9, 
68.7, 68.7, 68.4, 67.4, 67.4, 66.5, 66.5, 66.1, 66.1, 65.9, 65.9, 65.5, 65.5, 65.3, 
65.3, 62.5, 62.5, 62.4, 62.4, 47.4, 47.4, 47.2, 47.2, 46.9, 46.9, 46.6, 46.6, 46.1, 
46.1, 35.5, 35.0, 34.6, 28.5, 21.0, 21.0, 20.9, 20.9, 20.9, 20.9, 20.8. HRMS: 






ethylendiamine HCl salt (21): 
A freshly prepared 4M HCl 
solution in EtOAc (6.67 mL) 
was cooled to 0 °C and to the 
cooled solution was added dropwise a mannose trimer-Boc-diamine 19 (129.0 
mg, 0.1 mmol) solution in EtOAc (3.33 mL). After 15 min. at 0 °C the solution 
was gradually warmed to rt and stirred for 1 h. The reaction mixture was 
concentrated in vacuo and co-evaporated with toluene (3x) and Et2O (1x) 
yielding mannose trimer-diamine HCl salt 21 as a yellow solid ( 122.6 mg, 0.1 
mmol, quantitative). 1H NMR (400 MHz, Deuterium Oxide) δ 7.98 (d, J = 
15.3 Hz, 1H), 7.68 (s, 1H), 7.39 (s, 1H), 5.91 (d, J = 8.9 Hz, 1H), 5.52 (s, 1H), 
5.39 (d, J = 9.2 Hz, 1H), 5.34 – 4.95 (m, 8H), 4.55 – 4.22 (m, 3H), 4.23 – 3.95 
(m, 6H), 3.84 – 3.42 (m, 3H), 3.25 (d, J = 6.9 Hz, 2H), 3.04 – 2.86 (m, 3H), 
2.82 – 2.63 (m, 3H), 2.52 – 1.88 (m, 32H). 
 
 2,3-Di-O-acetyl-4,7-O-(di-tert-butylsilylidene)-cyclophellitol (35): To a 
solution of cyclophellitol (33) (47.1 mg, 0.25 mmol) in DMF 
(2.3 mL) was added pyridine (19.8 mg, 0.2 mL, 2.5 mmol) and 
the solution was cooled to -40 °C under argon atmosphere. To 
the cooled solution was added (tBu)2Si(OTf)2 (0.138 g, 102 µl, 0.313 mmol) 
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and the reaction mixture was gradually allowed to warm to 0 °C. At 0 °C the 
mixture was diluted with EtOAc and washed with H2O. The aquaeous phase 
was extracted with EtOAc (4x) and the combined organic layers was washed 
with H2O (3x), brine (2x), dried over MgSO4, filtered, and concentrated in 
vacuo. The crude was dissolved in pyridine (2.5 mL) and cooled to 0 °C. To 
the cooled solution was added Ac2O (0.25 mL) dropwise and the reaction 
mixture was allowed to warm to rt. After complete conversion the reaction 
mixture was cooled to 0 °C and quenched with MeOH. The reaction mixture 
was concentrated in vacuo and traces of pyridine were removed by co-
evaporation with toluene. Purification by column chromatography yielded 
protected cyclophellitol 35 as a colorless oil (57.7 mg, 0.15 mmol, 60%). 1H 
NMR (400 MHz, CDCl3) δ 5.14 (d, J = 8.4 Hz, 1H), 5.08 (t, J = 9.1 Hz, 1H), 
4.25 (dd, J = 10.6, 4.4 Hz, 1H), 4.16 (t, J = 10.9 Hz, 1H), 3.93 (t, J = 9.8 Hz, 
1H), 3.09 (d, J = 3.2 Hz, 1H), 3.05 (dd, J = 3.7, 1.2 Hz, 1H), 2.40 (dt, J = 11.1, 
4.3 Hz, 1H), 2.11 (s, 3H), 2.05 (d, J = 1.0 Hz, 3H), 1.00 (s, 9H), 0.97 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 170.3, 170.0, 74.3, 70.7, 70.2, 66.5, 53.8, 52.9, 
42.0, 27.3, 26.9, 22.7, 20.9, 20.8, 19.9. HRMS: [M+H]+ calculated for 
C19H33O7Si 401.19901, found 401.19883. 
 
2,3-Di-O-acetyl-cyclophellitol (36): To a solution of silylidene 
protected cyclophellitol 33 (38.4 mg, 0.1 mmol) in THF (0.5 
mL) was added pyridine (0.25 mL). and the mixture was cooled 
to 0 °C. To the cooled reaction mixture was added 1M HF·pyridine (0.25 mL, 
0.25 mmol) and stirred for 1 h at 0 °. The reaction was quenched with NaHCO3 
(s). The excess of solids were filtered over a plug of cotton wool, rinsed with 
acetone and in vacuo. Purification by column chromatography yielded 2,3-
acetylated cyclophellitol 36 as a colorless amorphous solid (26.8 mg, quant.). 
FT-IR: vmax (neat)/cm
-1 1031.61, 1233.01, 1372.86, 1749.37, 3443.82. 1H 
NMR (300 MHz, CDCl3) δ 5.05 (d, J = 8.4 Hz, 1H), 4.99 (t, J = 8.4 Hz, 1H), 
4.05 (ddd, J = 10.5, 6.3, 4.2 Hz, 1H), 3.95 (ddd, J = 10.8, 6.6, 4.2 Hz, 1H), 
3.63 (dd, J = 9.6, 5.4, Hz, 1H), 3.56 (t, J = 5.4 Hz, 1H), 3.38 – 3.34 (m, 2H), 




1H). 13C NMR (75 MHz, CDCl3) δ 171.3, 170.3, 71.0, 67.0, 63.0, 55.2, 53.3, 
43.7, 21.0, 20.9. HRMS: [M+H]+ calculated for C11H17O7 261.09622, found 
261.09695. 
 
2,3-Di-O-acetyl-7-deoxy-7-azido-cyclophellitol (40): To a 
solution of 2,3-acetylated cyclophellitol 34 (65.3 mg, 0.25 
mmol) in DCM (9.8 mL) was added pyridine (0.2 mL, 2.5 mmol) 
and the solution was cooled to -25 °C under argon atmosphere. To the solution 
was added triflic anhydride (52.5 µl, 0.36 mmol) and the reaction was stirred 
for 1 h at -25 °C. The reaction mixture was diluted with EtOAc and washed 
with 0.1 M HCl (aq.) (5 mL, pH ≤ 6), sat. NaHCO3 (aq) (pH ≥ 6), H2O (3x) 
and brine (2x), dried over MgSO4, filtered and concentrated in vacuo (30 °C, 
100 mbar). Triflated product 39 was co-evaporated once with toluene and used 
in the next step without further purification. The triflated product was 
dissolved in THF (2.5 mL) and cooled to -25 °C under argon atmosphere. To 
the cooled solution was added NaN3 (53.3 mg, 0.75 mmol) and 15-crown-5 
(46.25 µl, 0.25 mmol,) and the reaction mixture was gradually allowed to 
warm to 0 °C. After 20 min the reaction was complete and the reaction mixture 
was diluted with Et2O, silica gel was added and the solvents were removed 
under reduced pressure. The silica-immobilized product was purified by 
column chromatography yielding 2,3-acetylated azido cyclophellitol 40 as a 
colorless amorphous solid (64.1 mg, 0.225 mmol, 90 %). FT-IR: vmax 
(neat)/cm-1 1078.90, 1033.96, 1115.73, 1237, 94, 1370.57, 1451.48, 1749.61, 
2103.16, 2873.00, 2923.53, 3456.26. 1H NMR (400 MHz, CDCl3) δ 5.07 (d, 
J = 8.5 Hz, 1H), 4.96 (dd, J = 10.2, 8.4 Hz, 1H), 3.88 (dd, J = 12.2, 4.1 Hz, 
1H), 3.59 (dd, J = 12.2, 8.5 Hz, 1H), 3.51 (t, J = 10.1 Hz, 1H), 3.41 (d, J = 3.5 
Hz, 1H), 3.14 (d, J = 3.6 Hz, 1H), 2.24 (dddd, J = 10.0, 8.5, 4.1, 1.6 Hz, 1H), 
2.10 (s, 3H), 2.09 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.3, 170.1, 75.3, 
70.8, 66.4, 54.9, 54.1, 51.0, 42.2, 21.0, 20.9. HRMS: [M+H]+ calculated for 
C11H16N3O6 286.10336, found 286.10344.  
 




deoxy-7-azido-cyclophellitol (41): 2,3-acetylated azido 
cyclophellitol 40 (0.1 mmol, 28.5 mg) was dissolved in a 
0.2M pyridine solution in DCM (1 mL, 0.2 mmol) and the solution was cooled 
to 0 °C. To the cooled solution was added para-nitrophenyl chloroformate 
(40.4 mg, 0.2 mmol) and the solution was allowed to warm to rt. After 2 h the 
reaction mixture turned clear and TLC showed full conversion of the starting 
material. The reaction mixture was diluted with DCM, silica was added to 
immobilize the product. After removal of the solvents, the immobilized 
product was directly purified by column chromatography yielding p-nitro 
phenyl oxycarbonyl cyclophellitol 41 as a slightly yellow amorphous solid 
(46.6 mg, 0.1 mmol, quantitative yield). FT-IR: vmax (neat)/cm
-1 1210.93, 
1348.92, 1492.95, 1526.21, 1749.96, 2105.51, 2854.81, 2925.12. 1H NMR 
(400 MHz, CDCl3) δ 8.31 (d, J = 2.2 Hz, 1H), 8.29 (d, J = 2.1 Hz, 1H), 7.37 
(d, J = 2.2 Hz, 1H), 7.35 (d, J = 2.1 Hz, 1H), 5.27 (dd, J = 10.3, 8.1 Hz, 1H), 
5.15 (d, J = 8.1 Hz, 1H), 4.87 (t, J = 10.2 Hz, 1H), 3.72 (dd, J = 12.4, 5.0 Hz, 
1H), 3.66 (dd, J = 12.4, 7.9 Hz, 1H), 3.50 (d, J = 3.2 Hz, 1H), 3.23 (d, J = 3.5 
Hz, 1H), 2.58 (dddd, J = 9.8, 7.9, 5.0, 1.5 Hz, 1H), 2.12 (s, 3H), 2.05 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.0, 169.9, 155.3, 152.1, 145.7, 125.6, 
121.6, 73.7, 72.1, 71.0, 54.9, 53.8, 50.8, 40.0, 20.9, 20.8. HRMS: [M+H]+ 
calculated for C18H19N4O10 451.10957, found 541.10934. 
 
Man1-OAc-azido-cyclophellitol (42): 
p-Nitro phenyl oxycarbonyl 
cyclophellitol 41 (14.9 mg, 33 µmol) 
was dissolved in 0.3M Et3N sol. in 
DMF (333 µl, 100 µmol, 3 eq.) and cooled to 0 °C. To the solution was added 
a solution of mannose-diamine HCl salt 18 in a 0.01M Et3N sol. in DMF (333 
µl, 3.3 µmol, 0.1 eq.) and the reaction was allowed to warm to rt. After 2 h 
TLC showed full conversion of the starting material and the reaction mixture 
was diluted with Et2O. Upon addition of sat. NaHCO3 (aq.) the organic phase 




combined organic phase was washed with sat. NaHCO3 (aq.) (3x), H2O (4x), 
brine (2x), dried over MgSO4, filtered and concentrated in vacuo. Purification 
by size-exclusion chromatography yielded peracetylated-mannose-
cyclophellitol construct 42 as a colorless amorphous solid (22.3 mg, 24.1 
µmol, 73%). FT-IR: vmax (neat)/cm
-1 1220.07, 1368.04, 1536.15, 1707.27, 
1749.40, 2105.56, 2927.98. 1H NMR (400 MHz, CDCl3) δ 7.99 – 7.89 (m, 
1H), 7.61 – 7.52 (m, 1H), 7.31 (d, J = 8.6 Hz, 1H), 5.68 (d, J = 2.0 Hz, 1H), 
5.56 (dd, J = 10.0, 3.4 Hz, 1H), 5.49 (dd, J = 3.4, 1.9 Hz, 1H), 5.41 (t, J = 10.0 
Hz, 1H), 5.23 – 5.04 (m, 4H), 4.86 – 4.70 (m, 1H), 4.29 (dd, J = 12.4, 5.0 Hz, 
1H), 4.19 (dd, J = 10.3, 5.2 Hz, 1H), 4.09 (dd, J = 12.3, 2.3 Hz, 1H), 3.72 – 
3.39 (m, 5H), 3.39 – 3.26 (m, 1H), 3.18 (t, J = 2.9 Hz, 1H), 2.99 – 2.92 (m, 
4H), 2.85 (t, J = 13.5 Hz, 3H), 2.42 – 2.29 (m, 1H), 2.21 (s, 3H), 2.10 (s, 3H), 
2.07 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 2.01 – 1.97 (m, 3H). 13C NMR (100 
MHz, CDCl3) δ 170.5, 170.2, 170.0, 169.9, 169.9, 169.7, 156.1, 156.0, 155.6, 
155.4, 155.1, 155.1, 148.4, 140.6, 134.3, 133.9, 133.6, 132.4, 132.4, 132.3, 
132.2, 125.9, 125.6, 125.5, 125.4, 117.8, 96.8, 72.4, 72.3, 72.3, 71.0, 70.9, 
70.4, 69.2, 69.1, 68.9, 68.8, 68.6, 65.7, 65.5, 65.4, 62.1, 54.8, 54.2, 50.7, 50.6, 
47.4, 47.4, 47.0, 46.8, 46.6, 46.6, 46.1, 41.1, 41.0, 35.8, 35.5, 35.4, 34.8, 34.6, 
21.0, 20.9, 20.8, 20.8, 20.8. HRMS: [M+H]+ calculated for C38H49N6O21 




To a solution of peracetylated-
mannose-cyclophellitol construct 42 
(10.1 mg, 10.9 µmol) in MeOH (109 
µl) was added a 0.1M NaOMe sol. in MeOH (109 µl, 10.9 µmol) and the 
mixture was stirred for 2 h at rt. The reaction was quenched with Amberlite® 
IR-120 H+ till pH ≤7. The solids were filtered and the filtrate was concentrated 
in vacuo. Purification by column chromatograpy yielded mannose-
cyclophellitol 42 as a white powder after lyophilizing (12.6 mg, 18.7 µmol, 
79%). FT-IR: vmax (neat)/cm
-1 973.37, 1067.35, 1131.21, 1175.14, 1131.21, 
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1254.16, 1354.23, 1405.68, 1486.46, 1533.84, 1692.93, 2104.78, 2925.93, 
3384.84. 1H NMR (600 MHz, D2O) δ 8.04 – 7.92 (m, 1H), 7.75 – 7.66 (m, 
1H), 7.57 – 7.48 (m, 1H), 5.84 (s, 0.4H rotamer), 5.81 (d, J = 6.8 Hz, 0.6H 
rotamer), 5.20 – 5.05 (m, 2H), 4.46 (q, J = 9.7 Hz, 0.5H rotamer), 4.39 (t, J = 
10.2 Hz, 0.5H rotamer), 4.21 (dd, J = 3.7, 1.9 Hz, 1H), 4.04 (ddd, J = 9.9, 3.4, 
1.7 Hz, 1H), 3.85 (dd, J = 8.6, 4.6 Hz, 5H), 3.71 – 3.61 (m, 2H), 3.56 – 3.34 
(m, 4H), 3.34 – 3.15 (m, 3H), 2.98 (s, 1H), 2.93 (s, 1H), 2.91 (s, 1H), 2.89 (s, 
0.5H rotamer), 2.84 (s, 0.5H rotamer), 2.82 (s, 1H), 2.46 – 2.30 (m, 0.6H 
rotamer), 2.09 – 2.02 (m, 0.4H rotamer). 13C NMR (150 MHz, D2O) δ 158.4, 
158.2, 158.1, 158.0, 149.5, 149.4, 149.3, 149.2, 140.5, 140.5, 140.4, 136.1, 
135.7, 135.0, 134.7, 132.3, 131.9, 131.9, 126.8, 126.4, 126.3, 125.6, 125.3, 
118.9, 118.9, 118.8, 99.5, 99.4, 99.4, 75.3, 75.3, 75.3, 75.1, 75.1, 75.0, 72.2, 
72.0, 71.9, 71.8, 71.7, 71.6, 71.6, 71.1, 70.5, 67.2, 67.0, 67.0, 66.9, 66.6, 61.5, 
57.1, 57.0, 56.9, 56.9, 56.9, 56.8, 56.7, 51.2, 51.1, 51.0, 50.9, 47.4, 47.3, 47.2, 
47.2, 47.0, 46.9, 40.9, 40.8, 40.7, 35.6, 35.4, 35.3, 35.2, 35.0, 34.9, 34.8. 
HRMS: [M+H]+ calculated for C26H37N6O15 673.23184, found 673.23186. 
 
Man1-BODIPY-cyclophellitol (3): 
To a solution of Man1-OH-azido 
cyclophellitol 44 (744 µg, 1.1 µmol) 
and BODIPY-alkyn 46 (540 µg, 1.65 
µmol) in DMF (110 µl) was added a 
0.075M sodium ascorbate (aq.) solution (11 µl, 0.825 µmol) and a 0.05M 
CuSO4 (aq.) solution (11 µl, 0.55µmol) under argon atmosphere. The reaction 
was stirred overnight at rt and LC-MS showed full consumption of the starting 
material. Purification by HPLC followed by lyophilization yielded Man1-
BODIPY-cyclophellitol 1 as an orange-red powder (700 µg, 0.7 µmol, 64%). 
FT-IR: vmax (neat)/cm
-1 971.93, 1119.40, 1450.71, 2073.18, 2242.73, 2362.56, 
2486.52, 3363.59. LC-MS: Rt 6.37 in 12.5 min, 10→90% H2O/MeCN, 
ESI/MS [M+H]+ 1001.13. HRMS: [M+H]+ calculated for C45H60BF2N8O15 





Man3-OAc-azido-cyclophellitol (43):. p-Nitro phenyl oxycarbonyl 
cyclophellitol 41 (450 
mg, 0.1 mmol) was 
dissolved in 0.3M Et3N 
sol. in DMF (1 mL, 0.3 
mmol) and cooled to 0 
°C. To the solution was 
added a solution of mannose trimer-diamine HCl salt 21 in a 0.01M Et3N sol. 
in DMF (1 mL, 10 mmol) and the reaction was allowed to warm to rt. After 2 
h TLC showed full conversion of the starting material and the reaction mixture 
was diluted with Et2O. Upon addition of sat. NaHCO3 (aq.) the organic phase 
turned yellow. The aqueous phase was extracted with Et2O (3x) and the 
combined organic phase was washed with sat. NaHCO3 (aq.) (3x), H2O (4x), 
brine (2x), dried over MgSO4, filtered and concentrated in vacuo. Purification 
by size-exclusion yielded peracetylated-mannose trimer-cyclophellitol 
construct 43 as a colorless amorphous solid (76.6 mg, 51 µmol, 51%). FT-IR: 
vmax (neat)/cm
-1 1041.62, 1086.21, 1135.84, 1219.53, 1369.13, 1536.51, 
1709.80, 1747.60, 2105.92, 2852.59, 2925.64. 1H NMR (400 MHz, CDCl3) δ 
7.97 – 7.89 (m, 1H), 7.63 (d, J = 9.0 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 5.70 
(d, J = 2.2 Hz, 1H), 5.47 (dt, J = 3.8, 2.0 Hz, 1H), 5.34 (t, J = 10.1, 9.2 Hz, 
1H), 5.32 – 5.20 (m, 4H), 5.22 – 5.02 (m, 8H), 4.86 – 4.68 (m, 2H), 4.44 (dd, 
J = 9.8, 3.4 Hz, 1H), 4.35 (dd, J = 12.5, 5.4 Hz, 1H), 4.25 (dd, J = 12.3, 5.5 
Hz, 1H), 4.16 (d, J = 2.4 Hz, 1H), 4.14 – 4.03 (m, 3H), 4.02 – 3.97 (m, 1H), 
3.77 (dd, J = 11.2, 6.4 Hz, 1H), 3.71 – 3.39 (m, 6H), 3.33 (dt, J = 13.0, 7.2 
Hz, 1H), 3.18 (d, J = 3.4 Hz, 1H), 3.00 – 2.91 (m, 4H), 2.89 – 2.80 (m, 2H), 
2.35 (h, J = 5.0 Hz, 1H), 2.26 (s, 3H), 2.16 (s, 3H), 2.16 (s, 3H), 2.14 (s, 3H), 
2.12 (s, 3H), 2.10 (s, 6H), 2.08 (s, 3H), 2.06 (s, 3H), 2.00 (s, 3H), 1.98 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ 170.8, 170.7, 170.4, 170.2, 170.1, 170.0, 
169.8, 169.8, 169.6, 156.0, 155.9, 155.7, 155.5, 155.4, 155.0, 155.0, 155.0, 
148.3, 148.2, 140.2, 134.8, 134.4, 134.1, 132.4, 132.3, 132.1, 125.8, 125.4, 
125.1, 117.5, 99.2, 97.6, 96.2, 96.1, 74.2, 72.3, 72.3, 72.2, 70.9, 70.3, 69.8, 
69.6, 69.3, 68.9, 68.8, 68.7, 68.4, 67.4, 66.5, 66.1, 65.9, 65.6, 65.4, 62.5, 62.4, 
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54.7, 54.1, 50.6, 50.6, 50.5, 47.4, 47.3, 47.0, 46.8, 46.6, 46.5, 46.1, 41.0, 40.9, 
35.7, 35.3, 34.7, 34.6, 34.6, 29.8, 20.9, 20.9, 20.9, 20.9, 20.9, 20.8, 20.8, 20.7. 
HRMS: [M+H]+ calculated for C62H81N6O37 1501.46356, found 1501.46367. 
 
Man3-OH-azido-cyclophellitol (45): To a solution of peracetylated-
mannose-trimer-
cyclophellitol construct 
43 (30.8 mg, 20 µmol) 
in MeOH (200 µl) was 
added a 0.1M NaOMe 
sol. in MeOH (200 µl, 20 µmol) and stirred overnight at rt. The reaction was 
quenched with Amberlite® IR-120 H+ till pH ≤7. The solids were filtered and 
the filtrate was concentrated in vacuo. Purification by column chromatograpy 
yielded mannose-cyclophellitol 45 as a white powder after lyophilizing (13.72 
mg, 13.76 µmol, 69%). FT-IR: vmax (neat)/cm
-1 1053.15, 1131.99, 1253.41, 
1353.55, 1405.62, 1486.69, 1533.03, 1622.70, 1684.90, 2104.39, 2927.58, 
3363.18. 1H NMR (400 MHz, Deuterium Oxide) δ 8.03 (t, J = 9.1 Hz, 1H), 
7.76 (t, J = 8.8 Hz, 1H), 7.51 (t, J = 9.1 Hz, 1H), 5.88 – 5.75 (m, 1H), 5.22 (d, 
J = 1.8 Hz, 1H), 5.21 – 5.06 (m, 2H), 4.40 – 4.33 (m, 1H), 4.15 (dd, J = 9.5, 
3.3 Hz, 1H), 4.12 (dd, J = 3.4, 1.7 Hz, 1H), 4.04 – 3.89 (m, 5H), 3.87 (s, 1H), 
3.85 – 3.76 (m, 3H), 3.76 – 3.61 (m, 6H), 3.60 – 3.33 (m, 3H), 3.29 (q, J = 3.9 
Hz, 1H), 3.26 – 3.16 (m, 1H), 2.99 (d, J = 2.5 Hz, 1H), 2.96 – 2.88 (m, 3H), 
2.86 (d, J = 7.4 Hz, 2H), 2.32 (d, J = 18.5 Hz, 0.6H), 2.00 (t, J = 9.6 Hz, 0.4H), 
1.29 (s, 1H). 13C NMR (100 MHz, D2O) δ 174.0, 157.5, 139.7, 131.3, 117.9, 
102.3, 99.1, 98.3, 77.6, 74.4, 74.4, 73.3, 72.7, 72.5, 71.0, 70.6, 70.4, 70.1, 
69.9, 69.1, 66.7, 66.7, 66.1, 65.7, 65.6, 65.0, 60.9, 60.8, 56.0, 50.0, 46.4, 46.3, 
39.9, 39.8, 34.7, 34.4. LC-MS: Rt 4.12 in 12.5 min, 10→90% H2O/MeCN, 
ESI/MS [M + H]+ 996.93. HRMS: [M+H]+ calculated for C38H57N6O25 





Man3-BODIPY-cyclophellitol (4): To a solution of Man3-OH-azido 
cyclophellitol 45 (7.8 
mg, 7.8 µmol) and 
BODIPY-alkyn 46 (3.9 
mg, 11.7 µmol) in DMF 
(624 µl) was added a 
0.075M sodium ascorbate (aq.) solution (78 µl, 5.85 µmol) and a 0.05M 
CuSO4 (aq.) solution (78 µl, 3.9 µmol) under argon atmosphere. The reaction 
was stirred overnight at rt and LC-MS showed full consumption of the starting 
material. Purification by HPLC followed by lyophilization yielded Man3-
BODIPY-cyclophellitol 2 as an orange-red powder (3.136 mg, 2.37 µmol, 
30%). FT-IR: vmax (neat)/cm
-1 1681.21, 2074.42, 2229.80, 2342.27, 2360.78, 
3373.05.. LC-MS: Rt 5.81 in 12.5 min, 10→90% H2O/MeCN, ESI/MS [M + 
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Synthesis and immunological evaluation of a 







Antigen presenting cells (APCs), such as dendritic cells (DCs) play a pivotal 
role in the mammalian innate and adaptive immune system and thereby in the 
defence against external challenges, such as bacteria, viruses and toxins, but 
also internal challenges, such as malignantly transformed self-cells.2 APCs 
recognize pathogen related molecular structures with the aid of various classes 
of receptors such as Toll-like receptors (TLRs) and nucleotide-binding 
oligomerization domain-like receptors (NLRs). This recognition event can 
result in the upregulation of pro-inflammatory signalling molecules (both 
surface-bound and soluble), that alert the immune system to the presence of 
danger.3 Concomitantly, exogenous material is taken up by APCs through 
endocytosis, phagocytosis or marcopynocitic internalization. After uptake, the 
cargo is proteolytically degraded in the endo-lysosomal system by a family of 
proteases4 and further processed in the lysosomes.5 The degradation of 




histocompatibility complex II (MHC class II) at the outer membrane of 
APCs.6 The combination of the expression of pro-inflammatory receptors and 
MHC-II loaded with exogenous peptides will lead to the activation of CD4+ 
T-helper cells.  
Malignantly transformed self-cells and cells harbouring pathogens in their 
cytosol are cleared using a different pathway: the MHC-I-pathway of antigen 
presentation. On the MHC-I molecule 8-9-mer peptides derived from 
cytosolic and ER-associated proteins are continually expressed from various 
stages of the protein life cycle.7 In this cytosolic pathway to antigen 
presentation, proteins from within the cell are processed by proteasomes and 
downstream aminopeptidases and presented on MHC class I.8,9 In a process 
referred to as antigen cross-presentation10 DCs take up exogenous antigen and 
let this antigenic material ‘escape’ from the endosomally-restricted MHC-II 
pathway into their own MHC-I-loading pathway.11 Cross-presentation is the 
subject of intense study due to its relevance to disease and its mechanistic 
complexity. Besides the above mentioned PRRs that detect pathogen 
associated molecular patterns (PAMPs), APCs express various C-type lectin 
receptors (CLRs) which bind specific carbohydrates of pathogens but also 
carbohydrates structures of self-glycoproteins.12 It has been hypothesized that 
these lectins play a crucial role in antigen cross-presentation.13 Binding of a 
glycoconjugate by CLRs on APCs is followed by internalization thereby 
facilitating the processing and finally antigen presentation. There are multiple 
carbohydrate receptors on the surface of APCs and their expression varies 
between cell types. They have been shown to have overlapping binding 
specificity, which has complicated their structure. Despite this absence of 
knowledge about the exact structure of the carbohydrate-ligands for specific 
CLRs, considerable attention is directed to explore CLRs with the aid of 
natural and artificial glycoconjugates. Examples of CLRs that recognise 
mannose-containing structures are Dectin-2, Mincle, DC-SIGN, SIGNR1, 
Langerin, and the Mannose Receptor (MR). As discussed in Chapters 2 and 3 
(oligo)mannose conjugates are regularly exploited in targeting strategies to 
enable improved uptake of specific molecules, such as (fluorescently) labeled 
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inhibitors.14,15 In addition (oligo)mannose conjugates are used to target 
antigens to APCs to improve the uptake of antigens.16  
Recently it has been shown that the MR can strongly enhance antigen cross-
presentation by routing glycoprotein ligands to a very mild endosome (low 
proteolysis, near neutral pH), from which cross-presentation is favoured.17 In 
line with these results, it was recently reported that a bismannosylated 
synthetic long peptide showed enhanced cross-presentation in an MR-
dependent manner18 and the chemical introduction of additional glycans onto 
the glycoprotein ovalbumin was shown to further enhance cross-
presentation.19 However, it is still unclear how different glycans exactly 
enhance cross-presentation, which in part is due to the extensive heterogeneity 
of glycoproteins that have been studied.20,21 The position, branching, spacing 
and multivalency of (oligo)mannoses in a glycoconjugate are decisive for 
uptake by a mannose recognising CLR, the subsequent routing and finally for 
antigen presentation.  
 
 
Figure 1: Target compounds 1-20 discussed in this chapter. 
 
To gain more insight which carbohydrate structures promote cross-
presentation, this chapter presents the synthesis and initial immunological 





22 A set of 5 
different (oligo)mannosides were attached to the side chain of azido lysine 
residues. The resulting library of twenty mannosylated peptides (1-20, Figure 
1) has been evaluated on their ability to promote antigen presentation. 
 
 
Result and discussion 
 
The assembly of the mannosylated peptides 1-20 entails the following stages; 
i) the solution phase synthesis of five propargylated mono-, di- and tri-
mannosides (Scheme 1), ii) the automated solid phase synthesis of four 
oligopeptides containing one, two, three or six azide functions 26-29 (Table 
1), iii) the assembly of the library of twenty mannosylated peptides by the 
solution phase conjugation of the propargylated mannosides and azide 
containing peptides as depicted in Figure 2.  
 
Table 1: Peptide sequence of azidolysine-DEVA5K peptides 26-29. 
Compound Peptide Sequence 
26 Az1DEVA5K  
27 Az2DEVA5K  








Figure 2: Peptide conjugate assembly. 
 
Propargyl oligomannoside synthesis 
The propargyl mannopyranosides 21-25 were prepared using propargyl α-D-
mannopyranoside 2123 as starting compound (Scheme 1). In order to keep the 
anomeric alkyne moiety in the mannosides intact reductive transformations 
were avoided and acid/base labile protective groups were applied. En route to 
-linked 1,2-di-mannoside (1,2-Man2) (22) the equatorial hydroxyl functions 
in propargyl D-mannopyranose 21 were selectively masked with a 1,2-
butane diacetal moiety to give 31 in 66% yield. Subsequent silylation of the 
primary alcohol in 31 using TBDMS chloride and imidazole gave acceptor 32 
in quantitative yield. Condensation of 2,3,4,6-tetra-O-acetyl-α-D-
mannopyranosyl trichloroacetimidate 30 and acceptor 32 under influence of 
TfOH provided fully protected -(1-2) linked dimer 33 in 71% yield. Both the 
butane diacetal and the silyl ether in dimer 33 were removed by treatment with 
90% TFA. Cleavage of the glycosidic bonds could not be detected under these 
acidic conditions. Subsequently dimer 34 was globally deacetylated under 






Scheme 1: Synthesis of α-propargyl (oligo)mannosides 21-25. 
 
Reagents and conditions: (a) 2,3-butanedione, HC(OMe)3, MeOH, CSA, reflux, 66%; (b) 
TBDMSCl, imidazole, DMF, quantitative; (c) PhCH(OMe)2, CSA, DMF, 200 mBar, 60 °C 
55%; (d) i. TrtCl, DABCO, DCM; ii. Ac2O, DMAP, 97%; (e) BF3·Et2O, MeOH/toluene (1:1) 
70%; (f) i. PhC(OMe)3, CSA, MeCN; ii. H2O, 52%; (g) Donor 30, TfOH, DCM, activated 
molecular sieves, -25 to 0 °C, (33: 82%, 40: 79%, 42: 82%); (h) Donor 30, TMSOTf, DCM, 
activated molecular sieves, -20 to 0 °C, 80%; (i) TFA/H2O (9:1), 71%; (j) 70% AcOH (aq.), 55 
°C, 84%; (k) NaOMe, MeOH, (22: 82%, 23: 84%, 24: 66%, 25: 75%). 
 
To obtain-linked 1,3-di-mannoside (1,3-Man2) 23, imidate donor 30 and 
propargyl 4,6-O-benzylidene mannopyranose 35 were coupled in a regio and 
stereoselective fashion to give target dimer 36 in 80% yield together with the 
corresponding mannose trimer as minor by-product. Acidolysis of the 
benzylidene acetal and NaOMe mediated removal of the acetyl groups 
provided 1,3-Man2 23.  
Acceptor 39, needed to obtain -linked 1,6-di-mannoside (1,6-Man2) 24, was 
synthesized by a two-step one-pot tritylation/acetylation procedure24 followed 
by detritylation. Ensuing coupling with mannopyranosyl trichloroacetimidate 
30 led to the isolation of fully acylated 1,6-Man2 dimer 40 in 79%. 
Deprotection using NaOMe in MeOH gave 1,6-Man2 24 in 66% yield. 




Man3) 25 was obtained by double mannosylation of diol acceptor 41. 
Treatment of propargyl D-mannopyranose 21 with trimethyl orthobenzoate 
in presence of a catalytic amount of CSA followed by in situ hydrolysis of the 
formed orthoesters delivered after purification 2,4-di-O-benzoylated mannose 
41 in 52% yield and 2,6-di-O-benzoylated mannose in 35% yield. The 2,4-di-
O-benzoylated acceptor 41 was coupled with imidate donor 30 giving the 
peracylated mannose trimer 42 in 82% yield. Subsequently the trimer was 
saponificated under standard Zémplen conditions providing 1,3-1,6-Man3 25 
in 75%. With all the propargyl mannosides in hand attention was directed to 




The synthesis of the oligopeptides was carried out with an automated peptide 
synthesizer using standard Fmoc-chemisty (Scheme 2). Tentagel Rink amide 
was used as solid support together with commercially available Fmoc-
protected amino acids and HCTU as condensing agent. Fmoc-protected azido 
lysine 4325 was prepared using a reported procedure. The four target 
oligopeptides 26-29, contain one, two, three or six azide functions at the N-
terminal end of the common DEVSGLEQLESIINFEKLAAAAAK 
(DEVA5K) sequence. After construction of the immobilized protected 
DEVA5K elongation with azido lysine was undertaken. Incorporation of one 
azido lysine gave oligopeptide 26 and incorporation of six azido lysines 
resulted in oligopeptide 29. The remaining immobilized oligopeptide 27 and 
28 having two or three azide lysine residues were obtained by alternating 





Scheme 2: Synthesis of mannosyl-DEVA5K peptide conjugates 1-20 
 
Reagens and conditions: (a) SPPS using repetitive cycle of: i. 20% piperidine/DMF; ii. Fmoc-
AA-OH, HCTU, DiPEA, NMP; iii. Ac2O, DiPEA, HOBt, NMP; (b) SPPS using repetitive cycle 
of: i. 20% piperidine/DMF; ii. Fmoc-azidolysine 43 or glycine, HCTU, DiPEA, NMP; iii. 
Ac2O, DiPEA, HOBt, NMP; (c) i. 95%TFA, 2.5% H2O, 2.5% TIS. ii. RP-HPLC purification; 
(d) 0.05 M propargyl mannose sugar (aq.), 0.05 M sodium ascorbate (aq.), 0.05 M CuSO4 (aq.), 
rt. 
 
All protected immobilized peptides were cleaved from the solid support by 
treatment with 95% TFA and purified by RP-HPLC to yield Az1DEVA5K 26, 
Az2DEVA5K 27, Az3DEVA5K 28 and Az6DEVA5K 29. With the peptide 
backbones in hand the peptides were subjected to conjugation with the set of 
propargyl mannosides. 
Propargyl mannosides Man1 (21), 1,2-Man2 (22), 1,3-Man2 (23), 1,6-Man2 
(24) and 1,3-1,6-Man3 (25) were conjugated to oligopeptides Az1DEVA5K 
(26), Az2DEVA5K (27), Az3DEVA5K (28) and Az6DEVA5K (29) by Cu-
catalyzed azide-alkyne cycloaddition. In this reaction 1 equivalent of CuSO4 
and (n + 2) equivalents of both the propargyl mannoside and sodium ascorbate 
with respect to the number of azides in the oligopeptide were used and each 
reaction was monitored by LCMS. After completion of the reaction, the 
mixture was subjected to gel filtration (HW-40) to remove compounds of low 
molecular weight. The retention time of the target mannosylated peptides 
prove to be shorter than expected and Cu-cluster formation of the products 
was assumed. Subsequent HPLC purification gave the mannosylated peptides 
conjugated with Man1 1-4, 1,2-Man2 5-8 or 1,3-1,6-Man3 17-20 in relatively 
low yields (Table 1). In an alternative procedure HW-40 gel filtration of the 
crude cyclo-addition products was replaced by treatment with Cu-ion 
exchange resin CupriSorbTM prior to HPLC purification.26 This procedure led 
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to the isolation of a set of mannosylated peptides in an increased yield (Table 
1). 
 









26 (1) 13% (5) 9% (9) 25% (13) 48% (17) 12% 
27 (2) 5% (6) 8% (10) 17% (14) 22% (18) 6% 
28 (3) 7% (7) 8% (11) 20% (15) 14% (19) 5% 
29 (4) 7% (8) 14% (12) 43% (16) 35% (20) 12% 




Preliminary biological results 
 
Immunological evaluation 
In order to study whether the different glycan glycosylation pattern lead to 
different cross-presentation, the conjugates (1-20) were analysed for their 
ability to activate CD8+ T-cells, which reflects the degree of antigen 
presentation. Mouse bone marrow dendritic cells (BM-DCs) were incubated 
for 3h at 37 0C with an aliquot of each conjugate.27 After this incubation the 
DCs were washed and the B3Z T-cell hybridoma were added.28 These T-cells 
express the B3 T-cell receptor, which specifically recognises the peptide 
SIINFEKL presented in the H2-Kb subtype of MHC-I. Upon recognition of 
this peptide MHC-I complex, the B3Z is activated resulting in IL-2 
production, which can be quantified. To allow for spectrophotometric 
activation of the T-cells, expression of a β-galactosidase reporter protein has 
been coupled to the IL-2 promotor. The expressed β-Gal can be quantified 




substrate, that delivers a red colour upon hydrolysis by the enzyme.29 The T-
cell responses to conjugate 1-20 are plotted in Figure 4. 
 
 
Figure 3: T-cell response of mannosyl-DEVA5K conjugates 1-20. 
 
As shown in Figure 4 monomannoside conjugate (Man1)1 1 and (Man1)2 2 
provided with one or two monomannosides showed the highest T cell response 
compared to the other constructs. Increasing the number of monomannose 
copies (Man1) to three (Man1)3 3 or six (Man1)6 4 led to a decrease of T cell 
response. Surprisingly, the highest mannosylated conjugate (1,3-1,6-Man3)6 
20, having six copies of the trimannoside gave the lowest T cell response of 
all. Conjugates provided with dimannosides (1,2-Man2, 1,3-Man2, 1,6-Man2) 
5-16 and in particular (1,2-Man2) 5-8 showed a lower T cell response in 
comparison with the monomannoside conjugates (Man1). Whereas increasing 
the number of monomannosides (Man1)x to three (x=3) or six (x=6) copies led 
to a lower T cell response, an opposite trend was found for dimannosides (1,3-
Man2)x 9-12 and (1,6-Man2)x 13-16. By increasing the number of 
dimannosides (x= 2, 3, 6) an increase in T cell response was observed. Varying 
the number of dimannosides in the conjugate (1,2-Man2)x did not show a 
significant difference in T cell response. The T cell response of the conjugates 
having a trimannosides (1,3-1,6-Man3)x showed the highest T cell response 
with two (x=2, 18) or three (x=3, 19) copies. Surprisingly, T cell activation of 
the conjugate (1,3-1,6-man3)x was completely diminished by the presence of 
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six trimannosides (x = 6, 20). To assess the involvement of the mannose 
receptor in the uptake of the conjugates analogous experiments were 
performed in the presence of mannan, to block mannose receptor mediated 
uptake. Incubation in the presence of mannan reduced the T cell response to a 
level close to parent peptide DEVA5K. This strongly indicates a mannose 
receptor mediated uptake of the mannosylated peptide conjugates. As control, 
DCs were incubated with all the unconjugated azido peptides (26-29) and with 
the short peptide DEVA5K. All peptides lacking mannose sugars showed 
similar T cell response as the DEVA5K peptide (data not shown). Furthermore 
the presence of mannan did not affect the response of the unconjugated 






In this chapter the synthesis and preliminary immunological evaluation of a 
set of twenty mannosylated peptide conjugates is described. A mono-
mannoside, tri di-mannosides and one tri-mannoside (21-25) equipped with 
an alkyne were synthesized uneventfully on mmole scale. The propargylated 
(oligo)mannosides were conjugated to MHC-class-I epitope 
DEVSGLEQLESIINFEKLAAAAAK provided with one, two, three or six 
azido lysines via Cu(I) catalysed click chemistry. The isolation procedure and 
hence the yield of the conjugates could be considerably improved by the 
application of CupriSorbTM prior before HPLC purification. All mannosylated 
conjugates showed an increase in T cell response in comparison with a parent 
peptide. Reduction of T cell response of the conjugates in the presence of 
mannan to the level of the parent peptide is an indication of mannose receptor 
mediated uptake. The monomannoside conjugate (Man1)1 1 and (Man1)2 2 
provided with one or two mono-mannosides showed the highest T cell 
response compared to the other constructs. The relation of the structure of the 




unforeseen. The effectiveness of both the mannose receptor mediated uptake 
and the subsequent processing of the conjugates are the main issues that 
contribute to the degree of T cell response. Both a low mannose mediated 
uptake of a specific conjugate and/or a reduced proteolytic susceptibility and 
processability may explain a decreased T cell response.  
 
Experimental 
General: Traces of water in the starting materials were removed by co-
evaporation with toluene for all moisture and oxygen sensitive reactions and 
the reactions were performed under an argon atmosphere. Dichloromethane 
was distilled over P2O5 and stored over activated 3 Å molecular sieves under 
an argon atmosphere. Propargyl alcohol was distilled over K2CO3 prior to use. 
All other solvents and chemicals (Acros, Fluca, Merck) were of analytical 
grade and used as received. Column chromatography was performed on 
Screening Device silica gel 60 (0.040-0.063 mm). Size exclusion was 
performed on Sephadex LH20 (eluent DCM/MeOH, 1:1). TLC analysis was 
conducted on HPTLC aluminium sheet (Merck, TLC silica gel 60, F254). 
Copper was removed using CupriSorbTM (Seachem) chelating resin. 
Compounds were visualized by UV absorption (λ = 254 nm), staining with p-
anisaldehyde (3.7 mL in 135 mL EtOH, 1.5 mL AcOH and 5 mL H2SO4), 20% 
H2SO4 in EtOH or with a solution of (NH4)6Mo7O24·4H2O (25g/L) in 10% 
H2SO4 in H2O followed by charring at +/- 140 °C. 
1H, 13C and 2D-HMBC (1J-
coupling) NMR were recorded on a Bruker DPX 300 (300 and 75 MHz 
respectively), Bruker AV 400 (400 and 100 MHz respectively), Bruker DMX 
400 (400 and 100 MHz respectively), or Bruker DMX 600 (600 and 125 MHz 
respectively). Chemical shifts are given in ppm (δ) relative to the residual 
solvent peak or TMS (0 ppm) as internal standard. J couplings are given in 
Hz. Optical rotations were measured on a Propol automatic polarimeter. IR 
spectra (thin film) were conducted on a Perkin Elmer FTIR Spectrum Two 
UATR (Single reflection diamond). LC-MS measurements were conducted on 
a Thermo Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) 
coupled to a Thermo Finnigan Surveyor HPLC system equipped with a 
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standard C18 (Gemini, 4.6 mm x 50 mm, 5 µm particle size, Phenomenex) 
analytical column and buffers A: H2O, B: MeCN, C: 0.1% TFA (aq.). High-
resolution mass spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) 
mass spectrometer.  
 
Propargyl 3-O,4-O-(2′,3′-Dimethoxybutan-2′,3′-diyl)-α-
D-mannopyranoside (31): To a solution of propargyl 
mannose 21 (2.2 g, 10 mmol) in MeOH (100 mL) was 
added butane-2,3-dione (1.1 mL, 12 mmol), trimethyl orthoformate (6 mL, 55 
mmol), CSA (0.232 g, 1 mmol) and the reaction mixture was refluxed 
overnight. The reaction mixture was cooled to rt., neutralized with Et3N, 
concentrated in vacuo and directly purified by column chromatography 
without further aqueous workup. Purification by column chromatography 
yielded butane-2,3-acetal protected mannose 31 as a colourless amorphous 
solid (2.2 g, 6.6 mmol, 66%). 1H NMR (400 MHz, CDCl3) δ 5.06 (s, 1H), 4.24 
(d, J = 2.4 Hz, 2H), 4.13 (t, J = 9.8 Hz, 1H), 4.03 (dd, J = 10.3, 3.1 Hz, 1H), 
3.96 (s, 1H), 3.87 – 3.74 (m, 3H), 3.28 (s, 3H), 3.27 (s, 3H), 2.46 (t, J = 2.4 
Hz, 1H), 1.33 (s, 3H), 1.29 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 100.5, 
100.0, 98.7, 78.8, 75.1, 71.3, 69.6, 68.1, 62.9, 61.2, 54.5, 48.3, 48.0, 17.9. 
HRMS: [M+H]+ calculated for C15H25O8 333.15439, found 333.15444. 
 
Propargyl 3-O,4-O-(2′,3′-Dimethoxybutan-2′,3′-diyl)-6-
O-tertbutyldimethylsilyl-α-D-mannopyranoside (32): To 
a solution of butane-2,3-acetal protected mannose 31 (332 
mg, 1,0 mmol) in DMF (10 mL) was added TBDMSCl (0.19 g, 1.25 mmol) 
and the mixture was cooled to 0 °C. To the mixture was added imidazole (85 
mg, 1.25 mmol) and the reaction mixture was allowed to warm to rt. After 
complete conversion of the starting material the reaction was quenched with 
MeOH. The mixture was concentrated in vacuo and dissolved in Et2O. The 
organic layer was washed with H2O (3x), brine (2x), dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography 




quantitative). 1H NMR (400 MHz, CDCl3) δ 4.98 (s, 1H), 4.20 (d, J = 2.4 Hz, 
2H), 4.03 – 3.94 (m, 2H), 3.91 (s, 1H), 3.82 (dd, J = 11.3, 2.0 Hz, 1H), 3.77 
(dd, J = 11.3, 5.0 Hz, 1H), 3.68 (ddt, J = 7.3, 4.8, 2.2 Hz, 1H), 3.25 (s, 3H), 
3.22 (s, 3H), 2.48 (s, 1H), 2.40 (t, J = 2.4 Hz, 1H), 1.30 (s, 3H), 1.26 (s, 3H), 
0.86 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 100.4, 
99.9, 98.3, 79.0, 74.7, 72.1, 69.6, 68.4, 62.8, 61.6, 53.8, 48.2, 48.0, 25.9, 18.4, 





mannopyranoside (33): 2,3-Acetal protected mannose 
acceptor 32 (223 mg, 0.5 mmol) and trichloro imidate 
donor 30 (389 mg, 0.75 mmol) were dissolved in DCM (10 
mL) and stirred over activated molecular sieves for 0.5h at 
rt. The mixture was cooled to -25 °C and TfOH (4.4 µl, 50 
µmol) was added. The reaction mixture was allowed to gradually warm up 
and the reaction was quenched with Et3N at 0 °C. The mixture was diluted 
with DCM and the organic layer was washed with H2O. The aqueous layer 
was extracted with DCM (5x) and the combined organic layers was dried over 
MgSO4, filtered and concentrated in vacuo. Purification by size-exclusion 
chromatography yielded dimer 33 as an colourless oil (320 mg, 0.41 mmol, 
82%). 1H NMR (400 MHz, CDCl3) δ 5.43 (dd, J = 3.5, 1.9 Hz, 1H), 5.35 (dd, 
J = 10.0, 3.4 Hz, 1H), 5.24 (t, J = 9.9 Hz, 1H), 5.20 (d, J = 1.9 Hz, 1H), 4.97 
(s, 1H), 4.23 (dd, J = 12.1, 5.0 Hz, 1H), 4.20 (d, J = 1.5 Hz, 2H), 4.13 – 4.07 
(m, 1H), 4.09 – 4.01 (m, 1H), 4.01 – 3.97 (m, 2H), 3.91 (s, 1H), 3.84 (dd, J = 
11.3, 2.0 Hz, 1H), 3.77 (dd, J = 11.3, 5.8 Hz, 1H), 3.71 – 3.61 (m, 1H), 3.22 
(s, 3H), 3.20 (s, 3H), 2.41 (t, J = 2.4 Hz, 1H), 2.10 (s, 3H), 2.08 (s, 3H), 2.02 
(s, 3H), 1.95 (s, 3H), 1.22 (s, 3H), 1.18 (s, 3H), 0.86 (s, 9H), 0.06 (s, 3H), 0.05 
(s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.7, 169.9, 169.6, 169.6, 100.1, 
100.1, 99.6, 99.0, 97.3, 78.7, 75.8, 74.9, 72.8, 69.5, 69.1, 68.9, 68.5, 66.4, 
63.1, 62.5, 61.8, 53.7, 48.2, 47.9, 25.9, 20.9, 20.9, 20.8, 20.8, 18.3, 17.7, 17.5, 
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-5.1, -5.3. HMBC: 1Jα-1,2-man C-H = 176 Hz. HRMS: [M+H]
+ calculated for 
C35H57O17Si 777.33595, found 777.33598. 
 
Propargyl 2-O-(2,3,4,6-tetra-O-acetyl-α-D-
mannopyranosyl)-α-D-mannopyranoside (34): Dimer 33 
(311 mg, 0.4 mmol) was dissolved in TFA/H2O (9:1, 12.3 
mL) and stirred at rt. After 30 min. the reaction mixture was 
diluted with toluene and concentrated in vacuo. The crude was co-evaporated 
with toluene (3x) and directly purified by column chromatography without 
further aqueous workup. Purification by column chromatography yielded 
dimer 34 as a colourless amorphous solid (159 mg, 0.29 mmol, 71%). 1H NMR 
(400 MHz, CDCl3) δ 5.41 (dd, J = 3.3, 1.8 Hz, 1H), 5.31 (dd, J = 10.0, 3.3 Hz, 
1H), 5.24 (d, J = 1.6 Hz, 1H), 5.20 (t, J = 10.0 Hz, 1H), 5.05 (d, J = 1.8 Hz, 
1H), 4.29 (dd, J = 6.7, 1.6 Hz, 1H), 4.25 (s, 1H), 4.24 – 4.21 (m, 2H), 4.16 – 
4.12 (m, 1H), 4.10 (d, J = 6.9 Hz, 1H), 3.99 – 3.87 (m, 3H), 3.83 (dd, J = 12.3, 
3.0 Hz, 1H), 3.57 (dt, J = 9.7, 3.3 Hz, 1H), 3.37 (s, 3H), 2.49 (t, J = 2.4 Hz, 
1H), 2.14 (s, 6H), 2.08 (s, 3H), 2.00 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
171.6, 170.7, 170.1, 170.0, 99.6, 96.9, 80.3, 78.6, 75.3, 73.1, 70.7, 69.4, 69.2, 
68.9, 67.4, 66.2, 63.1, 61.7, 54.5, 21.0, 20.9, 20.8, 20.8. HRMS: [M+H]+ 
calculated for C23H33O15 549.18140, found 549.18138. 
 
Propargyl 2-O-(α-D-mannopyranosyl)-α-D-
mannopyranoside (22): To a solution of mannose dimer 34 
(137 mg, 0.25 mmol) in MeOH (2.5 mL) was added NaOMe 
(1.3 mg, 0.025 mmol) and the mixture was stirred at room 
temperature. After 4h the reaction was quenched with Amberlite IR-120 H+ 
till pH ≤7 and the solids were filtered. The filtrate was concentrated in vacuo 
and the crude was dissolved in methanol. The solution was added dropwise to 
vigorously stirred cold Et2O. The formed precipitate was filtered, rinsed with 
cold Et2O and dried over a stream of air yielding 1,2-Man2 dimer 22 as a white 
powder (78 mg, 0.21 mmol, 82%). 1H NMR (400 MHz, MeOD) δ 5.20 (d, J 




(dd, J = 3.1, 1.7 Hz, 1H), 3.88 – 3.76 (m, 4H), 3.73 (t, J = 4.2 Hz, 1H), 3.73 – 
3.57 (m, 5H), 3.50 (ddd, J = 8.9, 5.5, 1.9 Hz, 1H), 2.86 (t, J = 2.4 Hz, 1H). 13C 
NMR (100 MHz, MeOD) δ 104.2, 98.6, 80.3, 80.1, 76.0, 75.0, 74.8, 72.4, 
72.0, 71.8, 68.7, 68.4, 62.8, 62.7, 55.1. HRMS: [M+H]+ calculated for 
C15H25O11 381.13914, found 381.13911. 
 
Propargyl 4,6-O-benzylidene-α-D-mannopyranoside 
(35): To a solution of propargyl mannose 21 (436 mg, 2 
mmol) in MeCN (10 mL) was added benzaldehyde dimethyl acetal (0.36 mL, 
2.4 mmol), trichlorotriazine (0.1 g, 0.6 mmol) and sonicated at 60 °C. After 
complete conversion of the starting material the reaction mixture was 
concentrated in vacuo. Purification by column chromatography yielded 
compound 35 as a white amorphous solid (330 mg, 1.1 mmol, 55%). 1H NMR 
(400 MHz, MeOD) δ 7.50 (dd, J = 6.7, 3.1 Hz, 2H), 7.34 (dd, J = 5.1, 2.0 Hz, 
3H), 5.60 (s, 1H), 4.99 (d, J = 1.3 Hz, 1H), 4.29 (dd, J = 2.4, 0.9 Hz, 2H), 4.21 
(ddd, J = 9.3, 4.1, 1.5 Hz, 1H), 4.00 – 3.89 (m, 2H), 3.92 – 3.85 (m, 1H), 3.84 
– 3.77 (m, 1H), 3.75 (dd, J = 10.3, 4.0 Hz, 1H), 2.91 (t, J = 2.4 Hz, 1H). 13C 
NMR (100 MHz, MeOD) δ 139.2, 129.9, 129.0, 127.5, 103.3, 101.1, 80.0, 
76.2, 72.4, 69.6, 69.5, 65.6, 55.2. HRMS: [M+H]+ calculated for C16H19O6 




Benzylidene acceptor 35 (153 mg, 0.5 mmol) and 
trichloro imidate donor 30 (271 mg, 0.55 mmol) 
were dissolved in DCM (5 mL) and stirred over activated molecular sieves for 
0.5 h at rt. The mixture was cooled to -20 °C and TMSOTf (4.5 µl, 25 µmol) 
was added. The reaction was stirred for 2 h at -20 °C and quenched with Et3N 
(0.1 mL) at that temperature. The mixture was filtered and concentrated in 
vacuo. Purification by size-exclusion yielded dimer 36 as a colourless 
amorphous foam (253 mg, 0.4 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 
7.44 – 7.40 (m, 2H), 7.33 (dd, J = 5.0, 1.9 Hz, 3H), 5.59 (s, 1H), 5.39 (dd, J = 
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3.5, 1.8 Hz, 1H), 5.34 (dd, J = 9.8, 3.5 Hz, 1H), 5.27 (d, J = 1.8 Hz, 1H), 5.22 
(t, J = 9.9 Hz, 1H), 5.09 (d, J = 1.5 Hz, 1H), 4.28 (d, J = 5.3 Hz, 1H), 4.26 (d, 
J = 2.5 Hz, 2H), 4.25 – 4.19 (m, 1H), 4.20 – 4.13 (m, 2H), 4.13 – 4.04 (m, 
2H), 3.86 (d, J = 9.6 Hz, 1H), 3.85 (d, J = 9.8 Hz, 1H), 2.46 (t, J = 2.4 Hz, 
1H), 2.11 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H), 1.60 (s, 1H). 13C 
NMR (100 MHz, CDCl3) δ 170.8, 170.2, 169.8, 169.7, 137.2, 128.9, 128.2, 
126.1, 101.5, 99.0, 98.5, 78.5, 78.3, 75.3, 73.7, 70.9, 69.2, 69.1, 69.0, 68.6, 
66.4, 64.1, 62.8, 54.6, 20.8, 20.8. HMBC: 1Jα-1,3-man C-H = 176 Hz. HRMS: 




Dimer 36 (0.172 g, 0.27 mmol) was dissolved in 70% 
AcOH (aq.) (2.7 mL) and stirred for 4h at 55 °C. The mixture was cooled to 
rt, diluted with H2O and transferred to a separation funnel. To the solution was 
added solid NaHCO3 till neutral pH after which the aqueous layer was 
extracted with DCM (5x). The combined organic layers was dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography yielded dimer 37 as a colourless oil (0.124 g, 0.23 mmol, 
84%). 1H NMR (400 MHz, CDCl3) δ 5.47 – 5.36 (m, 2H), 5.30 – 5.20 (m, 
2H), 5.04 (s, 1H), 4.31 – 4.18 (m, 4H), 4.13 (d, J = 10.3 Hz, 1H), 4.06 (s, 1H), 
3.99 (d, J = 13.5 Hz, 1H), 3.94 (d, J = 11.5 Hz, 1H), 3.84 (d, J = 11.8 Hz, 1H), 
3.62 (d, J = 9.5 Hz, 1H), 3.11 (s, 4H), 2.41 (t, J = 2.1 Hz, 1H), 2.15 (s, 3H), 
2.11 (s, 3H), 2.07 (s, 3H), 2.01 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.0, 
170.9, 170.7, 169.9, 99.5, 98.6, 79.5, 78.8, 75.0, 73.0, 70.7, 69.7, 69.5, 69.1, 
66.3, 65.6, 62.9, 61.4, 54.6, 21.1, 21.0, 20.9. HRMS: [M+H]+ calculated for 





Propargyl 3-O-(α-D-mannopyranosyl)-α-D-mannopyranoside (23): To a 
solution of mannose dimer 37 (91.1 mg, 0.17 mmol) 
in MeOH (1.7 mL) was added NaOMe (0.9 mg, 17 
µmol) and the mixture was stirred at room 
temperature. After 6h the reaction was quenched with Amberlite IR-120 H+ 
till pH ≤7 and the solids were filtered. The filtrate was concentrated in vacuo 
and the crude was dissolved in methanol. The solution was added drop wise 
to vigorously stirred cold Et2O. The product precipitated and the formed solids 
were filtered, rinsed with cold Et2O and dried over a stream of air yielding 
dimer 23 as a white powder (61 mg, 0.16 mmol, 95%). 1H NMR (400 MHz, 
MeOD) δ 5.07 (d, J = 1.7 Hz, 1H), 4.95 (d, J = 1.8 Hz, 1H), 4.28 (d, J = 2.4 
Hz, 2H), 4.04 (dd, J = 2.9, 1.9 Hz, 1H), 3.97 (dd, J = 3.4, 1.8 Hz, 1H), 3.85 (t, 
J = 2.4 Hz, 1H), 3.82 (d, J = 2.3 Hz, 1H), 3.81 – 3.75 (m, 4H), 3.73 (dd, J = 
5.8, 2.4 Hz, 1H), 3.69 (dd, J = 5.8, 1.8 Hz, 1H), 3.62 (t, J = 9.5 Hz, 1H), 3.55 
(ddd, J = 6.7, 3.8, 3.0 Hz, 1H), 2.87 (t, J = 2.4 Hz, 1H). 13C NMR (100 MHz, 
MeOD) δ 103.9, 99.9, 80.5, 79.9, 76.1, 75.3, 74.9, 72.4, 72.1, 71.3, 68.7, 67.4, 




mannopyranoside (38): To a solution of propargyl mannose 
21 (1.6 g, 7.5 mmol) in pyridine (30 mL) was added trityl 
chloride (2.6 g, 9.4 mmol) and the mixture was stirred till complete conversion 
of the starting material. The reaction mixture was cooled to 0 °C and Ac2O 
(3.2 mL, 33.8 mmol) was added dropwise. The reaction mixture was allowed 
to warm to rt and the reaction was stirred overnight at rt. The mixture was 
cooled to 0 °C and the reaction was quenched with MeOH. Solvents were 
removed in vacuo and the crude was dissolved in EtOAc. The organic layer 
was washed with 1M HCl (aq.) (1x), sat. NaHCO3 (aq.) (1x), H2O (3x), brine 
(3x), dried over MgSO4, filtered and concentrated in vacuo yielding propargyl 
mannose 38 in qunantitative yield. The crude trityl mannose 38 was used 
without further purification. 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.2 
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Hz, 6H), 7.29 (t, J = 7.4 Hz, 6H), 7.22 (t, J = 7.2 Hz, 3H), 5.31 (d, J = 2.4 Hz, 
1H), 5.30 – 5.26 (m, 2H), 5.08 (d, J = 1.6 Hz, 1H), 4.33 (d, J = 1.0 Hz, 2H), 
3.90 (tt, J = 5.6, 2.9 Hz, 1H), 3.23 (dd, J = 10.3, 2.6 Hz, 1H), 3.18 (dd, J = 
10.3, 5.1 Hz, 1H), 2.47 (t, J = 2.3 Hz, 1H), 2.17 (s, 3H), 1.96 (s, 3H), 1.73 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 170.1, 170.0, 169.4, 143.8, 128.8, 127.9, 
127.1, 95.8, 86.7, 78.3, 75.5, 70.7, 69.7, 69.3, 66.6, 62.4, 54.5, 21.0, 20.8, 
20.6. HRMS: [M+H]+ calculated for C34H35O9 587.22756, found 587.22762. 
 
Propargyl 2,3,4-tri-O-acetyl-α-D-mannopyranoside (39): 
To a solution of trityl mannose 38 (4.4 g, 7.5 mmol) in a 
MeOH/toluene mixture (1:1, 75 mL) was added dropwise 
BF3·Et2O (1.0 mL, 8.25 mmol) and stirred till complete conversion of the 
starting material. The reaction mixture was diluted with EtOAc and washed 
with H2O (3x), brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded propargyl mannose 
acceptor 39 as a white amorphous solid (1.81 g, 5.25 mmol, 70%). 1H NMR 
(400 MHz, CDCl3) δ 5.40 (dd, J = 10.2, 3.4 Hz, 1H), 5.29 (dd, J = 3.6, 1.8 Hz, 
1H), 5.26 (t, J = 10.2 Hz, 1H), 5.05 (d, J = 1.8 Hz, 1H), 4.28 (d, J = 2.4 Hz, 
2H), 3.82 (ddd, J = 10.1, 4.1, 2.3 Hz, 1H), 3.72 (ddd, J = 12.8, 8.5, 2.3 Hz, 
1H), 3.63 (ddd, J = 12.8, 5.6, 4.1 Hz, 1H), 2.47 (t, J = 2.4 Hz, 1H), 2.40 (dd, 
J = 8.5, 5.7 Hz, 1H), 2.16 (s, 3H), 2.08 (s, 3H), 2.01 (s, 3H), 1.66 (s, 1H). 13C 
NMR (100 MHz, CDCl3) δ 171.0, 170.1, 170.0, 96.5, 78.2, 75.7, 71.3, 69.5, 
68.8, 66.5, 61.3, 55.1, 21.0, 20.9, 20.8. HRMS: [M+H]+ calculated for 




(40): Mannose acceptor 39 (0.479 g, 0.156 mmol) and 
trichloro imidate donor 30 (0.373 g, 0.72 mmol) were 
dissolved in DCM (9.6 mL) and stirred over activated molecular sieves for 
0.5h at rt. The mixture was cooled to -25 °C and TfOH (13 µl, 0.144 µmol) 




reaction was quenched with Et3N at 0 °C. The mixture was diluted with DCM 
and the organic layer was washed with H2O. The aqueous layer was extracted 
with DCM (5x) and the combined organic layers was dried over MgSO4, 
filtered and concentrated in vacuo. Purification by size-exclusion yielded 
dimer 40 as an colourless oil (0.257 g, 0.38 mmol, 79%). 1H NMR (400 MHz, 
CDCl3) δ 5.37 – 5.31 (m, 3H), 5.30 – 5.26 (m, 3H), 5.02 (d, J = 1.7 Hz, 1H), 
4.86 (d, J = 1.7 Hz, 1H), 4.30 (d, J = 2.4 Hz, 2H), 4.27 (dd, J = 12.2, 5.2 Hz, 
1H), 4.13 (dd, J = 12.3, 2.4 Hz, 1H), 4.11 – 4.04 (m, 1H), 3.99 (ddd, J = 10.1, 
5.7, 2.4 Hz, 1H), 3.79 (dd, J = 11.0, 5.7 Hz, 1H), 3.59 (dd, J = 11.0, 2.5 Hz, 
1H), 2.52 (t, J = 2.4 Hz, 1H), 2.17 (s, 3H), 2.16 (s, 3H), 2.12 (s, 3H), 2.06 (s, 
3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
170.8, 170.2, 170.1, 170.0, 169.9, 169.9, 169.9, 97.6, 96.1, 78.1, 75.7, 69.9, 
69.4, 69.4, 69.1, 69.1, 68.7, 66.7, 66.5, 66.0, 62.5, 55.0, 21.0, 20.9, 20.9, 20.8, 
20.8, 20.8. HMBC: 1Jα-1,6-man C-H = 173 Hz. HRMS: [M+H]
+ calculated for 
C29H40O18 675.21309, found 675.21300. 
 
Propargyl 6-O-(α-D-mannopyranosyl)-α-D-mannopyranoside (24): To a 
solution of mannose dimer 40 (0.257 g, 0.38 mmol) in 
MeOH (3.8 mL) was added NaOMe (5 mg, 0.095 mmol) 
and the mixture was stirred at room temperature. After 
1h the reaction was quenched with Amberlite IR-120 H+ 
till pH ≤7 and the solids were filtered. The filtrate was concentrated in vacuo 
and the crude was dissolved in methanol. The solution was added dropwise to 
vigorously stirred cold Et2O. The product precipitated and the formed solids 
were filtered, rinsed with cold Et2O and dried over a stream of air yielding 
1,6-Man2 dimer 24 as a white powder (94 mg, 0.25 mmol, 66%). 
1H NMR 
(400 MHz, MeOD) δ 4.93 (d, J = 1.6 Hz, 1H), 4.84 (d, J = 1.8 Hz, 1H), 4.25 
(t, J = 2.2 Hz, 2H), 3.92 (dd, J = 11.0, 5.2 Hz, 1H), 3.87 (d, J = 2.8 Hz, 1H), 
3.83 (d, J = 11.9 Hz, 2H), 3.78 – 3.69 (m, 3H), 3.67 (d, J = 3.4 Hz, 2H), 3.67 
– 3.61 (m, 3H), 2.88 (t, J = 2.4 Hz, 1H). 13C NMR (100 MHz, MeOD) δ 101.4, 
100.0, 80.0, 76.1, 74.3, 73.5, 72.6, 72.0, 71.9, 68.5, 68.3, 67.2, 62.8, 54.9. 
HRMS: [M+H]+ calculated for C15H25O11 381.13914, found 381.13913. 




Propargyl 2,4-di-O-benzoyl-α-D-mannopyranoside (41): 
To a suspension of propargyl mannose 21 (0.218 g, 1.15 
mmol) in MeCN (11.5 mL) was added PhC(OMe)3 (0.6 mL, 3.5 mmol) and 
CSA (26 mg, 115 µmol) and the mixture was stirred rt. After 2h H2O (0.5 mL) 
was added and the mixture was stirred overnight at rt. The reaction was 
mixture was neutralized wit Et3N, concentrated in vacuo and co-evaporated 
wit toluene (3x). Purification by column chromatography yielded benzoylated 
mannose 41 as a white amorphous solid (254 mg, 0.6 mmol, 52%). 1H NMR 
(400 MHz, CDCl3) δ 8.12 – 8.03 (m, 4H), 7.65 – 7.53 (m, 2H), 7.51 – 7.41 
(m, 3H), 5.52 (t, J = 9.9 Hz, 1H), 5.44 (dd, J = 3.5, 1.7 Hz, 1H), 5.24 (d, J = 
1.7 Hz, 1H), 4.44 (dd, J = 9.9, 3.5 Hz, 1H), 4.32 (d, J = 2.5 Hz, 2H), 3.99 (ddd, 
J = 10.1, 4.2, 2.3 Hz, 1H), 3.81 (dd, J = 12.6, 2.4 Hz, 1H), 3.73 (dd, J = 12.6, 
4.2 Hz, 1H), 2.51 (t, J = 2.4 Hz, 1H), 2.40 (s, 2H). 13C NMR (100 MHz, 
CDCl3) δ 167.4, 166.1, 133.8, 133.7, 130.1, 129.3, 129.1, 128.7, 128.7, 96.7, 
78.4, 75.6, 72.8, 71.2, 70.3, 68.7, 61.5, 55.4. HRMS: [M+H]+ calculated for 




mannopyranoside (42): Benzoylated mannose 
acceptor 41 (0.107 g, 0.25 mmol) and trichloro 
imidate 30 (390 mg, 0.75 mmol) were dissolved in DCM (5 mL) and stirred 
over activated molecular sieves for 0.5h at rt. The mixture was cooled to -25 
°C and TfOH (4.4 µl, 50 µmol) was added. The reaction mixture was allowed 
to gradually warm up and the reaction was quenched with Et3N at 0 °C. The 
mixture was diluted with DCM and the organic layer was washed with H2O. 
The aqueous layer was extracted with DCM (5x) and the combined organic 
layers was dried over MgSO4, filtered and concentrated in vacuo. Purification 
by size-exclusion yielded trimer 42 as an colourless oil (223 mg, 0.2 mmol, 
82%). 1H NMR (400 MHz, CDCl3) δ 8.16 (dd, J = 8.5, 1.5 Hz, 2H), 8.03 (dd, 




10.0 Hz, 1H), 5.55 (dd, J = 3.5, 1.8 Hz, 1H), 5.34 (dd, J = 10.1, 3.4 Hz, 1H), 
5.26 (d, J = 10.1 Hz, 2H), 5.23 (dd, J = 3.4, 1.8 Hz, 1H), 5.12 – 5.07 (m, 2H), 
4.98 (d, J = 1.8 Hz, 1H), 4.88 (dd, J = 2.8, 1.8 Hz, 1H), 4.81 (d, J = 1.7 Hz, 
1H), 4.49 (dd, J = 9.8, 3.4 Hz, 1H), 4.37 (d, J = 2.4 Hz, 2H), 4.24 – 4.04 (m, 
5H), 4.03 (t, J = 2.2 Hz, 1H), 4.00 (t, J = 2.3 Hz, 1H), 3.91 (dd, J = 10.8, 6.7 
Hz, 1H), 3.62 (dd, J = 10.8, 2.2 Hz, 1H), 2.56 (t, J = 2.4 Hz, 1H), 2.14 (s, 3H), 
2.12 (s, 3H), 2.05 (s, 3H), 1.98 (s, 3H), 1.94 (d, J = 0.9 Hz, 6H), 1.85 (s, 3H), 
1.83 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.8, 170.6, 170.0, 169.8, 169.7, 
169.2, 169.1, 166.0, 165.3, 133.7, 133.7, 130.1, 130.0, 129.1, 128.9, 128.8, 
128.6, 99.5, 97.3, 96.2, 78.1, 75.8, 75.0, 71.6, 70.1, 69.4, 69.3, 69.1, 68.8, 
68.7, 68.3, 66.8, 66.1, 65.9, 62.4, 62.4, 55.1, 20.9, 20.8, 20.8, 20.7, 20.7, 20.5, 




D-mannopyranoside (25): To a solution of 
mannose trimer 42 (223 mg, 0.2 mmol) in MeOH 
(4 mL) was added NaOMe (5.4 mg, 0.1 mmol) 
and the mixture was stirred at room temperature. After 1h the reaction was 
quenched with Amberlite IR-120 H+ untill pH ≤7 and the solids were filtered. 
The filtrate was concentrated in vacuo and the crude was dissolved in 
methanol. The solution was added dropwise to vigorously stirred cold Et2O. 
The product precipitated and the formed solids were filtered, rinsed with cold 
Et2O and dried over a stream of air yielding 1,3-1,6-Man3 trimer 25 as a white 
powder (82 mg, 0.15 mmol, 75%). 1H NMR (400 MHz, MeOD) δ 5.07 (d, J 
= 1.7 Hz, 1H), 4.92 (d, J = 1.8 Hz, 1H), 4.84 (d, J = 1.7 Hz, 1H), 4.26 (t, J = 
2.4 Hz, 2H), 4.04 (dd, J = 2.9, 1.7 Hz, 1H), 3.99 (dd, J = 3.4, 1.7 Hz, 1H), 3.94 
(dd, J = 11.1, 5.3 Hz, 1H), 3.88 (dd, J = 3.4, 1.7 Hz, 1H), 3.86 – 3.81 (m, 10H), 
3.80 (t, J = 3.6 Hz, 1H), 3.78 – 3.71 (m, 2H), 3.71 – 3.68 (m, 1H), 3.66 – 3.61 
(m, 2H), 2.89 (t, J = 2.4 Hz, 1H). 13C NMR (100 MHz, MeOD) δ 104.0, 101.4, 
100.1, 80.6, 79.9, 76.2, 74.9, 74.3, 73.8, 72.6, 72.4, 72.0, 72.0, 71.2, 68.7, 
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68.5, 67.2, 67.0, 62.8, 55.0. HRMS: [M+H]+ calculated for C21H35O16 
543.19196, found 543.19200. 
 
General procedure peptide synthesis 
The solid-phase peptide synthesis was performed on 100 μmol scale according 
to established methods on an ABI 433A (Applied Biosystems) automated 
instrument applying an Fmoc based protocol30 starting from Tentagel-S-RAM 
resin (loading 0.23 mmol/g). The consecutive steps performed in each cycle 
for HCTU chemistry on μmol scale: 1) Deprotection of the Fmoc-group with 
20% piperidine in NMP for 15 min; 2) NMP wash; 3) Coupling of the 
appropriate amino acid using a five-fold excess. Generally, the Fmoc amino 
acid (0.25 mmol) was dissolved in 0.25 M HCTU in NMP (1 mL), the 
resulting solution was transferred to the reaction vessel followed by 0.5 mL of 
1.0 M DiPEA in NMP to initiate the coupling. The reaction vessel was shaken 
for 30 min; 4) NMP wash; 5) capping with 0.5 M acetic anhydride in NMP in 
presence of 0.5 mmol DiPEA; 6) NMP wash; 7) DCM wash. 
 
H-Lys(N3)-Asp-Glu-Val-Ser-Gly-Leu-Glu-Gln-Leu-Glu-Ser-Ile-Asn-
Phe-Glu-Lys-Leu-Ala-Ala-Ala-Ala-Ala-Lys-NH2 (26): Az1DEVA5K 26 
(49.0 mg, 18.1 µmol, 18% based on theoretical loading of 0.23mmol/g). 





Az2DEVA5K 27 (49.0 mg, 16.8 µmol, 17% based on theoretical loading of 
0.23mmol/g). ESI/MS (m/z): [M+2H]2+ calculated for C126H210N38O41 








loading of 0.23mmol/g). ESI/MS (m/z): [M+2H]2+ calculated for 




Ala-Ala-Lys-NH2 (29): Az6DEVA5K 29 (18.0 mg, 5.2 µmol, 5% based on 
theoretical loading of 0.23mmol/g). ESI/MS (m/z): [M+2H]2+ calculated for 
C148H247N53O44 1735.93, found 1735.93. 
 
General procedure (oligo)mannoside conjugation 
The peptide was dissolved in a 0.05M propargyl mannose sugar solution (nazide 
+ 2 eq.) (aq.). To the solution was added a 0.05M sodium ascorbate solution 
(nazide + 2 eq.) (aq.) and a 0.05M CuSO4 solution (2 eq.) (aq.) and the reaction 
was monitored by HPLC. After full conversion to the product, two workup 
procedures were performed prior before purification by RP-HPLC. Gel 
filtration: The reaction mixture was diluted with MiliQ and purified by gel 
filtration (HW-40). The combined frations were concentrated, centrifuged and 
the supernatant was purified by RP-HPLC. Resin purification: The reaction 
mixture was diluted with MiliQ water and CupriSorbTM (50 mg) was added to 
the reaction mixture for 2 in which the solution turned from light blue to 
colourless. The resin was filtered and rinsed with MiliQ water. The filtrate 





(1): (Man1)1DEVA5K 1 
was conjugated following the general procedure using: Az1DEVA5K (6.80 
mg, 2.52 µmol), 0.05M propargyl mannose 21 sol. (151.2 µl, 7.56 µmol), 
0.05M sodium ascorbate sol. (151.2 µl, 7.56 µmol) and 0.05M CuSO4 (50.4 
µl, 2.52 µmol). Gel filtration followed by RP-HPLC (linear gradient 20 → 
40% MeCN in 12 min) followed by lyophilisation yielded (Man1)1DEVA5K 1 
as a white powder (0.97 mg, 0.33 µmol, 13%). LC-MS analysis (linear 
gradient 10 → 90% MeCN in 12 min), tR: 5.067 min, ESI/MS (m/z): [M+2H]
2+ 
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calculated for C127H211N33O45 1459.76, found 1459.73; [M+3H]
3+ calculated 




(Man1)2DEVA5K 2 was conjugated following the general procedure using: 
Az2DEVA5K 27 (8.35 mg, 2.87 µmol), 0.05M propargyl mannose 21 sol. 
(229.6 µl, 11.48 µmol), 0.05M sodium ascorbate sol. (229.6 µl, 11.48 µmol) 
and 0.05M CuSO4 (5.74 µl, 114.8 µmol). Gel filtration followed by RP-HPLC 
purification by RP-HPLC (linear gradient 20 → 45% MeCN in 12 min) 
followed by lyophilisation yielded (Man1)2DEVA5K 2 as a white powder (0.50 
mg, 0.15 µmol, 5%). LC-MS analysis (linear gradient 10 → 90% MeCN in 12 
min), tR: 5.033 min, ESI/MS (m/z): [M+2H]
2+ calculated for C144H238N38O53 





Ala-Lys-NH2 (3): (Man1)3DEVA5K 3 was conjugated following the general 
procedure using: Az3DEVA5K 28 (4.85 mg, 1.55 µmol), 0.05M propargyl 
mannose 21 sol. (155.0 µl, 7.75 µmol), 0.05M sodium ascorbate sol. (155.0 
µl, 7.75 µmol) and 0.05M CuSO4 (4.65 µl, 93.0 µmol). Gel filtration followed 
by RP-HPLC (linear gradient 20 → 45% MeCN in 12 min) followed by 
lyophilisation yielded (Man1)3DEVA5K 3 as a white powder (0.42 mg, 0.11 
µmol, 7%). LC-MS analysis (linear gradient 10 → 90% MeCN in 12 min), tR: 
5.027 min, ESI/MS (m/z): [M+2H]2+ calculated for C161H265N43O61 1888.94, 




Leu-Ala-Ala-Ala-Ala-Ala-Lys-NH2 (4): (Man1)6DEVA5K 4 was conjugated 




0.05M propargyl mannose 21 sol. (110.4 µl, 5.52 µmol), 0.05M sodium 
ascorbate sol. (110.4 µl, 5.52 µmol) and 0.05M CuSO4 (4.14 µl, 82.8 µmol). 
Gel filtration followed by RP-HPLC (linear gradient 20 → 45% MeCN in 12 
min) followed by lyophilisation yielded (Man1)6DEVA5K 4 as a white powder 
(0.22 mg, 0.05 µmol, 7%). LC-MS analysis (linear gradient 10 → 90% MeCN 
in 12 min), tR: 4.900 min, ESI/MS (m/z): [M+3H]
3+ calculated for 






Man2)1DEVA5K 5 was conjugated following the general procedure using: 
Az1DEVA5K 26 (9.06 mg, 3.36 µmol), 0.05M 1,2-Man2 22 sol. (201.6 µl, 
10.08 µmol), 0.05M sodium ascorbate sol. (201.6 µl, 10.08 µmol) and 0.05M 
CuSO4 (3.36 µl, 67.2 µmol). Gel filtration followed by RP-HPLC (linear 
gradient 20 → 45% MeCN in 12 min) followed by lyophilisation yielded (1,2-
Man2)1DEVA5K 5 as a white powder (0.98 mg, 0.32 µmol, 9%). LC-MS 
analysis (linear gradient 10 → 90% MeCN in 12 min), tR: 5.060 min, ESI/MS 
(m/z): [M+2H]2+ calculated for C133H221N33O50 1540.78, found 1540.80; 




NH2 (6): (1,2-Man2)2DEVA5K 6 was conjugated following the general 
procedure using: Az2DEVA5K 27 (8.41 mg, 2.89 µmol), 0.05M 1,2-Man2 22 
solution (231.2 µl, 11.56 µmol), 0.05M sodium ascorbate sol. (231.2 µl, 11.56 
µmol) and 0.05M CuSO4 (5.78 µl, 115.6 µmol). Gel filtration followed by RP-
HPLC (linear gradient 20 → 45% MeCN in 12 min) followed by 
lyophilisation yielded (1,2-Man2)2DEVA5K 6 as a white powder (0.83 mg, 
0.23 µmol, 8%). LC-MS analysis (linear gradient 10 → 90% MeCN in 12 
min), tR: 4.990 min, ESI/MS (m/z): [M+2H]
2+ calculated for C156H258N38O63 
1836.40, found 1836.27; [M+3H]3+ calculated for C156H259N38O63 1224.60, 
found 1224.53. 






Ala-Ala-Ala-Lys-NH2 (7): (1,2-Man2)3DEVA5K 7 was conjugated following 
the general procedure using: Az3DEVA5K 28 (5.37 mg, 1.72 µmol), 0.05M 
1,2-Man2 22 sol. (172.0 µl, 8.60 µmol), 0.05M sodium ascorbate sol. (172.0 
µl, 8.60 µmol) and 0.05M CuSO4 (5.16 µl, 103.2 µmol). Gel filtration 
followed by RP-HPLC (linear gradient 20 → 45% MeCN in 12 min) followed 
by lyophilisation yielded (1,2-Man2)3DEVA5K 7 as a white powder (0.55 mg, 
0.13 µmol, 8%). LC-MS analysis (linear gradient 10 →90% MeCN in 12 
min), tR: 4.937 min, ESI/MS (m/z): [M+3H]
3+ calculated for C179H296N43O76 





Man2)6DEVA5K 8 was conjugated following the general procedure using: 
Az6DEVA5K 29 (3.20 mg, 0.92 µmol), 0.05M 1,2-Man2 22 sol. (147.2 µl, 7.36 
µmol), 0.05M sodium ascorbate sol. (147.2 µl, 7.36 µmol) and 0.05M CuSO4 
(5.52 µl, 110.4 µmol). Gel filtration followed by RP-HPLC (linear gradient 
20 → 45% MeCN in 12 min) followed by lyophilisation yielded (1,2-
Man2)6DEVA5K 8 as a white powder (0.72 mg, 0.13 µmol, 14%). LC-MS 
analysis (linear gradient 10 → 90% MeCN in 12 min), tR: 4.990 min, ESI/MS 






Man2)1DEVA5K 9 was conjugated following the general procedure using: 
Az1DEVA5K 26 (7.32 mg, 2.71 µmol), 0.05M 1,3-Man2 23 sol. (162.6 µl, 8.13 
µmol), 0.05M sodium ascorbate sol. (162.6 µl, 8.13 µmol) and 0.05M CuSO4 
(2.71 µl, 54.2 µmol). Resin purification followed by RP-HPLC (linear 




Man2)1DEVA5K 9 as a white powder (2.11 mg, 0.68 µmol, 25%). LC-MS 
analysis (linear gradient 10 →90% MeCN in 12 min), tR: 5.017 min, ESI/MS 
(m/z): [M+2H]2+ calculated for C133H221N33O50 1540.78, 1540.73; [M+3H]
3+ 




NH2 (10) (1,3-Man2)2DEVA5K 10 was conjugated following the general 
procedure using: Az2DEVA5K 27 (7.41 mg, 2.55 µmol), 0.05M 1,3-Man2 23 
sol. (204.0 µl, 10.2 µmol), 0.05M sodium ascorbate sol. (204.0 µl, 10.2 µmol) 
and 0.05M CuSO4 (102.0 µl, 5.1 µmol). Resin purification followed by RP-
HPLC (linear gradient 20 → 45% MeCN in 12 min) followed by 
lyophilisation yielded (1,3-Man2)2DEVA5K 10 as a white powder (1.61 mg, 
0.44 µmol, 17%). LC-MS analysis (linear gradient 10 →90% MeCN in 12 
min), tR: 4.957 min, ESI/MS (m/z): [M+2H]
2+ calculated for C156H258N38O63 





Ala-Ala-Ala-Lys-NH2 (11): (1,3-Man2)3DEVA5K 11 was conjugated 
following the general procedure using: Az3DEVA5K 28 (5.09 mg, 1.63 µmol), 
0.05M 1,3-Man2 23 sol. (163.0 µl, 8.15 µmol), 0.05M sodium ascorbate sol. 
(163.0 µl, 8.15 µmol) and 0.05M CuSO4 (97.8 µl, 4.89 µmol). Resin 
purification followed by RP-HPLC (linear gradient 20 → 40% MeCN in 12 
min) followed by lyophilisation yielded (1,3-Man2)3DEVA5K 11 as a white 
powder (0.1.42 mg, 0.33 µmol, 20%). LC-MS analysis (linear gradient 10 
→90% MeCN in 12 min), tR: 4.903 min, ESI/MS (m/z): [M+3H]
3+ calculated 








Man2)6DEVA5K 12 was conjugated following the general procedure using: 
Az6DEVA5K 29 (2.7 mg, 0.78 µmol), 0.05M 1,3-Man2 23 sol. (124.8 µl, 6.24 
µmol), 0.05M sodium ascorbate sol. (124.8 µl, 6.24 µmol) and 0.05M CuSO4 
(93.6 µl, 4.68 µmol). Resin purification followed by RP-HPLC (linear 
gradient 10 → 90% MeCN in 12 min) followed by lyophilisation yielded (1,3-
Man2)6DEVA5K 12 as a white powder (1.93 mg, 0.34 µmol, 43%). LC-MS 
analysis (linear gradient 10 → 90% MeCN in 12 min), tR: 4.813 min, ESI/MS 






Man2)1DEVA5K 13 was conjugated following the general procedure using: 
Az1DEVA5K 26 (7.40 mg, 2.74 µmol), 0.05M 1,6-Man2 24 sol. (164.4 µl,8.22 
µmol), 0.05M sodium ascorbate sol. (164.4 µl, 8.22 µmol) and 0.05M CuSO4 
(54.8 µl, 2.74 µmol). Resin purification followed by RP-HPLC (linear 
gradient 20 → 40% MeCN in 12 min) followed by lyophilisation yielded (1,6-
Man2)1DEVA5K 13 as a white powder (3.99 mg, 1.3 µmol, 48%). LC-MS 
analysis (linear gradient 10 →90% MeCN in 12 min), tR: 5.013 min, ESI/MS 
(m/z): [M+2H]2+ calculated for C133H221N33O50 1540.78, found 1540.73, 




NH2 (14): (1,6-Man2)2DEVA5K 14 was conjugated following the general 
procedure using: Az2DEVA5K 27 (8.11 mg, 2.79 µmol), 0.05M 1,6-Man2 24 
sol. (223.2 µl, 11.16 µmol), 0.05M sodium ascorbate sol. (223.2 µl, 11.16 
µmol) and 0.05M CuSO4 (111.6 µl, 5.58 µmol). Resin purification followed 
by RP-HPLC (linear gradient 20 → 40% MeCN in 12 min) followed by 
lyophilisation yielded (1,6-Man2)2DEVA5K 14 as a white powder (2.30 mg, 
0.63 µmol, 22%). LC-MS analysis (linear gradient 10 →90% MeCN in 12 
min), tR: 4.970 min, ESI/MS (m/z): [M+2H]









Ala-Ala-Ala-Lys-NH2 (15): (1,6-Man2)3DEVA5K 15 was conjugated 
following the general procedure using: Az3DEVA5K 28 (5.02 mg, 1.61 µmol), 
0.05M 1,6-Man2 24 sol. (161.0 µl, 8.0.5 µmol), 0.05M sodium ascorbate sol. 
(161.0 µl, 8.05 µmol) and 0.05M CuSO4 (69.6 µl, 3.48 µmol). Resin 
purification followed by RP-HPLC (linear gradient 20 → 40% MeCN in 12 
min) followed by lyophilisation yielded (1,6-Man2)3DEVA5K 15 as a white 
powder (0.93 mg, 0.22 µmol, 14%). LC-MS analysis (linear gradient 10 
→90% MeCN in 12 min), tR: 4.893 min, ESI/MS (m/z): [M+3H]
3+ calculated 





Man2)6DEVA5K 16 was conjugated following the general procedure using: 
Az6DEVA5K 29 (2.6 mg, 0.75 µmol), 0.05M 1,6-Man2 24 sol. (120.0 µl, 6.0 
µmol), 0.05M sodium ascorbate sol. (120.0 µl, 6.0 µmol) and 0.05M CuSO4 
(90.0 µl, 4.5 µmol). Resin purification followed by RP-HPLC (linear gradient 
10 → 90% MeCN in 12 min) followed by lyophilisation yielded (1,6-
Man2)6DEVA5K 16 as a white powder (1.33 mg, 0.23 µmol, 35%). LC-MS 
analysis (linear gradient 10 →90% MeCN in 12 min), tR: 4.810 min, ESI/MS 




Man3)1DEVA5K 17 was conjugated following the general procedure using: 
Az1DEVA5K 26 (7.45 mg, 2.76 µmol), 0.05M 1,3-1,6-Man3 25 sol. (165.6 µl, 
8.28 µmol), 0.05M sodium ascorbate sol. (165.5 µl, 8.28 µmol) and 0.05M 
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CuSO4 (55.2 µl, 2.76 µmol). Gel filtration followed by RP-HPLC (linear 
gradient 20 → 40% MeCN in 12 min) followed by lyophilisation yielded (1,3-
1,6-Man3)1DEVA5K 17 as a white powder (1.11 mg, 0.34 µmol, 12%). LC-
MS analysis (linear gradient 10 → 90% MeCN in 12 min), tR: 4.993 min, 
ESI/MS (m/z): [M+2H]2+ calculated for C139H231N33O55 1621.31, found 




Lys-NH2 (18): (1,3-1,6-Man3)2DEVA5K 18 was conjugated following the 
general procedure using: Az2DEVA5K 27 (8.34 mg, 2.87 µmol), 0.05M 1,3-
1,6-Man3 25 sol. (229.6 µl, 11.48 µmol), 0.05M sodium ascorbate sol. (229.6 
µl, 11.48 µmol) and 0.05M CuSO4 (114.8 µl, 5.74 µmol). Gel filtration 
followed by RP-HPLC (linear gradient 20 → 45% MeCN in 12 min) followed 
by lyophilisation yielded (1,3-1,6-Man3)2DEVA5K 18 as a white powder (0.73 
mg, 0.18 µmol, 6%). LC-MS analysis (linear gradient 10 →90% MeCN in 12 
min), tR: 4.903 min, ESI/MS (m/z): [M+2H]
2+ calculated for C168H278N38O73 





Leu-Ala-Ala-Ala-Ala-Ala-Lys-NH2 (19): (1,3-1,6-Man3)3DEVA5K 19 was 
conjugated following the general procedure using: Az3DEVA5K 28 (4.90 mg, 
1.57 µmol), 0.05M 1,3-1,6-Man3 25 sol. (157.0 µl, 7.85 µmol), 0.05M sodium 
ascorbate sol. (157.0 µl, 7.85 µmol) and 0.05M CuSO4 (94.2 µl, 4.71 µmol). 
Gel filtration followed by RP-HPLC (linear gradient 25 → 50% MeCN in 12 
min) followed by lyophilisation yielded (1,3-1,6-Man3)3DEVA5K 19 as a 
white powder (0.36 mg, 0.08 µmol, 5%). LC-MS analysis (linear gradient 10 
→90% MeCN in 12 min), tR: 4.837 min, ESI/MS (m/z): [M+3H]
3+ calculated 








Lys-NH2 (20): (1,3-1,6-Man3)6DEVA5K 20 was conjugated following the 
general procedure using: Az6DEVA5K 29 (2.50 mg, 0.72 µmol), 0.05M 1,6-
Man2 25 sol. (115.2 µl, 5.76 µmol), 0.05M sodium ascorbate sol. (115.2 µl, 
5.76 µmol) and 0.05M CuSO4 (86.4 µl, 4.32 µmol). Gel filtration followed by 
RP-HPLC (linear gradient 10 → 90% MeCN in 12 min) followed by 
lyophilisation yielded (1,3-1,6-Man3)6DEVA5K 20 as a white powder (0.58 
mg, 0.09 µmol, 12%). LC-MS analysis (linear gradient 10 →90% MeCN in 
12 min), tR: 4.717 min, ESI/MS (m/z): [M+3H]
3+ calculated for 
C274H452N53O140 2243.0, found 2242.9; [M+4H]
4+ calculated for 
C274H453N53O140 1682.5, found 1683.1; [M+5H]
5+ calculated for 
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Synthesis of mannose configured cyclophellitol 









Carbohydrates are structurally the most diverse class of biopolymers. They 
not only occur as oligosaccharides and polysaccharides but are also 
constituents of glycoproteins and glycolipids.
2
 These glycoconjugates are 
involved in numerous fundamental biological processes, such as 
communication processes
3
 and cell-cell recognition.
4,5
 Gaining insight into 
the role of carbohydrates and glycoconjugates in these biological processes 
is complicated by their complex structure, their transient occurrence and 
their biosynthesis that is not directly controlled by the genetic code.
6
 The 
metabolism of glycoconjugates is guided by glycosyltransferases, enzymes 
that specifically introduce glycosidic bonds, and glycosidases, enzymes that 
specifically cleave glycosidic bonds.
7
 Establishment of the activity of these 
enzymes in a defined biological context is an important approach to 
elucidate their role and the function of the corresponding glycans. In this 




rapidly advancing field of research in the past decade.
8
 Central and vital for 
this type of research is the development of activity based probes (ABPs). 
These probes are characterized by the presence of an irreversible activity 




Recently, major advances in the development of APBs for glycosidases have 
been made.
10
 Key to the success of these ABPs is the classical Koshland 
double-replacement mechanism of retaining glycosidases.
11
 As shown in 
Figure 1a two carboxylic acid residues (Asp or Glu) in the active site of the 
enzyme are involved in the two-step process.
12
 In the first step protonation 
by one carboxylic acid residue of the glycan substrate and nucleophilic 
displacement by the second carboxylate leads to a covalent enzyme-glycosyl 
intermediate with inversion of configuration. In the next step the formed 
carboxylate anion assists in the hydrolysis of the enzyme-glycosyl 
intermediate to give the stripped glycan with retention of configuration with 
respect to the substrate. Fluorinated glycosides and cyclitol epoxides are two 




Figure 1: a) Classical Koshland double replacement mechanism of retaining beta-
glucosidases. b) Structure of cyclophellitol. c) Proposed mechanism of cyclophellitol binding 
to retaining beta-glucosidases. 
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Cyclophellitol (Figure 1b), the cyclitol analogue of D-glucopyranose with an 
β-configured epoxide, is an irreversible and naturally occurring β-
glucosidase inhibitor.
13
 The inhibition mechanism comprises protonation of 
the epoxide in the active site by the general acid/base catalyst, followed by 
nucleophilic attack of the carboxylate to give a covalent cyclophellitol-





Figure 2: Structures of cyclophellitol based ABPs. a) Structures of BODIPY conjugated 
cyclophellitol 1 and 2 and its aziridine derivative 3. b) Structures of functionalized aziridine 
cyclophellitol 4-7. c) Structures of α/β-galactose configured cyclophellitol 8-15. d) Structures 
of α/β-galactose configured functionalized aziridine cyclophellitol 16-19. e) Structures of 
mannose configured α/β-cyclophellitol 20, 21 and α/β-mannose configured aziridine 
cyclophellitol derivatives 22 and 23. 
 
Based on the mode of action of cyclophellitol, Witte et al.
15
 developed two 
ABPs (1 and 2, Figure 2a) allowing highly specific and efficient labelling of 
active glucocerebrosidase, key enzyme in Gaucher disease.
16




describes the synthesis of Man1- and Man3-BODIPY-cyclophellitol probes 
designed to selectively target the probes to Gaucher macrophages. Next to 
the epoxide based probes, broad spectrum ABPs for β-glucosidases were 
developed
17
 by replacement of the epoxide electrophilic trap in 
cyclophellitol by functionalized aziridines
18,19
 (as in 4-7, Figure 2b). In this 
manner the reporter group or ligation handle could be varied and installed at 
a position in the ABP pointing towards the aglycon site, where most glycosyl 
hydrolases (GHs) are more relaxed in their substrate specificity. 
The synthesis of cyclophellitol analogs derived from the common 
monosaccharides found in mammalian and bacterial glycans will provide an 
ABP toolbox that can be used to interrogate different GHs that use the 
Koshland double-replacement mechanism. Willems et al. synthesized both 
α- and -galactopyranose configured cyclophellitol analogues 8-15 and the 
α-aziridine derivatives 18 and 19 (Figure 2c-d).
20,21 
Synthesis of β-Aziridine 
derivative 16 and 17 is currently in progress. With these probes GH27 
human retaining α-galactosidases could be detected.
22  
This chapter describes the synthesis of four cyclophellitol analogs having the 
D-mannose configuration (2-epi-cyclophellitol), bearing either an α- or - 
configured epoxide (20, 21, Figure 2e) or a α- or - aziridine function (22, 
23), to use these both as covalent inhibitors (the epoxides and non-
functionalized aziridines) and as a starting point for the generation of ABPs. 
 
 
Results and discussion  
 
Up to now only one low yielding synthesis has been described for mannose 
configured cyclophellitol,
23
 whereas the corresponding aziridine has not 
been reported. To develop a straightforward route of synthesis towards these 
2-epi-cyclophellitol targets, it was reasoned that the Madsen route towards 
cyclophellitol
24
 (see Chapter 3) could be adapted, starting from the 
appropriate epimeric starting material, that is, D-ribose instead of D-xylose. 
Scheme 1 shows the synthesis of cyclohexene 32, the common precursor for 
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the 2-epi-cyclophellitol target epoxides and aziridines. Treatment of D-ribose 
with acetyl chloride in methanol under kinetic conditions gave methyl-D-
ribofuranose (24) as an α/β anomeric mixture. Selective tritylation of the 
primary alcohol in 24 and ensuing benzylation of the cis-diol to give fully 
protected ribose 26 followed by acid mediated detritylation furnishing ribose 
27
25
 in 72% yield over 4 steps. Substitution of the primary alcohol in 27 by 
iodine and subsequent reductive ring opening of 28 with activated zinc 
yielded aldehyde 29
26
, the required starting compound for the ensuing 
indium catalyzed Barbier reaction. 
In this key reaction the indium reagent derived from ethyl-4-bromocrotonate 
was formed in situ and added to aldehyde 29. Following this procedure diene 
30 was formed with excellent stereoselectivity (95:5 with respect to the 
undesired C-4 epimer). 
 
Scheme 1: Synthesis of cyclohexene precursor 32. 
 
Reagents and conditions: (a) acetyl chloride, MeOH, 0 °C to rt.; (b) trityl chloride, pyridine, 
rt.; (c) BnBr, NaH, DMF, 0 °C to rt.; (d) pTsOH, DCM/MeOH (1:1), rt, 72% over four steps; 
(e) i. (Ph)3P, imidazole, THF, reflux; ii. I2, THF, reflux, 93%; (f) act. Zn, THF/H2O (9:1), 60 
°C, sonicate, 40%; (g) ethyl 4-bromocrotonate, indium (powder), La(OTf)3, 61%; (h) Grubbs 
II, DCM, reflux 93%; (i) i. DIBAL-H, THF, 0 °C to rt. ii. NaBH4, EtOAc/H2O (2:1), 95%. 
 
This stereoselectivity can be explained by a similar transition state as 
proposed by Madsen and co-workers in the Barbier reaction leading to the 
cyclophellitol octadiene precursor. As depicted in Figure 3, a 6-membered 
ring transition state, in which the aldehyde and benzyl ether moieties in 29 




stereocenters (C-4 and C-5) in 30. Purification by column chromatography 
resulted in the isolation of homogenous 30 in 61% yield. RCM of diene 30 
using Grubbs 2
nd
 generation catalyst gave cyclohexene 31 in 93% yield. 
Reduction of the ethyl ester in 31 was accomplished by treatment with 
DIBAL-H and sodium borohydride to furnish primary alcohol 32, the 




Figure 3: Possible transition state of the indium catalyzed Barbier reaction of aldehyde 29 
with ethyl bromocrotonate leading to diene 30. 
 
 
The transformation of cyclohexene 32 into the four target compounds is 
shown in Scheme 2. Epoxidation of cyclohexene 32 using mCPBA resulted 
in a mixture of the α- and β-epoxides 33 and 34 in a 3:2 α/β-ratio and a 
combined 64% yield. Column chromatography gave the individual epoxides, 
the identity of which was ascertained by NMR experiments in combination 
with DFT calculations. The latter calculations were performed because the 
stereochemistry of the newly formed epoxides cannot be simply derived 
from the coupling constants of the ring protons. 
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Scheme 2: Scheme overview synthesis of target compounds 20, 21, 22 and 23. 
 
Reagents and conditions: (a) mCPBA, DCE, reflux (33: 38%, 34: 26%); (b) Pd/C, H2 (g), 
MeOH; (c) Pd/C, H2 (g), 1,4-dioxane/tBuOH (9:1), rt. (20: 40%, 21: 36%); (d) BnBr, NaH, 
DMF, 0 °C to rt (52%); (e) NaN3, LiClO4; (f) MsCl, pyridine (40: 88%, 41: 72%); (g) 
LiAlH4, THF, 0 °C (31%); (h) Cl3CCN, DBU, DCM, 0 °C to rt, 94%; (i) I2, NaHCO3, 
THF/H2O (4:1), 60 °C, 80%; (j) i. 1,4-dioxane/H2O/AcOH (1:1:8), rt.; ii. NaHCO3, MeOH, 
93%; (k) Li, NH3 (l), -60 °C, quantitative. 
 
The spectroscopic data and calculated coupling constants for both the 
4
H3 
and the opposite 
3
H4 half chair - and - epoxides are summarized in Table 
1. Comparison of the experimental 
3
J coupling constants of the two epoxide 
isomers with the calculated values show that the coupling constants for the 
protons of epoxide 34 match best with the series of coupling constants 
calculated for the -epoxide in a 
4
H3 conformation, where there is also good 
agreement between the recorded coupling constants of epoxide 35 and the 
calculated -epoxide in a 
4
H3 half chair. The measured and calculated 







Figure 4: Absolute configuration of a) α-epoxide 34 b) and β-epoxide 35. *Calculated 
coupling constants. 
 
Table 1: Calculated and experimental J coupling α-epoxide 34 and β-epoxide 35. 
 
To conclude the synthesis of the epoxides, the removal of the benzyl groups 
in epoxides 33 and 34 was undertaken (Scheme 2). Hydrogenolysis of the 
benzyl groups in 34 with Pd/C and H2 in MeOH gave a mixture of products. 
With the aid of NMR spectroscopy and mass spectrometry it was revealed 
entry correlation 
3
H4 J calc. (Hz) 
4










1 H1-H2 3.6 3.6 3.2 3.4 3.6 3.7 
2 H2-H3 0.01 3.8 2.8 4.8 3.1 5.0 
3 H3-H4 4.8 8.5 2.7 5.4 2.9 5.0 
4 H4-H5 4.4 8.2 8.2 8.1 10.1 9.7 
5 H5-H6 1.6 7.9 7.5 7.8 8.8 6.9 
6 H6-H7 0.5 2.3 4.1 2.3 5.6 5.0 
7 H6-H7’ 6.4 8.3 10.4 8.3 6.8 7.1 
8 H6-H1 1.3 1.1 0.1 1.9 0.0 2.0 
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that the crude reaction mixture contained the desired compound 21 next to 
side product 35, originating from ring opening of the epoxide by methanol. 
Changing the solvent mixture of the hydrogenolysis to 1,4-dioxane/tBuOH 
(9:1) prevented the undesired epoxide ring opening and led to the isolation 
of target epoxides 20 and 21 in 40% and 36% yield, respectively, after 
crystallization. 
β-Configured aziridine (22) was obtained by adaptation of the procedure that 
was used to prepare β-cyclophellitol aziridine
18
 (Scheme 2). First, the 
trichloroacetimidate function was regioselectively introduced at the primary 
hydroxyl group by treatment of cyclohexene 32 with trichloroacetonitrile 
and DBU to give 36. Next, stereospecific iodo-cyclisation gave oxazine 37 
in 80% yield. Hydrolysis of oxazine could be effected by treatment with 
80% AcOH (1,4-dioxanes/H2O/AcOH, 1:1:8) at ambient temperature. It is of 
interest to note that for the same opening of cyclophellitol oxazine heating at 
60 °C in an HCl solution is prescribed. Base treatment of the crude 1,2-trans 
amino iodide provided β-aziridine 38 in 93% yield. The removal of the 
benzyl protective groups required some optimization. Using a reported 
procedure, in which Birch reduction is followed by treatment with Amberlite 
IR-H
+ 
to remove the lithium salts, gave an inseparable mixture of 
compounds. Treating the crude product with Amberlite IR-NH4
+
 was 
successful and β-manno-aziridine 22 was isolated in 70% overall yield 
starting from cyclohexene 38. 
α-Mannose configured aziridine cyclophellitol 23 was obtained from β-
manno-epoxide 33 as depicted in Scheme 2. Perbenzylation of β-epoxide 33 
was followed by epoxide opening by the azide anion in presence of LiClO4 
to afford a 1:1 mixture of azido alcohol regioisomers 40 and 41. Separation 
by column chromatography gave the individual isomers 40 and 41 in 48% 
and 52% yield, respectively. Mesylation of the free hydroxyl in 40 and 41 
yielded compound 42 and 43, suitable for α-aziridine formation. To this end 
cyclitol 43 was subjected to LiAlH4 treatment. Monitoring of the reaction by 
TLC-MS showed formation of the amine product, the desired aziridine and 




more of the amine into the desired aziridine was accompanied by an increase 
of hydrolyzed side product and decrease of yield. After 4h the mixture was 
quenched and purification by column chromatography provided the 
benzylated α-aziridine 44 in a yield of 31%. Finally, removal of the benzyl 
groups by Birch reduction and treatment of resulting mixture with Amberlite 
NH4
+
 IR-120 as described for the β-aziridine yielded α-manno-aziridine 23 





This chapter describes the synthesis of the α- and β-mannose configured 
cyclophellitol derivatives 20 and 21 and the corresponding aziridine 
analogues 22 and 23. The key indium catalyzed Barbier reaction, in which 
two new stereocenters were introduced, proceeded with excellent 
stereoselectively. Central intermediate cyclohexene 32 was used for the 
synthesis of both the - and β-epoxides 20 and 21 and the β-aziridine 22, 
while the α-aziridine 23 was constructed from the β-epoxide 20. 
The obtained epoxides and aziridines can be explored as mechanism based 
covalent inhibitors for - and -mannosidases, that hydrolyze mannosidic 
linkages with retention of configuration, such as the glycosyl hydrolases 








. Aziridines 22 and 23 
can also be further processed by installation of N-alkyl and N-acyl groups to 





General: Traces of water in the starting materials were removed by co-
evaporation with toluene for all moisture and oxygen sensitive reactions and 
the reactions were performed under an argon atmosphere. Dichloromethane 
was distilled over P2O5 and stored over activated 3 Å molecular sieves under 
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an argon atmosphere. All other solvents and chemicals (Acros, Fluca, 
Merck) were of analytical grade and used as received. Column 
chromatography was performed on Screening Device silica gel 60 (0.040-
0.063 mm). Size exclusion was performed on Sepadex LH20 (eluent 
DCM/MeOH, 1:1). TLC analysis was conducted on HPTLC aluminium 
sheet (Merck, TLC silica gel 60, F254). Compounds were visualized by UV 
absorption (λ = 254 nm), staining with p-anisaldehyde (3.7 mL in 135 mL 
EtOH, 1.5 mL AcOH and 5 mL H2SO4), 20% H2SO4 in EtOH or with a 
solution of (NH4)6Mo7O24·4H2O (25g/L) in 10% H2SO4 in H2O followed by 




C NMR were recorded on a Bruker DPX 
300 (300 and 75 MHz respectively), Bruker AV 400 (400 and 100 MHz 
respectively), Bruker DMX 400 (400 and 100 MHz respectively) or Bruker 
DMX 600 (600 and 125 MHz respectively). Chemical shifts are given in 
ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal 
standard. J couplings are given in Hz. Optical rotations were measured on a 
Propol automatic polarimeter. IR spectra (thin film) were conducted on a 
Perkin Elmer FTIR Spectrum Two UATR (Single reflection diamond). LC-
MS measurements were conducted on a Thermo Finnigan LCQ Advantage 
MAX ion-trap mass spectrometer (ESI+) coupled to a Thermo Finnigan 
Surveyor HPLC system equipped with a standard C18 (Gemini, 4.6 mm x 50 
mm, 5µm particle size, Phenomenex) analytical column and buffers A: H2O, 
B: MeCN, C: 0.1% TFA (aq.). High-resolution mass spectra were recorded 
on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer.  
 
methyl 2,3-di-O-benzyl-D-ribofuranoside (27): To a 0 °C 
cooled solution of D-(-)-ribose (37.5 g, 250 mmol) in MeOH 
(500 mL) was added dropwise AcCl (3.5 mL, 50 mmol) and the reaction 
mixture was allowed to warm to rt. After complete conversion of the starting 
material the reaction was quenched with Et3N till pH ≥7 and the mixture was 
concentrated in vacuo giving OMe-ribose 24 as an α/β mixture (1:0.3). The 
crude OMe-ribose 24 was co-evaporated with toluene and dissolved in 




mmol) and the mixture was stirred overnight at rt. The reaction was 
quenched with MeOH and the mixture was concentrated in vacuo. The 
product was dissolved in EtOAc and the organic phase was washed with 
H2O (3x), brine (2x), dried over MgSO4, filtered and concentrated in vacuo. 
The crude tritylated OMe-ribose 25 was taken up in DMF (1 L) and to the 
solution was added BnBr (90 mL, 750 mmol) and the mixture was cooled to 
0 °C. To the cooled mixture was added (60%) NaH (25 g, 625 mmol) in 
small portions over a period of 6h. The reaction was gradually allowed to 
warm to rt and stirred overnight. The reaction mixture was cooled to 0 °C 
and quenched with MeOH after which the solvents were removed in vacuo. 
The product was dissolved in Et2O and the organic phase was washed with 
H2O (3x), brine (2x), and dried over MgSO4. The crude was filtered over a 
bed of silica to remove the bulk of impurities, concentrated and dissolved in 
DCM/MeOH (1:1) (1 L). To the solution was added pTsOH (4.8 g, 25 
mmol) and the reaction mixture was stirred overnight at rt. The mixture was 
neutralized with Et3N and concentrated in vacuo. Purification by column 
chromatography yielded benzylated OMe-ribose 27 as a colourless oil (57.4 





H NMR (400 MHz, CDCl3) δ 7.40 – 7.23 (m, 
10H), 4.88 (s, 1H), 4.65 (d, J = 12.0 Hz, 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.56 
(d, J = 11.7 Hz, 1H), 4.47 (d, J = 11.7 Hz, 1H), 4.27 (dt, J = 6.9, 3.4 Hz, 
1H), 4.11 (dd, J = 7.0, 4.7 Hz, 1H), 3.85 (d, J = 4.7 Hz, 1H), 3.78 (d, J = 
12.2 Hz, 1H), 3.55 (ddd, J = 10.9, 7.3, 3.5 Hz, 1H), 3.34 (s, 3H), 2.15 (s, 
1H). 
13
C NMR (100 MHz, CDCl3) δ 137.7, 137.7, 128.5, 128.0, 127.9, 
127.9, 106.8, 82.3, 80.1, 77.3, 72.7, 72.5, 62.8, 55.6. 
(β-product)
 1
H NMR (400 MHz, CDCl3) δ 7.41 – 7.27 (m, 10H), 4.85 (d, J = 
4.1 Hz, 1H), 4.74 (d, J = 12.7 Hz, 1H), 4.66 (d, J = 12.3 Hz, 1H), 4.65 – 4.54 
(m, 2H), 4.17 (q, J = 3.5 Hz, 1H), 3.84 (dd, J = 6.9, 3.5 Hz, 1H), 3.73 (dd, J 
= 6.9, 4.2 Hz, 1H), 3.63 (dd, J = 12.0, 3.3 Hz, 1H), 3.45 (s, 3H), 3.39 (dd, J 
= 12.7, 3.5 Hz, 1H), 1.97 (s, 1H). 
13
C NMR (100 MHz, CDCl3) δ 138.2, 
137.8, 128.4, 128.4, 128.2, 128.0, 127.9, 127.8, 102.7, 83.2, 78.1, 74.7, 72.7, 
72.6, 62.7, 55.6. 





(28): To a solution of benzylated α-OMe-ribose 27 (51.7 g, 
113.8 mmol) in THF (455 mL) was added imidazole (15.5 g, 227.6 mmol), 
Ph3P (44.8 g, 170.7 mmol) and the mixture was heated till reflux. After 
complete consumption of the starting material a 1M I2 solution (170.7 mL, 
170 mmol) in THF was added dropwise to the boiling reaction mixture and 
refluxed overnight. The mixture was cooled to rt and Et2O was added, upon 
addition of Et2O crystalline precipitate was formed. The mixture was cooled 
to -20 °C and the solids were filtered. The filtrate was washed with 10% 
Na2S2O3 (aq.) (2x), H2O (3x), brine (2x) dried over MgSO4, filtered and 
concentrated in vacuo. The crude was immobilized on silica and purification 
by column chromatography yielded iodo ribose 28 as a colourless oil (47.8 





H NMR (300 MHz, CDCl3) δ 7.34 – 7.28 (m, 10H), 4.92 
(s, 1H), 4.65 (d, J = 11.7 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.57 (d, J = 
12.0 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H), 4.14 (t, J = 6.6 Hz, 1H), 3.94 (dd, J 
= 6.6, 4.5 Hz, 1H), 3.88 (d, J = 4.5 Hz, 1H), 3.38 – 3.33 (m, 4H), 3.26 (dd, J 
= 10.5, 6.0 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 137.7, 128.6, 128.1, 
128.0, 106.3, 81.8, 20.4, 80.2, 72.7, 72.5, 55.4, 8.8. 
 
 (2R,3R)-2,3-dibenzyloxypent-4-enal (29): Iodo ribose 28 (47.8 
g, 105.4 mmol) was dissolved in THF/H2O (9:1) (1 L) and the 
solution was purged with argon under sonication. To the solution 
was added activated zinc (65.4 g, 1.0 mol) and the mixture was further 
sonicated at 60 °C under argon atmosphere. After complete conversion of 
the starting material the excess of zinc was filtered and rinsed with DCM. 
The crude mixture was diluted with brine and the product was extracted with 
DCM (5x). The combined organic phase was dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography yielded 
aldehyde 29 as a colourless oil (12.47 g, 42 mmol, 40%). Spectroscopic data 
were in accordance with known literature data.
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CDCl3) δ 9.63 (d, J = 2.1 Hz, 1H), 7.39 – 7.24 (m, 10H), 5.87 (dt, J = 17.6, 
10.5, 7.6 Hz, 1H), 5.38 (d, J = 9.1 Hz, 1H), 5.34 (d, J = 16.9 Hz, 1H), 4.69 
(d, J = 12.0 Hz, 1H), 4.64 (d, J = 12.2 Hz, 2H), 4.40 (d, J = 12.0 Hz, 1H), 
4.16 (dd, J = 7.6, 4.6 Hz, 1H), 3.89 (dd, J = 4.6, 2.2 Hz, 1H). 
13
C NMR (100 
MHz, CDCl3) δ 201.7, 137.8, 137.3, 134.1, 128.6, 128.5, 128.1, 127.8, 
120.2, 85.0, 80.3, 73.1, 70.6. 
 
ethyl (2S,3R,4S,5R)-4,5-bis(benzyloxy)-3-hydroxy-2-
vinylhept-6-enoate (30) To a solution of aldehyde 29 (1.01 g, 
3.41 mmol) in H2O (15.4 mL) was added 75% ethyl 4-
bromocrotonate (2.04 mL, 11.1 mmol), La(OTf)3 (4.00 g, 6.83 mmol), 
indium powder (0.90 g, 7.85 mmol) and the mixture was vigorously stirred 
overnight at rt. The reaction mixture turned into a white slurry in which sand 
was added till small balls were formed. The mixture was filtered over a pad 
of celite and rinsed with Et2O. The layers were separated and the aqueous 
layer was extracted with Et2O (3x). The combined organic phase was washed 
with H2O (3x), brine (3x), dried over MgSO3, filtered and concentrated in 
vacuo. Purification by column chromatography yielded manno diene 30 as a 
colourless oil (0.853 g, 2.078 mmol, 61%). 
1
H NMR (400 MHz, CDCl3) δ 
7.37 – 7.26 (m, 10H), 5.89 (ddd, J = 17.5, 10.4, 7.2 Hz, 1H), 5.72 (ddd, J = 
17.1, 10.3, 9.4 Hz, 1H), 5.41 (dt, J = 9.2, 1.3 Hz, 1H), 5.37 (t, J = 1.2 Hz, 
1H), 5.14 (dd, J = 10.3, 1.4 Hz, 1H), 5.08 (d, J = 17.1 Hz, 1H), 4.68 (d, J = 
11.2 Hz, 1H), 4.64 (d, J = 11.7 Hz, 1H), 4.44 (d, J = 11.3 Hz, 1H), 4.40 (d, J 
= 11.7 Hz, 1H), 4.24 (ddd, J = 9.5, 6.8, 1.3 Hz, 1H), 4.17 (t, J = 6.6 Hz, 1H), 
4.13 (q, J = 7.3 Hz, 2H), 3.44 (dd, J = 5.8, 1.3 Hz, 1H), 3.34 (t, J = 9.5 Hz, 
1H), 3.14 (d, J = 6.9 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, 
CDCl3) δ 172.6, 137.9, 137.9, 135.5, 133.1, 128.5, 128.5, 128.1, 128.0, 
128.0, 127.8, 120.0, 119.6, 80.2, 79.0, 73.2, 72.0, 71.0, 60.9, 55.0, 14.2. 
HRMS: [M+H]
+








2-enecarboxylate (31) To a solution of manno diene 30 (0.575 
g, 1.4 mmol) in DCM (56 mL) was added Grubbs 2
nd
 catalyst 
(95 mg, 0.11 mmol, 8 mol%) and the reaction mixture was refluxed in the 
dark for 2 h. The mixture was concentrated in vacuo and directly purified by 
column chromatography without further workup yielding cyclohexene ethyl 
ester 31 as a slightly brown oil (0.498 g, 1.302 mmol, 93%). [α]D
22
 + 42.8° (c 
= 1.0, DCM). 
1
H NMR (400 MHz, CDCl3) δ 7.40 – 7.27 (m, 10H), 5.89 
(ddd, J = 9.9, 5.2, 2.8 Hz, 1H), 5.82 (dd, J = 9.9, 2.4 Hz, 1H), 4.74 (d, J = 
11.9 Hz, 1H), 4.69 (s, 2H), 4.62 (d, J = 11.8 Hz, 1H), 4.55 (ddd, J = 10.4, 
8.8, 1.8 Hz, 1H), 4.21 (qd, J = 7.1, 0.8 Hz, 2H), 4.09 (t, J = 4.4 Hz, 1H), 3.46 
(dd, J = 10.2, 4.0 Hz, 1H), 3.13 (ddt, J = 8.9, 2.5, 0.9 Hz, 1H), 2.91 (d, J = 
1.9 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ 171.6, 
138.6, 138.1, 128.6, 128.5, 128.1, 128.0, 128.0, 127.8, 127.5, 126.7, 80.3, 
72.2, 71.9, 69.6, 67.3, 61.4, 51.2, 14.3. HRMS: [M+H]
+
 calculated for 
C23H27O5 383.18530, found 383.18548. 
 
(1S,2R,5S,6S)-5,6-bis(benzyloxy)-2-(hydroxymethyl)cyclohex-3-enol 
(32): To a 0 °C cooled solution of cyclohexene ethyl ester 31 
(0.463 g, 1.2 mmol) in THF (40 mL) was added a 1M DIBAL-
H sol. (6 mL, 6 mmol) in THF dropwise and the mixture was 
warmed to rt. After 30 min the mixture was cooled to 0 °C and to the 
mixture was added EtOAc (2.4 mL, 24.4 mmol), H2O (1.2 mL) and NaBH4 
(0.295 g, 7.8 mmol) in small portions. After stirring for 20 min at 0 °C TLC 
showed full conversion of the starting material and the mixture was diluted 
with EtOAc. The mixture was transferred to a separation funnel and H2O 
was added giving a white slurry. 1M HCl (aq.) was added till a clear two 
phase system was formed. The layers were separated and the aqueous layer 
was extracted with EtOAc (3x). The combined organic phase was washed 
with sat. NaHCO3 (aq.), H2O (3x), brine (3x), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography yielded 
manno cyclohexene 32 as a white amorphous solid [α]D
22




DCM). (0.387 g, 1.137 mmol, 95%). 
1
H NMR (600 MHz, CDCl3) δ 7.39 – 
7.27 (m, 10H), 5.88 (ddd, J = 9.9, 5.3, 2.8 Hz, 1H), 5.64 (dd, J = 9.9, 2.3 Hz, 
1H), 4.72 (d, J = 11.6 Hz, 1H), 4.68 (d, J = 12.3 Hz, 1H), 4.67 (d, J = 12.1 
Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.13 – 4.08 (m, 2H), 3.81 – 3.73 (m, 2H), 
3.46 (dd, J = 10.2, 3.9 Hz, 1H), 2.97 (s, 1H), 2.64 (s, 1H), 2.44 – 2.37 (m, 
1H). 
13
C NMR (150 MHz, CDCl3) δ 138.6, 137.9, 130.7, 128.7, 128.5, 
128.1, 128.1, 128.1, 127.9, 81.1, 71.8, 71.7, 70.1, 69.4, 65.9, 46.6. HRMS: 
[M+H]
+
 calculated for C21H25O4 341.17474, found 341.17501.  
 
Epoxidation  
To a solution of manno cyclohexene 32 (0.953 g, 2.8 mmol) in DCE (48 mL) 
was added mCPBA (55%) (1.32 g, 4.2 mmol) and the mixture was heated to 
reflux. After complete conversion of the starting material the mixture was 
cooled to rt and silica was added to the mixture after which the solvents were 
removed in vacuo. The immobilized product was directly purified by column 
chromatography yielding benzylated β-manno cyclophellitol 33 (0.283 g, 
0.794 mmol, 29%) and benzylated α-manno cyclophellitol 34 (0.180 g, 




 + 64.7° (c = 
1.0 DCM). 
1
H NMR (600 MHz, CDCl3) δ 7.45 – 7.41 (m, 2H), 
7.39 – 7.27 (m, 8H), 4.85 (d, J = 12.1 Hz, 1H), 4.65 (d, J = 
11.6 Hz, 1H), 4.63 (d, J = 12.1 Hz, 1H), 4.42 (d, J = 11.6 Hz, 1H), 4.10 – 
4.05 (m, 2H), 3.93 (dd, J = 10.7, 5.1 Hz, 2H), 3.91 (t, J = 9.7 Hz, 1H), 3.28 
(dd, J = 3.7, 2.0 Hz, 1H), 3.24 (dd, J = 4.9, 3.7 Hz, 1H), 3.20 (dd, J = 10.1, 
5.0 Hz, 1H), 2.76 (s, 1H), 2.61 (s, 1H), 2.10 (dddd, J = 9.1, 7.1, 5.2, 2.0 Hz, 
1H). 
13
C NMR (151 MHz, CDCl3) δ 137.8, 137.5, 128.7, 128.6, 128.5, 
128.2, 128.1, 79.7, 71.5, 71.4, 68.5, 67.1, 64.5, 54.6, 50.4, 44.8. HRMS: 
[M+H]
+




 -32.3° (c = 
1.0 DCM). 
1
H NMR (400 MHz, CDCl3) δ 7.40 – 7.27 (m, 
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10H), 4.83 (d, J = 12.0 Hz, 1H), 4.65 (d, J = 11.9 Hz, 1H), 4.62 (d, J = 11.6 
Hz, 1H), 4.51 (d, J = 11.6 Hz, 1H), 4.28 (t, J = 2.9 Hz, 1H), 3.93 (dd, J = 
9.8, 3.4 Hz, 1H), 3.91 (d, J = 10.2 Hz, 1H), 3.83 (dd, J = 10.7, 5.8 Hz, 1H), 
3.53 (dd, J = 10.1, 3.1 Hz, 1H), 3.26 (t, J = 3.1 Hz, 1H), 3.07 (d, J = 3.6 Hz, 
1H), 2.69 (s, 2H), 2.18 (dt, J = 8.8, 5.9 Hz, 1H). 
13
C NMR (100 MHz, 
CDCl3) δ 138.2, 137.8, 128.8, 128.6, 128.2, 128.1, 128.1, 128.0, 79.6, 74.0, 
72.6, 71.6, 67.5, 63.7, 54.5, 53.7, 44.1. HRMS: [M+H]
+
 calculated for 
C21H25O5 357.16965, found 357.16967 
 
β-5-epi-cycloophellitol (20): Benzylated β-manno 
cyclophellitol 33 (41 mg, 0.115 mmol) was dissolved in 
dioxanes/tBuOH (9:1) (2.5 mL) and purged with argon gas. To 
the solution was added Pd/C (10%) and the mixture was stirred under a H2 
atmosphere. After complete conversion of the starting material to the fully 
debenzylated product the mixture was filtered over a pad of celite and rinsed 
with H2O. The filtrate was concentrated in vacuo. The product was 
crystallized in MeOH yielding β-manno cyclophellitol 20 as a colourless 
crystalline solid (8.1 mg, 46 µmol, 40%). mp 164 °C. 
1
H NMR (500 MHz, 
D2O) δ 4.37 (t, J = 5.1 Hz, 1H), 3.99 (dd, J = 11.2, 4.2 Hz, 1H), 3.83 (dd, J = 
11.2, 8.0 Hz, 1H), 3.56 (dd, J = 4.0, 1.9 Hz, 1H), 3.52 (dt, J = 8.3, 3.7 Hz, 
2H), 3.46 (dd, J = 10.1, 8.9 Hz, 1H). 
13
C NMR (126 MHz, D2O) δ 72.3, 65.9, 
65.3, 60.8, 56.1, 53.6, 44.1. HRMS: [M+H]
+
 calculated for C7H13O5 
177.07575, found 177.07576 
 
α-5-epi-cyclophellitol (21): Benzylated β-manno 
cyclophellitol 34 (71.2 mg, 0.2 mmol) was dissolved in 
dioxanes/tBuOH (9:1) (5 mL) and purged with argon gas. To 
the solution was added Pd/C (10%) and the mixture was stirred under a H2 
atmosphere. After complete conversion of the starting material to the fully 
debenzylated product, the mixture was filtered over a pad of celite and rinsed 
with H2O. The filtrate was concentrated in vacuo. The product was 




(12.6 mg, 72 µmol, 36%). mp 135-137 °C. 
1
H NMR (400 MHz, MeOD) δ 
4.30 – 4.26 (m, 1H), 3.91 (dd, J = 10.8, 4.0 Hz, 1H), 3.67 (dd, J = 10.8, 7.9 
Hz, 1H), 3.46 (dd, J = 8.2, 2.0 Hz, 1H), 3.41 (dd, J = 10.2, 3.3 Hz, 1H), 3.24 
(t, J = 3.1 Hz, 1H), 3.19 (dd, J = 3.6, 0.8 Hz, 1H), 1.94 (td, J = 8.2, 3.9 Hz, 
1H). 
13
C NMR (100 MHz, MeOD) δ 72.2, 69.1, 67.5, 62.4, 56.9, 55.1, 46.6. 
HRMS: [M+H]
+
 calculated for C7H13O5 177.07575, found 177.07575 
 
(1S,2R,5S,6S)-5,6-bis(benzyloxy)-2-
(methylthrichloroacetimidate)cyclohex-3-enol (36) To a 
solution of manno cyclohexene 32 (68.1 mg, 0.2 mmol) in DCM 
(4.25 mL) was added a 0.6 M Cl3CCN (0.5 mL, 0.3 mmol) in 
DCM and the mixture was cooled to 0 °C. To the cooled solution 
was added dropwise a 0.4 M DBU (0.25 mL, 0.1 mmol) solution in DCM to 
the reaction mixture. The mixture was warmed to rt and stirred for 30 min. 
The mixture was diluted with DCM and silica was added. The solvents were 
removed in vacuo and the immobilized product was directly purified by 
column chromatography yielding cyclohexene imidate 36 as a colourless oil 
(75.4 mg, 0.16 mmol, 73%). 
1
H NMR (400 MHz, CDCl3) δ 8.31 (s, 1H), 
7.39 – 7.26 (m, 10H), 5.95 – 5.84 (m, 2H), 4.74 (d, J = 11.7 Hz, 1H), 4.67 
(d, J = 12.0 Hz, 1H), 4.64 (d, J = 12.0 Hz, 1H), 4.61 (dd, J = 6.5, 4.1 Hz, 
1H), 4.56 (d, J = 11.7 Hz, 1H), 4.16 – 4.06 (m, 2H), 3.48 (dd, J = 10.1, 3.8 
Hz, 1H), 2.87 (s, 1H), 2.62 (ddd, J = 8.3, 7.8, 3.5 Hz, 1H). 
13
C NMR (100 
MHz, CDCl3) δ 163.0, 138.6, 138.0, 131.0, 128.6, 128.5, 128.1, 128.1, 
128.0, 127.8, 125.8, 81.2, 71.8, 71.3, 69.5, 69.5, 66.8, 44.3. TLC-MS: [M + 
Na]
+
 508.0  
 
 iodo oxazine (37) To a solution of cyclohexene imidate 36 
(0.484 g, 1 mmol) in THF/H2O (4:1) (25 mL) was added 
NaHCO3 (0.294 g, 10 mmol), I2 (0.888 g, 3.5 mmol) and the 
mixture was heated till reflux. After complete conversion of the 
starting material the mixture was cooled to rt and diluted with EtOAc. To the 
solution was added 10% Na2S2O3 (aq.) till the organic phase was colourless. 
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The two phases were separated and the aqueous phase was extracted with 
EtOAc (3x). The combined organic layers were washed with H2O (3x), brine 
(3x), dried over MgSO4, filtered and concentrated in vacuo. Purification by 
column chromatography yielded iodo oxazine 37 as a yellow oil (0.459 g, 
0.75 mmol, 75%). 
1
H NMR (400 MHz, CDCl3) δ 7.31 (ddq, J = 9.6, 6.9, 2.1 
Hz, 10H), 5.05 (t, J = 2.4 Hz, 1H), 4.88 (dd, J = 11.2, 1.6 Hz, 1H), 4.79 (d, J 
= 12.3 Hz, 1H), 4.53 (d, J = 11.5 Hz, 1H), 4.45 (d, J = 12.3 Hz, 1H), 4.41 (d, 
J = 11.6 Hz, 1H), 4.19 (dd, J = 7.0, 2.6 Hz, 1H), 4.16 (dd, J = 5.6, 2.7 Hz, 
1H), 4.13 – 4.11 (m, 1H), 4.10 (d, J = 2.7 Hz, 1H), 4.07 (q, J = 2.6 Hz, 1H), 
2.63 (s, 1H), 2.50 (ddt, J = 9.9, 4.7, 2.6 Hz, 1H). 
13
C NMR (100 MHz, 
CDCl3) δ 151.6, 137.5, 128.7, 128.5, 128.4, 128.2, 128.1, 127.9, 79.3, 77.1, 
71.8, 71.1, 67.2, 64.7, 59.3, 33.8, 26.9. TLC-MS: [M + Na]
+
 633.8. HRMS: 
[M+H]
+
 calculated for C9H14INO4 328.00403, found 328.00409. 
 
β-2,3-O-dibenzyl-2-epi-cyclophellitol azirine (38) Iodo 
oxazine 37 (0.459 g, 0.75 mmol) was dissolved in a 1,4-
dioxane/H2O/AcOH (1:1:8) mixture (30 mL) and stirred 
overnight at rt. The mixture was concentrated in vacuo, co-evaporated with 
toluene (3x) and the residue was dissolved in MeOH (30 mL). To the 
solution was added NaHCO3 (1.26 g, 15 mmol) and stirred overnight at rt. 
The solids were filtered over a pad of celite and the filtrate was concentrated 
in vacuo. The crude was dissolved in DCM and washed with H2O (1x). The 
aqueous layer was extracted with DCM (5x) and the combined organic 
layers was dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography using neutral and activated silica 
followed by precipitation in cold Et2O yielded benzylated aziridine 38 as a 
white powder (0.155 g, 0.437 mmol, 58%). 
1
H NMR (400 MHz, CD2Cl2) δ 
7.46 – 7.25 (m, 10H), 4.77 (d, J = 11.5 Hz, 1H), 4.62 (d, J = 11.5 Hz, 1H), 
4.49 (d, J = 11.6 Hz, 1H), 4.43 (d, J = 11.5 Hz, 1H), 4.18 (t, J = 5.2 Hz, 1H), 
3.92 (dd, J = 10.7, 5.7 Hz, 1H), 3.84 (dd, J = 10.8, 4.8 Hz, 1H), 3.77 (t, J = 
9.8 Hz, 1H), 3.23 (dd, J = 10.1, 4.7 Hz, 1H), 2.82 (s, 2H), 2.42 – 2.29 (m, 
2H), 2.05 (s, 1H). 
13




128.7, 128.5, 128.3, 81.2, 71.6, 71.5, 69.7, 66.1, 64.9, 44.7. HRMS: [M+H]
+
 
calculated for C21H26NO4 356.18563, found 356.18570. 
 
 β-5-epi-cycloophellitol aziridine (22) NH3 gas was 
condensated at -60 °C and liquid NH3 was collected (± 2.5 mL). 
To the liquid NH3 was added lithium (16.5 mg, 2.5 mmol), 
upon addition of the lithium the solution turned dark blue. The mixture was 
stirred till all the lithium was completely dissolved and a solution of 
benzylated aziridine 38 (35.5 mg, 0.1 mmol) in THF (2 mL) was added drop 
wise. The reaction was stirred for 30 min at -60 °C and H2O (1.5 mL) was 
added dropwise to the reaction mixture. The mixture was gradually warmed 
to rt and co-evaporated with H2O (3x). The crude product was dissolved in 
H2O and treated with Amberlite IR-120 NH4
+
 for 2 h. The resin was filtered, 
the filtrate was concentrated in vacuo and retreated with Amberlite IR-120 
NH4
+
 (3x). The product was dissolved in MeOH and precipitated in 0 °C 
ether under vigorous stirring. The precipitate was filtered and dried over a 
stream of air yielding β-aziridine 22 as a white powder (17.4 mg, 0.1 mmol, 
quantitative). 
1
H NMR (400 MHz, Deuterium Oxide) δ 4.27 (t, J = 5.3 Hz, 
1H), 3.89 (dd, J = 10.9, 4.5 Hz, 1H), 3.70 (dd, J = 10.9, 8.7 Hz, 1H), 3.44 
(dd, J = 9.3, 4.9 Hz, 1H), 3.35 (t, J = 8.8 Hz, 1H), 2.66 – 2.52 (m, 3H), 2.01 
(ddd, J = 8.3, 4.6, 3.6 Hz, 1H). 
13
C NMR (100 MHz, D2O) δ 73.4, 66.4, 65.5, 
62.3, 43.6, 33.1, 32.6. HRMS: [M+H]
+
 calculated for C7H13NO4 176.09173, 
found 176.09170. 
 
β-3,4,5,7-O-tetrabenzyl-5-epi-cyclophellitol (39): To a 0 °C 
cooled solution of β-manno cyclophellitol 33 (0.104 g, 0.29 
mmol) in DMF (2.9 mL) was added BnBr (86 µl, 0.725 mmol) 
and NaH (60%) (29 mg, 0.725 mmol) in small portions and the reaction 
mixture was allowed to warm to rt. After complete conversion of the starting 
material the mixture was cooled to 0 °C and quenched with MeOH. The 
solvent was removed in vacuo and the crude was dissolved in Et2O. The 
product was washed with H2O (3x), brine (2x), dried over MgSO4, filtered 
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and concentrated in vacuo. Purification by column chromatography yielded 
per-benzylated β-manno cyclophellitol 39 as a white amorphous solid (80.6 
mg, 0.15 mmol, 52%). 
1
H NMR (400 MHz, CDCl3) δ 7.46 – 7.41 (m, 2H), 
7.40 – 7.26 (m, 16H), 7.24 – 7.18 (m, 2H), 4.83 (d, J = 12.5 Hz, 1H), 4.79 
(d, J = 11.2 Hz, 1H), 4.72 (d, J = 12.5 Hz, 1H), 4.60 (s, 2H), 4.56 (d, J = 
12.1 Hz, 1H), 4.51 (d, J = 12.0 Hz, 1H), 4.42 (d, J = 11.2 Hz, 1H), 4.04 (t, J 
= 4.6 Hz, 1H), 3.77 (dd, J = 8.8, 4.9 Hz, 1H), 3.69 (t, J = 8.8 Hz, 1H), 3.60 
(dd, J = 8.7, 7.6 Hz, 1H), 3.47 (dd, J = 4.8, 2.1 Hz, 1H), 3.46 (t, J = 4.9 Hz, 
1H), 3.27 (t, J = 4.0 Hz, 1H), 2.30 (dddd, J = 8.8, 7.6, 4.9, 2.6 Hz, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 138.5, 138.5, 138.4, 138.3, 128.6, 128.5, 128.5, 
128.5, 128.3, 128.2, 128.0, 128.0, 127.8, 127.8, 127.8, 127.7, 79.7, 74.4, 
73.6, 73.4, 72.7, 71.5, 70.9, 69.4, 54.7, 52.0, 42.6. HRMS: [M+H]
+
 
calculated for C35H36O5 537.26355, found 537.26347.  
 
Azido ringopening 
To a solution of per-benzylated β-manno cyclophellitol 39 (53.7 mg, 0.1 
mmol) in MeCN (2 mL) was added LiClO4 (16 mg, 0.15 mmol), NaN3 (65 
mg, 1.0 mmol) and the reaction mixture was stirred overnight at 80 °C under 
an argon atmosphere. The reaction mixture was cooled to rt and quenched 
with H2O. The product was extracted with DCM (5x) from the water and the 
combined organic layers were dried over MgSO4, filtered and concentred in 
vacuo giving a 1:1 mixture of two products. Purification by column 
chromatography yielded 0-azido-1-hydroxy 40 (28.0 mg, 0.048 mmol, 48%) 






H NMR (400 MHz, CDCl3) δ 5.15 (d, J 
= 11.6 Hz, 1H), 4.90 (d, J = 10.7 Hz, 1H), 4.75 (d, J = 11.8 Hz, 
1H), 4.71 (d, J = 11.9 Hz, 1H), 4.67 (d, J = 11.7 Hz, 1H), 4.54 
(d, J = 10.6 Hz, 1H), 4.51 (d, J = 12.1 Hz, 1H), 4.45 (d, J = 12.1 Hz, 1H), 




(dd, J = 9.2, 2.4 Hz, 1H), 3.44 (dd, J = 9.8, 2.1 Hz, 1H), 3.40 (dd, J = 10.2, 
2.8 Hz, 1H), 1.34 (tt, J = 11.2, 2.3 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
138.6, 138.6, 138.5, 138.3, 128.7, 128.6, 128.5, 128.2, 128.0, 128.0, 127.9, 





 calculated for C35H37N3O5 





H NMR (400 MHz, Chloroform-d) δ 
7.41 – 7.14 (m, 20H), 4.72 – 4.37 (m, 8H), 3.98 – 3.84 (m, 
3H), 3.75 (t, J = 4.7 Hz, 1H), 3.72 (t, J = 3.9 Hz, 1H), 3.66 
(dd, J = 8.1, 2.9 Hz, 1H), 3.62 (dd, J = 9.5, 5.5 Hz, 1H), 3.45 (s, 1H), 2.57 





calculated for C35H37N3O5 580.28060, found 580.28056.  
 
(1R,2S,3R,4R,5S,6S)-2-azido-4,5,6-tris(benzyloxy)-3-((benzyloxy)methyl) 
cyclohexyl methanesulfonate (42) To a 0 °C cooled solution 
of 40 (22.9 mg, 39.5 µmol) in pyridine (1.2 mL) was added 
dropwise a 0.5M mesyl chloride solution (0.237 mL, 119 
µmol) in toluene and the mixture was allowed to warm to rt. After complete 
conversion of the starting material the reaction was quenched with H2O and 
the product was extracted with EtOAc (5x). The combined organic phase 
was washed with brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded mesylated compound 
42 (18.7 mg, 28.4 µmol, 72%). FT-IR: vmax (neat)/cm
-1 
962.12, 991.55, 
1075.14, 1091.00, 1179.40, 1360.29, 1454.53, 1496.68, 2112.75, 2918.66, 
3030.95. 
1
H NMR (400 MHz, CDCl3) δ 7.36 – 7.22 (m, 16H), 7.21 – 7.15 
(m, 4H), 4.69 (dd, J = 10.3, 6.2 Hz, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.47 (q, J 
= 6.3, 5.8 Hz, 5H), 4.38 (d, J = 11.7 Hz, 1H), 4.31 (d, J = 11.8 Hz, 1H), 4.08 
(t, J = 3.3 Hz, 1H), 4.03 (t, J = 10.0 Hz, 1H), 3.87 (t, J = 9.5 Hz, 1H), 3.77 
(dd, J = 9.4, 5.9 Hz, 1H), 3.73 (t, J = 3.2 Hz, 1H), 3.67 (dd, J = 9.7, 3.2 Hz, 
1H), 3.06 (s, 3H), 2.93 (s, 1H). 
13
C NMR (100 MHz, CDCl3) δ 138.3, 137.7, 
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137.6, 128.6, 128.6, 128.5, 128.5, 128.2, 128.1, 128.1, 128.0, 127.7, 79.7, 








cyclohexyl methanesulfonate (43) To a 0 °C cooled solution 
of 41 (21.0 mg, 36.2 µmol) in pyridine (1.0 mL) was added 
dropwise a 0.5M mesyl chloride solution (0.217 mL, 108 
µmol) in toluene and the mixture was allowed to warm to rt. After complete 
conversion of the starting material the reaction was quenched with H2O and 
the product was extracted with EtOAc (5x). The combined organic phase 
was washed with brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded mesylated compound 
43 (21.0 mg, 32 µmol, 88%). 
1
H NMR (400 MHz, CDCl3) δ 7.46 – 7.39 (m, 
2H), 7.37 – 7.25 (m, 16H), 7.17 (dd, J = 7.4, 2.2 Hz, 2H), 4.94 (d, J = 11.8 
Hz, 1H), 4.89 (d, J = 10.8 Hz, 1H), 4.86 (d, J = 11.9 Hz, 1H), 4.60 (d, J = 
11.7 Hz, 1H), 4.58 (d, J = 11.7 Hz, 1H), 4.54 – 4.44 (m, 2H), 4.43 (d, J = 
12.0 Hz, 1H), 4.37 (dd, J = 10.5, 2.5 Hz, 1H), 4.30 (t, J = 2.4 Hz, 1H), 4.24 
(t, J = 10.8 Hz, 1H), 4.10 (dd, J = 10.8, 9.5 Hz, 1H), 3.79 (dd, J = 9.4, 1.9 
Hz, 1H), 3.61 (dd, J = 9.4, 2.5 Hz, 1H), 3.43 (dd, J = 9.6, 2.3 Hz, 1H), 3.07 
(s, 3H), 1.38 (dt, J = 11.4, 2.4 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
138.5, 138.4, 138.2, 138.0, 128.6, 128.5, 128.5, 128.4, 128.3, 128.0, 127.8, 
127.8, 127.7, 127.6, 83.1, 82.3, 76.3, 75.8, 75.1, 75.0, 73.1, 72.6, 64.7, 59.1, 




 calculated for 
C36H39N3O7S 658.25815, found 658.25822. 
 
 α-3,4,5,7-O-tetrabenzyl-5-epi-cyclophellitol aziridine (44) 
A solution of mesyl 43 (21 mg, 32 µmol) in THF (0.3 mL) was 
added dropwise to a 0 °C 0.1 M LiAlH4 solution (0.5 mL, 50 
µmol) in THF. After 4 h the reaction was diluted with THF and quenched 
with 3M NaOH (aq.) (0.167 mL, 0.5 mmol). The mixture was dried over 




chromatography yielded perbezylated α-manno aziridine 44 (5.5 mg, 10 
µmol, 31%). 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.37 (m, 2H), 7.37 – 7.24 
(m, 16H), 7.23 – 7.19 (m, 2H), 4.93 (d, J = 12.2 Hz, 1H), 4.84 (d, J = 11.3 
Hz, 1H), 4.73 (d, J = 12.4 Hz, 1H), 4.70 (d, J = 11.9 Hz, 1H), 4.64 (d, J = 
11.8 Hz, 1H), 4.52 (d, J = 12.1 Hz, 1H), 4.46 (t, J = 11.2 Hz, 2H), 4.22 (t, J 
= 2.5 Hz, 1H), 3.76 (dd, J = 9.7, 2.6 Hz, 1H), 3.71 (dd, J = 9.8, 7.7 Hz, 1H), 
3.61 (dd, J = 9.2, 4.0 Hz, 1H), 3.51 (t, J = 8.7 Hz, 1H), 2.46 (dd, J = 6.0, 2.4 
Hz, 1H), 2.36 (d, J = 5.8 Hz, 1H), 2.26 (td, J = 8.0, 4.1 Hz, 1H). 
13
C NMR 
(100 MHz, CDCl3) δ 139.3, 139.1, 139.0, 138.6, 128.5, 128.5, 128.4, 128.4, 
128.2, 127.8, 127.8, 127.7, 127.6, 127.5, 80.8, 75.7, 75.2, 74.7, 73.3, 73.1, 
73.1, 70.9, 43.4, 34.6, 31.9. TLC-MS [M+H]
+
 536.3 HRMS: [M+H]
+
 
calculated for C35H37NO4 536.27954, found 536.27957. 
 
α-5-epi-cyclophellitol aziridine (23) NH3 gas was condensated 
at -60 °C and liquid NH3 was collected (± 2.5 mL). To the 
liquid NH3 was added lithium (3 mg, 0.43 mmol), upon 
addition of the lithium the solution turned dark blue. The mixture was stirred 
till all the lithium was completely dissolved and a solution of perbenzylated 
α-manno-aziridine 44 (5.5 mg, 10 µmol) in THF (1.0 mL) was added drop 
wise. The reaction was stirred for 30 min at -60 °C and H2O (1.0 mL) was 
added dropwise to the reaction mixture. The mixture was gradually warmed 
to rt and co-evaporated with H2O (3x). The crude product was dissolved in 
H2O and treated with Amberlite IR-120 NH4
+
 for 2 h. The resin was filtered, 
the filtrate was concentrated in vacuo and retreated with Amberlite IR-120 
NH4
+
 (3x) yielding α-aziridine 23 (1.8 mg, 10 µmol, quantitative).
 1
H NMR 
(600 MHz, D2O) δ 3.89 (s, 1H), 3.47 (dd, J = 11.0, 3.9 Hz, 1H), 3.27 (dd, J = 
11.0, 7.7 Hz, 1H), 3.04 (t, J = 9.7 Hz, 1H), 3.01 (dd, J = 10.3, 3.3 Hz, 1H), 
2.08 (d, J = 6.0 Hz, 1H), 1.90 (d, J = 5.8 Hz, 1H), 1.43 (td, J = 8.3, 3.8 Hz, 
1H). 
13
C NMR (150 MHz, D2O) δ 72.1, 69.1, 68.3, 63.2, 46.2, 36.8, 32.3. 
HRMS: [M+H]
+
 calculated for C7H13NO4 176.09173, found 176.09169. 
 
  






H NMR coupling constants were obtained by first finding 
the lowest energy conformation of both epoxide isomers, for which a library 
of gas phase conformations was generated using conformer distribution 
option included in Spartan 04 program employing DFT/B3LYP 6-31G(d). 
All conformers were further optimized by Gaussion 03 at DFT/B3LYP 6-
311G(d,p), their zero-point energies were calculated and the energies 
corrected for solvent by another optimization step employing a Polarizable 
Continuum Model set for water. The energies of these conformers, corrected 
for their zero-point energies, were compared and of the lowest energy 
conformer an NMR calculation was performed using Gauche-Independent 
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Tuning the imidate leaving group of 2-deoxy-2-









Glycoconjugates are a highly diverse class of biomolecules, playing an 
important role in many biological processes.
2
 The metabolism of 
glycoconjugates and the enzymes involved are extensively studied. 
Glycosidases, enzymes that hydrolyse glycosidic linkages, are engaged in a 














 Specific inhibitors of glycosidases are therefore 
interesting targets as potential therapeutics, as well as useful tools for 
structural and mechanistic characterisation of these enzymes.
13,14
 In this 
framework attention has been focussed on the development of mechanism 
based covalent inhibitors and activity-based probes (ABPs), which are 
increasingly being used as research tools (see chapter 3 and 5).
15,16,17
  
The classical Koshland double-replacement mechanism of retaining 
glycosidases operates in two steps, the first of which is the formation of a 
glycosyl-enzyme intermediate (the “glycosylation” step), which is 




Withers et al. introduced the 2-deoxy-2-fluoroglucosides 1 and 2 (Figure 2) 
as mechanism based inhibitors for retaining β-glucosidases.
18
 The design of 
inhibitors such as 1 and 2 is based on the stabilization of the inhibitor-
enzyme intermediate by the introduction of an electron-withdrawing fluorine 





Figure 1: Mechanism-based inhibition of retaining beta-glucosidases with 2-deoxy-2-
fluoroglucosides. 
 
The electron-withdrawing fluorine substituent at the C-2 position of the 
inhibitor also reduces the rate of the formation of the inhibitor-enzyme 
intermediate. To counterbalance this effect, potent anomeric leaving groups 
are installed on the inhibitors. The 2-deoxy-2-fluoroglucosides 1 and 2, 
provided with dinitrophenol or fluoride as leaving groups, were converted 
and evaluated as ABPs by Witte et al. (Figure 2a). Introduction of an azide 
at the C-6 of 1 and 2 gave two-step labelling probes 3 and 4, which in turn 
were coupled to a BODIPY dye to give the fluorescent labelled ABPs 5 and 
6.
19
 These labelled 2-deoxy-2-fluoroglucosides probes completely labelled 
the glucosidase GBA-1, provided that prolonged reaction times (6 h) and 
relatively high concentrations were used. Increasing the rate of formation of 
the inhibitor-enzyme intermediate can be achieved by tuning the ability of 
the leaving group on the anomeric position of the 2-deoxy-2-fluoro probes. 
Walvoort et al. investigated the influence of the leaving group at the 
anomeric centre by the synthesis and evaluation of APBs 7-10 (Figure 2b). It 
was shown that both phosphate probe 9 and imidate probe 10 label GBA-1 
more efficiently than probes 5 and 6. It was also shown that imidate probe 10 
is more hydrolytic stabile than phosphate probe 9.
20
 Rempel et al. reported 
the synthesis and evaluation of various 2-deoxy-2-fluorinated glycosides 
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bearing an dialkyl phosphate or phosphonate as leaving group (11-16, Figure 
2c).
21,22
 In agreement with the pKa of the leaving groups it was shown that 
phosphate probes such as 14 are less hydrolytic stabile than phosphonate 
probes such as 15. The β-D-gluco-, β-D-manno- and β-D-galacto-configured 
phosphonate derivatives function as efficient inhibitors of the corresponding 
β-D-gluco-, β-D-manno- and β-D-galactosidases. Contrary, the α-D-gluco- 
and α-D-manno-configured phosphonate derivatives proved to be less 
efficient covalent inhibitors. The finding that the inhibitory potency of a 2-
fluoroglycoside based inhibitor can be fine tuned by varying the nature of 
the leaving group at the anomeric centre of the inhibitor and the activity of 
N-phenyl trifluoroacetimide imidate 10, was an incentive to further explore 
N-phenyl trifluoroacetimide imidate ABPs.  
 
 
Figure 2: a) First generation 2-deoxy-2-fluoro glucosyl inhibitors 1-2, modified 2-deoxy-2-
fluoro glucosyl ABPs 3-6. b) 2-Deoxy-2-fluoro glucosyl probes with varying leaving groups. 
c) Phosphate-/phosphonate- 2-deoxy-2-fluoro glucosyl 11-12, mannosyl 13-15 and galactosyl 
16 inhibitors. d) 2-Deoxy-2-fluoro glucosyl probes bearing various imidate leaving groups 17-
20, 2-deoxy-2-fluoro mannosyl ABPs 21-22, 2-deoxy-2-fluoro galactosyl ABPs 23-24.  
 
Because several retaining glycosidases, processing different epimeric 
glycans following the same two-step mechanism described in Figure 1, are 




trifluoroacetimide probe 17-β can potentially function as ABPs. Therefore 
this chapter describes a study to the synthesis of N-phenyl trifluoroacetimide 
imidate probes to give probes in the α- gluco- (17-α), the α-manno- (21-α) 
and the α- (23-α) and β-galacto (23-β) configuration (Figure 2d). Because 
the imidate substituent can also be readily adapted, thereby potentially 
further fine-tuning the reactivity of the probes, also different groups on the 
imidate nitrogen were explored. An electron donating methoxy substituent 
and an electron withdrawing nitro substituent were installed on the phenyl 
ring of the N-phenyl trifluoroacetimide imidate ABPs (19-20) having either 
an α- or β-gluco configuration. Some of the prepared 6-azido derivatives (17, 
21 and 23) were transformed in the corresponding fluorescently labelled 
ABPs (18, 22 and 24) by the installation of a BODIPY group.  
 
 
Results and discussion  
 
All N-phenyl trifluoroacetimide imidate ABPs (17-24) were accessed 
through a similar route of synthesis, passing by the corresponding 
thioglycoside precursors (28, 35 and 44) as depicted in Scheme 1. Per-
acetylated glucal 25 was used as a starting compound for both gluco- and 
manno-configured target compounds. Using the same procedure as described 
by Walvoort et al.
20
 commercially available glucal 25 was treated with 
Selectfluor
®
 to provide, after anomeric acetylation and column 
chromatography, 2-fluoro glucose 26 and 2-fluoro mannose 33 in 14% and 
28% yield respectively (Scheme 1). The p-thiocresol was introduced at the 
anomeric centre of the gluco-configured 26 by preparing the anomeric 
bromide and subsequent treatment of this bromide with thiocresol under 
phase transfer conditions to give, after global deacetylation using NaOMe in 
MeOH, 2-fluoroglucoside 28. Selective tosylation of the primairy hydroxyl 
followed by substitution of the tosylate with an azide yielded thioglucoside 
30 in 88% over two steps. To access 2-fluoromannoside 34, the anomeric 
acetate in 2-fluoro mannose 33 was first converted into the -bromide, 
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which was treated with sodium p-thiocresolate to give β-thiomannoside 34. 
Deacetylation, selective tosylation and azide substitution as described for the 
gluco-configured epimer, gave 6-azido thiomannoside 37 in 38% over five 
steps. The synthesis of 2-fluoro-6-azido thiogalactoside 46 starts from 
peracetylated galactal 41 and follows the same sequence of events as 
described for glucose epimer 30. The reaction of galactal with  Selectfluor
®
 
provided only the product with the galactose configuration, as formation of 
the talo-epimer was not observed. Having the three epimeric 2-fluoro-6-
azido thioglycosides (30, 37 and 46) in hand the syntheses of the respective 
two- step ABPs (17, 21 and 23) and the BODIPY labelled ABPs (18-20, 22 
and 24) were undertaken.  
 







Reagents and conditions: (a) i. Selectfluor®, MeNO2/H2O, (5:1); ii. Ac2O, pyridine 0 °C to rt 
26: 14%, 33: 28%, 42: 66%; (b) i. HBr (33% in AcOH), DCM, 0 °C to rt; ii. P-thiocresol, 
TBABr, KOH, CHCl3, H2O, 0 °C to rt, 27: 82%, 43: 68; (c) i. HBr (33% in AcOH), DCM, 0 
°C to rt; ii. p-thiocresol, NaH (60%), DMF, 0 °C to rt, 79%; (d) NaOMe, MeOH, rt, 28, 35 
and 44 quantitatively; (e) TsCl, pyridine, 0 °C to rt, 29: 88%, 36: 63%, 45: 83%; (f) NaN3, 
DMF, 80 °C, 30 quantitatively, 37: 76%, 46: 74%; (g) NBS, acetone/H2O (3:1), 0 °C to rt, 
68%; (h) i. NBS, acetone/H2O (3:1), 0 °C to rt; ii. Ac2O, pyridine, 0 °C to rt, 38: 51%, 47: 
32%; (i) NaOMe, MeOH, 39, 48 (quantitative); (j) Cs2CO3, imidate reagents, acetone, rt 
(results are summarized in Table 1); (k) 0.075M Sodium ascorbate (aq.), 0.05M CuSO4 (aq.), 
DMF, 32: 90%, 40: 97%, 49: 90%. 
 
Treatment of 2-fluoro-6-azido thioglucoside 30 with NBS in a mixture of 
acetone and water gave the corresponding hemiacetal 31. The same 
procedure was used to hydrolyse 2-fluoro-6-azido-mannoside 37 and 2-
fluoro-6-azido galactoside 46 to their corresponding hemiacetals. 
Unfortunately the desired products could not be purified by column 
chromatography. After acetylation of the crude reaction products to give 
peracetylated 2-fluoro-6-azido mannoside 38 and peracetylated 2-fluoro-6-
azido galactose purification could be accomplished. Saponification of 38 and 
47 under Zémplen conditions provided 2-fluoro-6-azido mannoside 39 and 
2-fluoro-6-azido galactoside 48 in 51% and 32%, respectively, starting from 
thiomannoside 37 and thiogalactoside 46. 
Next, the obtained 2-fluoro-6-azido glycosides 31, 39 and 48 were subjected 
to a Cu-catalyzed azide alkyne cycloaddition with BODIPY alkyne 50
23
 
giving 2-fluoro-6-BODIPY glucose 32 (90%), 2-fluoro-6-BODIPY mannose 
40 (97%) and 2-fluoro-6-BODIPY galactose 49 (90%). Finally, the imidates 
were introduced on the 2-fluoro glycosides using the relevant 
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imidoylchloride reagents (51-53) in combination with Cs2CO3. The results 
are summarized in Table 1.  
 








1 31 R = H (51) 3% (17-α) 2% (17-β) 
2 32 R = H (51) 2% (18-α) ˂1% (18-β) 
3 32 R = OMe (52) 1% (19-α) 1% (19-β) 
4 32 R = NO2 (53) 2% (20-α) 3% (20-β) 
5 39 R = H (51) 10% (21-α) --- (21-β) 
6 40 R = H (51) 6% (22-α) --- (22-β) 
7 48 R = H (51) --- (23-α) --- (23-β) 
8 49 R = H (51) --- (24-α) --- (24-β) 
a α/β-ratio determined by 1H-NMR of the crude based on the anomeric signal of the α- and β-
product.  
 
The projected imidates prove to be unstable and very sensible towards acid. 
Purification by HPLC using 100 mM (NH4)2CO3 (aq.) as eluens proceeded 
uneventful but decomposition of both the crude and purified products led to 
a dramatic loss of product. Decomposition of the purified products could be 
suppressed by cooling of the collected fractions to -80 °C and immediate 
lyophilisation. Following this procedure, the treatment of 2-fluoro-6-azido 
glucoside 31 with N-phenyl trifluoroacetimide 51 led to product 17. The 




17-α in 3% and 17-β in 2%. Three different imidates (51-53) were coupled 
to BODIPY glucoside 32 (Entry 2-4) leading to the individual α and β 
anomers (18-20). All glucosyl imidates were isolated in low yields, ranging 
from ˂1% for 18-β (Entry 2) to 3% for 20-β (Entry 4). 2-Fluoro-6-azido 
mannoside 21-α was obtained as a single anomer from the reaction of 39 
with imidate 51 in 10% after HPLC purification (Entry 5). A similar reaction 
using 2-fluoro-6-BODIPY mannoside 40 gave the α-product 22-α in a 
somewhat lower yield of 6% (Entry 6). Finally, the 2-fluoro galactoside 48 
and 2-fluoro-6-BODIPY galactoside 49 were subjected to a base mediated 
reaction with imidate reagent 51. Unfortunately, TLC and HPLC analysis 
did not show the formation of the desired products (Entry 7-8). This can be 







In summary, the synthesis of 2-deoxy-2-fluoro glycoside probes 17-22 is 
described. The probes turned out to be rather unstable and therefore 
purification was very difficult leading to poor overall yields. Nevertheless 
six new imidate probes were successfully prepared. In the glucose series, 
probes having the α- and β-anomeric configuration were obtained. In the 
manno series only the α-anomers were obtained. Unfortunately the 
corresponding galactosyl probes could not be obtained. Possibly this is the 
result of the higher reactivity of galactose probes with respect to the other 
epimers. The probes that were successfully synthesized can be evaluated for 
their inhibitory properties on relevant glycosidases (glucosidases, 










General: Traces of water in the starting materials were removed by co-
evaporation with toluene for all moisture and oxygen sensitive reactions and 
the reactions were performed under an argon atmosphere. Dichloromethane 
was distilled over P2O5 and stored over activated 3 Å molecular sieves under 
an argon atmosphere. All other solvents and chemicals (Acros, Fluca, 
Merck) were of analytical grade and used as received. Column 
chromatography was performed on Screening Device silica gel 60 (0.040-
0.063 mm). Size exclusion was performed on Sepadex LH20 (eluent 
DCM/MeOH, 1:1). TLC analysis was conducted on HPTLC aluminium 
sheet (Merck, TLC silica gel 60, F254). Compounds were visualized by UV 
absorption (λ = 254 nm), staining with p-anisaldehyde (3.7 mL in 135 mL 
EtOH, 1.5 mL AcOH and 5 mL H2SO4), 20% H2SO4 in EtOH or with a 
solution of (NH4)6Mo7O24·4H2O (25g/L) in 10% H2SO4 in H2O followed by 




C NMR were recorded on a Bruker DPX 
300 (300 and 75 MHz respectively), Bruker AV 400 (400 and 100 MHz 
respectively), Bruker DMX 400 (400 and 100 MHz respectively) or Bruker 
DMX 600 (600 and 125 MHz respectively). Chemical shifts are given in 
ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal 
standard. J couplings are given in Hz. Optical rotations were measured on a 
Propol automatic polarimeter. IR spectra (thin film) were conducted on a 
Perkin Elmer FTIR Spectrum Two UATR (Single reflection diamond). LC-
MS measurements were conducted on a Thermo Finnigan LCQ Advantage 
MAX ion-trap mass spectrometer (ESI+) coupled to a Thermo Finnigan 
Surveyor HPLC system equipped with a standard C18 (Gemini, 4.6 mm x 50 
mm, 5µm particle size, Phenomenex) analytical column and buffers A: H2O, 
B: MeCN, C: 0.1% TFA (aq.). High resolution mass spectra were recorded 






glucopyraniside (26) and Acetyl 2-deoxy-2-fluoro-3,4,6-tri-
O-acetyl-α/β-D-mannopyraniside (33): To a 0 °C solution of acetylated 
glucal 25 (35.9 g, 131.9 mmol) in nitromethane/H2O (5:1) (360 mL) was 
added Selectfluor
®
 (59.8 g, 169 mmol) and the reaction mixture was allowed 
to warm to rt and stirred overnight. The mixture was heated to 100 °C for 1 h 
and concentrated in vacuo. The concentrate was dissolved in DCM and 
washed with sat. NaHCO3 (1x), H2O (1x), brine (1x), dried over MgSO4, 
filtered and concentrated in vacuo. The crude was dissolved in pyridine (200 
mL) and cooled to 0 °C. To the cooled solution was added dropwise Ac2O 
(15 mL) and the mixture was allowed to rt. After completion the reaction 
was quenched with MeOH and the mixture was concentrated in vacuo. The 
product was dissolved in EtOAc, washed with 1M HCl (aq.) (3x), sat. 
NaHCO3 (3x), H2O (3x), brine (2x), dried over MgSO4, filtered and 
concentrated in vacuo giving a mixture of 2-deoxy-2-fluoro-glucose 26 and 
2-deoxy-2-fluoro-mannose 33. Purification by column chromatography 
yielded 2-deoxy-2-fluoro-glucose 26 (6.3 g, 18.0 mmol, 14%) and 2-deoxy-
2-fluoro-mannose 33 (10.7 g, 37.6 mmol, 28%) both as a colourless oil. 






glucopyranoside (27): To a 0 °C cooled solution of 2-deoxy-
2-fluoro glucose 26 (3.26 g, 8.79 mmol) in DCM (6 mL) was added 
dropwise 33% HBr in AcOH (7.6 mL, 44.0 mmol) and the reaction was 
stirred at 4 °C overnight, followed by stirring for 2h at rt. The mixture was 
poured in ice-water and diluted with EtOAc. The two phases were separated 
and the organic phase was washed with H2O (2x), brine (2x), dried over 
Na2SO4, filtered and concentrated in vacuo. The crude bromide was taken up 
in CHCl3 (10 mL) and to the solution was added p-thiocresol (1.64 g, 13.2 
mmol) and a solution of TBABr (0.567 g, 1.76 mmol) in H2O (11.9 mL). 
The mixture was cooled to 0 °C and under vigorous stirring was added 
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dropwise a KOH (1.0 g, 17.6 mmol) solution in H2O (11.9 mL) over a period 
of 10 minutes. The reaction mixture was allowed to warm to rt and was 
vigorously stirred overnight. The two phases were separated and the organic 
phase was washed with brine, dried over MgSO4, filtered and concentrated 
in vacuo. Purification by column chromatography yielded peracetylated 2-
deoxy-2-fluoro-thio glucoside 27 as a white amorphous solid (2.97 g, 7.17 
mmol, 82%). 
1
H NMR (400 MHz, CDCl3): δ 7.46 (d, J = 8.4 Hz, 2H), 7.15 
(d, J = 8.0 Hz, 2H), 5.31 (dt, , J = 14.0, 9.6 Hz, 1H), 4.93 (t, J = 10.0 Hz, 
1H), 4.62 (dd, J = 9.6, 1.6 Hz, 1H), 4.16-4.22 (m, 2H), 4.11 (dt, J = 46.4, 9.6 
Hz, 1H), 3.72 (ddd, J = 10.0, 4.4, 3.2 Hz, 1H), 2.38 (s, 3H), 2.09 (s, 3H), 
2.07 (s, 3H), 2.02 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 170.7, 170.1, 
169.7, 139.5, 135.0, 129.9, 126.1, 87.0, 84.4, 75.9, 74.0 (d, J = 20 Hz), 68.1 
(d, J = 7 Hz), 62.1, 21.4, 20.9, 20.8, 20.7; HRMS: [M+H]
+
 calculated for 
C19H24FO7S 415.12213, found 415.12207. 
 
Tolyl 2-deoxy-2-fluoro-1-thio-β-D-glucopyranoside (28): To 
a solution of 27 (1.53 g, 3.70 mmol) in MeOH (30 mL) was 
added NaOMe (200 mg, 3.7 mmol) and stirred for 3 h. The reaction was 
quenched with Amberlite-H
+
 IR-120 till pH≤7, filtered and concentrated in 
vacuo yielding 2-deoxy-2-fluoro thio glucose 28 as a white amorphous solid 
without further purification (1.07 g, 3.70 mmol, quantitatively). 




glucopyranoside (29): To a 0 °C cooled solution of 2-deoxy-
2-fluoro thio glucose 28 (634 mg, 2.2 mmol) in pyridine (11 mL) was added 
TsCl (641 mg, 2.4 mmol), the mixture was allowed to warm to rt and stirred 
overnight. The reaction was quenched with MeOH and concentrated in 
vacuo followed by co-evaprated with toluene (3x) of the crude. Purification 
by column chromatography yielded tosylated 2-deoxy-2-fluoro thio glucose 
29 as a white amorphous solid (859 mg, 1.94 mmol, 88%). 
1
H NMR (400 




Hz, 2H), 4.53 (dd, J = 9.6, 1.6 Hz, 1H), 4.30 (s, 2H), 3.97 (dt, J = 49.6, 8.8 
Hz, 1H), 3.70-3.78 (m, 1H), 3.49 (d, J = 4.8 Hz, 2H), 2.45 (s, 3H), 2.34 (s, 
3H); 
13
C NMR (100 MHz, CDCl3): δ 145.3, 139.1, 134.4, 132.7, 130.1, 
129.9, 128.2, 126.9, 89.3 (d, J = 186 Hz), 84.5 (d, J = 24 Hz), 76.8, 76.4 (d, 
J = 19 Hz), 69.1 (d, J = 8 Hz), 68.3, 21.8, 21.4. 
 
Tolyl 6-azido-2,6-di-deoxy-2-fluoro-1-thio--D-
glucopyranoside (30): To a solution of tosylated glucose 29 
(0.929 g, 2.1 mmol) in DMF (25 mL) was added NaN3 (0.410 g, 6.3 mmol) 
and the mixture was stirred overnight at 80 °C. The reaction mixture was 
diluted with EtOAc and the product was washed with sat. NaHCO3 (aq.) 
(2x), H2O (2x), brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded 6-azido-2-deoxy-2-
fluoro thio glucose 30 as a colourless amorphous solid (0.651 g, 2.1 mmol, 






6-Azido-2,6-dideoxy-2-fluoro-/-D-glucopyranose (31): To 
a 0 °C cooled solution of 6-azido-2-deoxy-2-fluoro thio glucose 
30 (0.392 g, 1.25 mmol) in a acetone/H2O mixture (3:1, 12.5 mL) was added 
NBS (1.33 g, 7.5 mmol). The reaction mixture was allowed to warm to rt 
and was stirred overnight. During the reaction the mixture turned from 
orange to a colorless clear solution. The reaction was quenched with 10% 
Na2S2O3 (aq.) and diluted with brine. The water layer was extracted with 
EtOAc (5x) and the combined organic layers were washed with brine (2x), 
dried over MgSO4, filtered and concentrated in vacuo. Purification by 
column chromatography yielded deprotected 6-azido-2-deoxy-2-fluoro 
glucose 31 as a white amorphous solid. Spectroscopic data were in 
accordance with known literature data.
19 
  




BODIPY 2-fluoro glucoside (32): Deprotected 
6-azido-2-deoxy-2-fluoro glucose 31 (0.142 g, 
0.687 mmol) was dissolved in DMF (55 mL) 
and the solution was purged with argon for 30 
min. To the solution was added a 0.075 M sodium ascorbate solution (aq.) 
(6.87 mL, 0.52 mmol), a 0.05M CuSO4 (aq.) (6.87 mL, 0.34 mmol) and the 
reaction was stirred for 2h. The mixture was taken up in brine and the 
product was extracted with EtOAc (2x). The combined organic layers were 
washed with brine (3x) dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded 2-deoxy-2-fluoro 
BODIPY glucose 32 as an orange solid (0.332 g, 0.619 mmol, 90%). LC-
MS: Rt 6.55 min (C18 column, linear gradient 10  90% B in 15 min). 




mannopyranoside (34): To a 0 °C cooled solution of 2-
deoxy-2-fluoro mannose 33 (7.32 g, 20.9 mmol) in dry DCM (14 mL) was 
added 33% HBr in AcOH (18 mL, 60 mmol) dropwise. Ac2O (0.2 mL, 2.2 
mmol) was added and the mixture was allowed to warm to rt and stirred 
overnight. The reaction was quenched with ice water and the product 
extracted with EtOAc (3x). The combined organic layers were washed with 
sat. NaHCO3 (3x), H2O (3x), brine (2x), dried over MgSO4, filtered and 
concentrated in vacuo. The crude bromide was dissolved in DMF (42 mL) 
and p-thiocresol (3.89 g, 31.45 mmol) was added to the solution. The 
mixture was cooled to 0 °C and to the cooled mixture was added 60% NaH 
(1.05 g, 26.13 mmol) in small portions. The mixture was allowed to warm to 
rt and stirred overnight. The reaction was quenched with 0.02M HCl (aq.) 
and taken up in EtOAc. The two phases were separated and the organic 
phase was washed with sat. NaHCO3 (aq.) (1x), H2O (3x), brine (2x), dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column 




amorphous solid (6.9 g, 16.6 mmol, 79%). 
1
H NMR (400 MHz, CDCl3): δ 
5.38 (t, J = 10.0 Hz, 1H), 5.06 (dd, J = 47.2, 2.4 Hz, 1H), 4.91-5.04 (m, 1H), 
4.79 (d, J = 26.4 Hz, 1H), 4.27 (dd, J = 12.4, 5.6 Hz, 1H), 4.16 (dd, J = 12.4, 
2.8 Hz, 1H), 3.64-3.69 (m, 1H), 2.35 (s, 3H), 2.03-2.12 (m, 9H); 
13
C NMR 
(100 MHz, CDCl3): δ 170.9, 170.5, 169.6, 138.7, 132.8, 130.0, 129.5, 89.0 
(d, J = 186 Hz), 85.8 (d, J = 18 Hz), 76.4, 72.5 (d, J = 18 Hz), 65.7, 62.6, 
21.3, 20.9, 20.9, 20.8; FT-IR: vmax (neat)/cm
-1
 1742, 1368, 1218, 1092, 1049, 
960, 916, 834, 811, 776; HRMS: [M+H]
+
 calculated for C19H24FO7S 
415.12213, found 415.12281. 
 
Tolyl 2-deoxy-2-fluoro-1-thio-β-D-mannopyranoside (35): 
To a solution of 34 (860 mg, 2.1 mmol) in MeOH (20 mL) was 
added NaOMe (0.108 g, 2.0 mmol) and stirred overnight. The reaction was 
quenched with Amberlite-H
+
 IR-120 till pH≤7, filtered and concentrated in 
vacuo yielding 2-deoxy-2-fluoro thio mannose 35 as a white amorphous 
solid without further purification (606 mg, 2.1 mmol, quantitatively). 
1
H 
NMR (400 MHz, MeOD): δ 4.99 (d, J = 28 Hz, 1H), 4.86 (dd, J = 49.2, 2.8 
Hz, 1H), 3.89 (dd, J = 12.0, 2.4 Hz, 1H), 3.71 (dd, J = 12.0, 6.0 Hz, 1H), 
3.55-3.66 (m, 2H), 3.28-3.35 (m, 1H), 2.33 (s, 3H); 
13
C NMR (100 MHz, 
MeOD): δ 138.6, 132.1, 130.8, 93.9 (d, J = 181 Hz), 86.7 (d, J = 18 Hz), 
82.5, 74.8 (d, J = 18 Hz), 68.4 (d, J = 8 Hz), 62.8, 21.1; FT-IR: vmax 
(neat)/cm
-1
 3357, 1493, 1090, 1058, 1005, 849, 805, 766, 689, 487; HRMS: 
[M+H]
+
 calculated for C13H18FO4S: 289.34406, found 289.34409. 
 
Tolyl 2-deoxy-2-fluoro-6-O-tosyl-1-thio-β-D-
mannopyranoside (36): To a 0 °C cooled solution of 2-deoxy-
2-fluoro thio mannose 35 (606 mg, 2.1 mmol) in pyridine (10.5 mL) was 
added TsCl (0.478 g, 2.51 mmol), the mixture was allowed to warm to rt and 
stirred overnight. The reaction was quenched with MeOH and concentrated 
in vacuo followed by co-evaprated with toluene (3x) of the crude. 
Purification by column chromatography yielded tosylated 2-deoxy-2-fluoro 
thio mannose 36 as a white amorphous solid (0.592 g, 1.34 mmol, 63%). 
1
H 
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NMR (400 MHz, CDCl3): δ 7.82 (d, J = 8.0 Hz, 2H), 7.33-7.38 (m, 4H), 
7.10 (d, J = 8.0 Hz, 2H), 4.94 (dd, J = 49.2, 2.4 Hz, 1H), 4.72 (d, J = 28.4 
Hz, 1H), 4.37 (d, J = 11.2 Hz, 1H), 4.32 (dd, J = 11.2, 5.4 Hz, 1H), 3.78 (t, J 
= 9.4 Hz, 1H), 3.59 (ddd, J = 27.2, 9.6, 2.6 Hz, 1H), 3.45-3.48 (m, 1H), 2.43 
(s, 3H,), 2.34 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 145.3, 139.1, 134.4, 
132.7, 130.1, 129.9, 128.2, 126.9, 89.3 (d, J = 186 Hz), 84.5 (d, J = 24 Hz), 
76.8, 76.4 (d, J = 19 Hz), 69.1 (d, J = 8 Hz), 68.3, 21.8, 21.4. ;FT-IR: vmax 
(neat)/cm
-1
 3367, 1494, 1358, 1190, 1175, 1079, 983, 946, 810, 687, 760. 
 
Tolyl 6-azido-2,6-di-deoxy-2-fluoro-1-thio--D-
mannopyranoside (37): To a solution of tosylated mannose 
36 (0.593 g, 1.34 mmol) in DMF (13.4 mL) was added NaN3 (260 mg, 4.0 
mmol) and the mixture was stirred overnight at 80 °C. The reaction mixture 
was diluted with EtOAc and the product was washed with sat. NaHCO3 (aq.) 
(2x), H2O (2x), brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded 6-azido-2-deoxy-2-
fluoro thio mannose 37 as a colourless amorphous solid (318 mg, 1.0 mmol, 
76%). 
1
H NMR (400 MHz, MeOD): δ 7.42 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 
8.0 Hz, 2H), 4.97 (d, J = 28.0 Hz, 1H), 4.86 (dd, J = 50.0, 2.0 Hz, 1H), 3.37-
3.64 (m, 5H), 2.31 (s, 3H); 
13
C NMR (100 MHz, MeOD): δ 139, 132.9, 
131.8, 130.7, 93.7 (d, J = 181 Hz), 86.8 (d, J = 18 Hz), 80.8, 74.6 (d, J = 18 
Hz), 69.1, 52.9, 21.1; FT-IR: vmax (neat)/cm
-1
 3356, 2093, 1493, 1278, 1060, 
1018, 998, 982, 951, 869, 843, 807, 767, 689, 573; HRMS [M+H]
+
 




mannopyraniside (38): To a 0 °C cooled solution of 6-azido-
2-deoxy-2-fluoro thio mannose 37 (305 mg, 1.0 mmol) in a acetone/H2O 
mixture (3:1, 12.5 mL) was added NBS (1.33 g, 7.5 mmol). The reaction 
mixture was allowed to warm to rt and was stirred overnight. During the 




reaction was quenched with 10% Na2S2O3 (aq.) and diluted with brine. The 
product was extracted with EtOAc (5x) and the combined organic layers 
were washed with brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. The concentrate was taken up in pyridine (4 mL), cooled to 0 °C and 
Ac2O (1.0 mL) was added to the cooled solution. The mixture was allowed 
to warm to rt and stirred overnight. The reaction was quenched with MeOH, 
concentrated in vacuo and dissolved in EtOAc. The product was washed 
with 1M HCl (aq.) (2x), sat. NaHCO3(aq.) (1x), H2O (3x), brine (2x), dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography yielded acetylated 6-azido-2-deoxy-2-fluoro mannose 38 as 
a colourless oil (0.165 g, 0.495 mmol, 51%). 
1
H NMR (400 MHz, CDCl3): δ 
6.28 (d, J = 6.8 Hz, 1H), 5.36 (t, J = 10.0 Hz, 1H), 5.27 (ddd, J = 28.0, 10.0, 
2.0 Hz, 1H), 4.77 (dd, J = 48.8, 1.8 Hz, 1H), 4.00-4.04 (m, 1H), 3.33-3.42 
(m, 2H), 2.19 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3): δ 170.2, 169.4, 168.0, 89.9 (d, J = 31 Hz), 86.0 (d, J = 181 Hz), 
71.9, 69.3 (d, J = 16 Hz), 66.3, 50.8, 20.8, 20.7, 20.6; FT-IR: vmax (neat)/cm
-1
 





334.10450, found 334.10476. 
 
6-Azido-2,6-dideoxy-2-fluoro-/-D-mannopyranose (39): 
To a solution of acetylated 6-azido-2-deoxy-2-fluoro mannose 
38 (0.143 g, 0.428 mmol) in MeOH (10 mL) was added NaOMe (4 mg, 0.04 
mmol) and stirred overnight. The reaction was quenched with Amberlite-H
+
 
IR-120 till pH≤7, filtered and concentrated in vacuo yielding 6-azido-2-
deoxy-2-fluoro mannose 39 as a colorless oil without further purification as 
an α/β mixture (α/β = 9:1, 87.4 mg, 0.422 mmol, quantitatively). 
1
H NMR 
(400 MHz, MeOD): δ 5.22 (dd, J = 7.2, 2.0 Hz, 1H-α), 4.83 (d, J = 20.0 Hz, 
1H-β), 4.60 (dd, J = 51.6, 2.2 Hz, 1H-β), 4.56 (dt, J = 50.4, 2.2 Hz, 1H-α), 
3.87-3.91 (m, 1H, H-α), 3.79 (ddd, J = 30.8, 9.6, 2.4 Hz, 1H-α), 3.61 (td, J = 
9.6, 0.8 Hz, 1H-α), 3.52 (dd, J = 13.2, 2.4 Hz, 1H-α), 3.41 (dd, J = 13.2, 6.0 
Hz, 1H-α);
 13
C NMR (100 MHz, MeOD): δ 94.3 (d, J = 16 Hz, C-β), 93.1 (d, 
J = 33 Hz, C-α), 92.7 (d, J = 182 Hz, C-β), 92.1 (d, J = 177 Hz, C-α), 73.1 
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(C-α), 71.2 (d, J = 17 Hz, C-α), 69.5 (C-α), 52.7 (C-α); FT-IR: vmax 
(neat)/cm
-1
 3354, 2107, 1283, 1064.  
 
BODIPY 2-fluoro mannoside (40): 
Deprotected 6-azido-2-deoxy-2-fluoro 
mannose 39 (32.7 mg, 0.157 mmol) was 
dissolved in DMF (12 mL) and the solution 
was purged with argon for 30 min. To the solution was added a 0.075M 
sodium ascorbate solution (aq.) (1.50 mL, 0.113 mmol), a 0.05M CuSO4 
(aq.) (1.50 mL, 0.075 mmol) and the reaction was stirred for 2h. The mixture 
was taken up in brine and the product was extracted with EtOAc (2x). The 
combined organic layers were washed with brine (3x) dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography 
yielded BODIPY 2-deoxy-2-fluoro mannoside 40 as an orange solid (82.0 
mg, 0.153 mmol, 97%). 
1
H NMR (400 MHz, CDCl3): δ 7.75 (s, 1H), 7.70 (s, 
1H), 6.07 (s, 2H), 5.17 (dd, J = 7.0, 1.4 Hz, 1H), 4.47-4.89 (m, 3H), 4.07 
(ddd, J = 9.6, 9.6, 2.0 Hz, 1H), 3.83 (ddd, J = 30.8, 9.6, 2.4 Hz, 1H), 3.42 (t, 
J = 9.6 Hz, 1H), 2.80-2.85 (m, 2H), 2.68 (t, J = 7.6 Hz, 2H), 2.42 (s, 6H), 
2.29 (s, 6H), 1.81 (p, J = 7.4 Hz, 2H), 1.56-1.61 (m, 2H); 
13
C NMR (100 
MHz, CDCl3): δ 154.8, 148.3, 147.9, 142.3, 132.6, 124.6, 122.6, 93.1 (d, J = 




galactopyraniside (42): To a 0°C solution of acetylated 
galactal 41 (7.5 g, 27.5 mmol) in nitromethane/H2O (5:1) (83 mL) was added  
Selectfluor
®
 (11.7 g, 33 mmol) and the reaction mixture was allowed to 
warm to rt and stirred for 70 h. The mixture was heated to 100 °C for 30 min 
and cooled to rt. The mixture was diluted with brine and extracted with 
DCM (5x). The combined organic layers were washed with sat. NaHCO3 
(1x), H2O (x), brine (1x), dried over MgSO4, filtered and concentrated in 




cooled solution was added pyridine (4.2 mL), Ac2O (3.2 mL, 34 mmol) and 
the mixture was allowed to rt. After stirring overnight, the mixture was 
cooled to 0 °C and additionally pyridine (3 mL), Ac2O (2 mL, 21 mmol) was 
added and the mixture was allowed to warm to rt. After 2 h the reaction was 
quenched with MeOH and the mixture was concentrated in vacuo. The 
product was dissolved in EtOAc, washed with 1M HCl (aq.) (3x), sat. 
NaHCO3 (3x), H2O (3x), brine (2x) dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography yielded 2-
deoxy-2-fluoro galactoside 42 as a yellow oil (8.7 g, 18.0 mmol, 66%). 





galactopyranoside (43): To a 0 °C cooled solution of 2-deoxy-
2-fluoro galactoside 42 (3.35 g, 9.56 mmol) in dry DCM (6.4 mL) was added 
33% HBr in AcOH (8.2 mL, 9.6 mmol) dropwise. Ac2O (0.1 mL, 1.1 mmol) 
was added and the mixture was allowed to warm to rt and stirred overnight. 
The reaction was quenched with ice water and the product extracted with 
EtOAc (3x). The combined organic layers were washed with sat. NaHCO3 
(3x), H2O (3x), brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. The crude bromide was taken up in CHCl3 (100 mL) and to the 
solution was added p-thiocresol (1.8 g, 14.3 mmol) and a solution of TBABr 
(0.616 g, 1.91 mmol) in H2O (13.5 mL). The mixture was cooled to 0 °C and 
under vigorous stirring was added dropwise a KOH (1.1 g, 19.1 mmol) 
solution in H2O (13.5 mL) over a period of 10 minutes. The reaction mixture 
was allowed to warm to rt and was vigorously stirred overnight. The two 
phases were separated and the organic phase was washed with brine, dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography yielded peracetylated 2-deoxy-2-fluoro-thio galactoside 43 
as a white amorphous solid (2.68 g, 6.46 mmol, 68%). 
1
H NMR (400 MHz, 
CDCl3): δ 7.49 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 7.6 Hz, 2H), 5.43 (s, 1H), 
5.12 (ddd, J = 13.2, 9.2, 3.6 Hz, 1H), 4.68 (dd, J = 10.0, 2.6 Hz, 1H), 4.46 
(dt, J = 49.6, 9.6 Hz, 1H), 4.18 (dd, J = 11.2, 6.8 Hz, 1H), 4.10 (dd, J = 11.2, 
Tuning the imidate leaving group of 2-deoxy-2-fluoro glycoside-based glycosidase inhibitors 
187 
 
6.4 Hz, 1H), 2.36 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3): δ 170.5, 170.1, 170.1, 170.1, 139.1, 134.2, 129.9, 127.4, 
85.7 (d, J = 187 Hz), 85.6 (d, J = 24 Hz), 74.5, 72.2 (d, J = 20 Hz), 68.1 (d, J 
= 8 Hz), 61.5, 21.4, 20.8, 20.8, 20.6; HRMS: [M+H]
+
 calculated for 
C19H24FO7S 415.12213, found 415.12222. 
 
Tolyl 2-deoxy-2-fluoro-1-thio-β-D-galactopyranoside (44): 
To a solution of (860 mg, 2.1 mmol) in MeOH (20 mL) was 
added NaOMe (108 mg, 2.0 mmol) and stirred overnight. The 
reaction was quenched with Amberlite-H
+
 IR-120 till pH≤7, filtered and 
concentrated in vacuo yielding 2-deoxy-2-fluoro thio mannose 44 as a white 
amorphous solid without further purification (597 mg, 2.1 mmol, 
quantitatively). 
1
H NMR (400 MHz, MeOD): δ 7.45 (d, J = 8.0 Hz, 2H), 
7.14 (d, J = 8.0 Hz, 2H), 4.66 (dd, J = 9.6, 2.0 Hz, 1H), 4.30 (dt, J = 50.8 Hz, 
1H), 3.92 (t, J = 3.2 Hz, 1H), 3.68-3.78 (m, 3H), 3.58 (t, J = 6.0 Hz, 1H), 
2.32 (s, 3H,); 
13
C NMR (100 MHz, MeOD): δ 133.9, 130.6, 90.7, 86.7 (d, J 
= 24 Hz,), 80.8, 74.3, 62.4; HRMS: [M+H]
+
 calculated for C13H18FO4S: 
289.34406, found 289.34461. 
 
Tolyl 2-deoxy-2-fluoro-6-O-tosyl-1-thio-β-D-
galactopyranoside (45):  
To a 0 °C cooled solution of 2-deoxy-2-fluoro-thio galactoside 44 (0.591 g, 
2.05 mmol) in pyridine (10 mL) was added TsCl (0.434 g, 2.25 mmol), the 
mixture was allowed to warm to rt and stirred overnight. The reaction was 
quenched with MeOH and concentrated in vacuo followed by co-evaprated 
with toluene (3x) of the crude. Purification by column chromatography 
yielded tosylated 2-deoxy-2-fluoro-thio galactoside 45 as a white amorphous 
solid (0.750 g, 1.369 mmol, 83%). 
1
H NMR (400 MHz, MeOD): δ 7.79 (d, J 
= 8.0 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 
8.0 Hz, 2H), 4.61 (d, J = 9.2 Hz, 1H), 4.09-4.32 (m, 3H), 3.80-3.84 (m, 2H), 
3.72 (ddd, J = 14.0, 8.8, 3.6 Hz, 1H), 2.43 (s, 3H), 2.33 (s, 3H); 
13
C NMR 




(d, J = 182 Hz), 86.1 (d, J = 25 Hz), 77.5, 73.9 (d, J = 18 Hz), 70.9, 70.9 (d, 
J = 6 Hz), 21.6, 21.1. 
 
 Tolyl 6-azido-2,6-di-deoxy-2-fluoro-1-thio--D-
galactopyranoside (46): To a solution of tosylated galactoside 
45 (650 mg, 1.5 mmol) in DMF (20 mL) was added NaN3 (390 mg, 6.0 
mmol) and the mixture was stirred overnight at 80 °C. The reaction mixture 
was diluted with EtOAc and the product was washed with sat. NaHCO3 (aq.) 
(2x), H2O (2x), brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography yielded 6-azido-2-deoxy-2-
fluoro-thio galactoside 46 as a colourless amorphous solid (342 mg, 1.1 
mmol, 74%). 
1
H NMR (400 MHz, MeOD): δ 7.45 (d, J = 8.0 Hz2H), 7.14 
(d, J = 8.0 Hz, 2H), 4.68 (dd, J = 9.6, 2.0 Hz, 1H), 4.29 (dt, J = 50.4, 9.2 Hz, 
1H), 3.69-3.83 (m, 3H), 3.60 (dd, J = 12.8, 8.8 Hz, 1H), 3.27-3.31 (m, 1H), 
2.32 (s, 3H); 
13
C- NMR (100 MHz, MeOD): δ 139.4, 134.3, 130.6, 130.1, 
90.5 (d, J = 182 Hz), 86.8 (d, J = 24 Hz), 79.1 (C-5), 74.1 (d, J = 18 Hz), 
71.4 (d, J = 9 Hz), 52.6, 21.1; HRMS: [M+H]
+
 calculated for C13H17FN3O3S 
314.09692, found 314.09701. 
 
Acetyl 6-azido-2,6-dideoxy-2-fluoro-3,4-di-O-acetyl-α/β-D-
galactopyraniside (47): To a 0 °C cooled solution of 6-azido-
2-deoxy-2-fluoro thio galactoside 46 (325 mg, 1.0 mmol) in a acetone/H2O 
mixture (3:1, 10.3 mL) was added NBS (1.1 g, 6.2 mmol). The reaction 
mixture was allowed to warm to rt and was stirred overnight. During the 
reaction the mixture turned from orange to a colourless clear solution. The 
reaction was quenched with 10% Na2S2O3 (aq.) and diluted with brine. The 
product was extracted with EtOAc (5x) and the combined organic layers 
were washed with brine (2x), dried over MgSO4, filtered and concentrated in 
vacuo. The concentrate was taken up in pyridine (4 mL), cooled to 0 °C and 
Ac2O (1.0 mL) was added to the cooled solution. The mixture was allowed 
to warm to rt and stirred overnight. The reaction was quenched with MeOH, 
concentrated in vacuo and dissolved in EtOAc. The product was washed 
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with 1M HCl (aq.) (2x), sat. NaHCO3(aq.) (1x), H2O (3x), brine (2x), dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography yielded acetylated 6-azido-2-fluoro galactoside 47 as a 
colourless oil (0.110 g, 0.329 mmol, 32%). 
1
H NMR (400 MHz, MeOD): δ 
6.49 (d, J = 4.0 Hz, 1H-α), 5.83 (d, J = 8.0, 4.0 Hz, 1H-β), 5.51 (t, J = 3.0 
Hz, 1H-α), 5.43-5.45 (m, 1H, H-β), 5.39 (dd, J = 10.8, 3.6 Hz, 1H-α), 5.20 
(ddd, J = 13.4, 9.6, 3.6 Hz, 1H-β), 4.90 (ddd, J = 49.2, 10.4, 4.0 Hz, 1H-α), 
4.66 (ddd, J = 51.6, 9.6, 8.0 Hz, 1H-β), 4.21 (t, J = 6.4 Hz,H-α), 4.00 (t, J = 
6.4 Hz, 1H-β), 3.51 (dd, J = 12.8, 7.2 Hz, 1H-β), 3.43 (dd, J = 12.8, 7.2 Hz, 
1H-α), 3.20-3.25 (m, 2H); 
13
C NMR (100 MHz, MeOD): δ 170.1, 170.0, 
169.8, 168.8, 168.8, 91.6 (d, J = 25 Hz), 88.9 (d, J = 23 Hz), 86.7 (d, J = 187 
Hz), 84.1 (d, J = 190 Hz), 73.7, 71.0 (d, J = 27 Hz), 70.9, 68.2, 68.2, 50.2, 
50.0, 20.9, 20.8, 20.7, 20.6, 20.6; HRMS [M+H]
+
 calculated for 
C12H17FN3O7
 
334.10450, found 334.10444. 
 
6-Azido-2,6-dideoxy-2-fluoro-/-D-galactopyranose (48): 
To a solution of acetylated 6-azido-2-deoxy-2-fluoro galactoside 
47 (0.110 g, 0.329 mmol) in MeOH (10 mL) was added NaOMe (3 mg, 0.06 
mmol) and stirred overnight. The reaction was quenched with Amberlite-H
+
 
IR-120 till pH≤7, filtered and concentrated in vacuo yielding 6-azido-2-
fluoro galactoside 48 as a colourless oil without further purification (68.1 
mg, 0.33 mmol, quantitatively). 
1
H NMR (400 MHz, MeOD): δ 5.32 (d, J = 
4.0 Hz, 1H-α), 4.68 (dd, J = 7.6, 3.2 Hz, 1H-β), 4.65 (ddd, J = 50.4, 10.0, 4.0 
Hz, 1H-α), 4.25 (ddd, J = 52.0, 9.2, 3.6 Hz, H-β), 4.13-4.17 (m, 1H), 3.98-
4.05 (m, 1H-α), 3.86 (dt, J = 3.6, 1.2 Hz, 1H-α), 3.80 (dt, J = 3.8, 1.0 Hz, 
1H-β), 3.68-3.76 (m, 2H), 3.49-3.60 (m, 2H), 3.29-3.42 (m, 2H);
 13
C NMR 
(100 MHz, CDCl3): δ 96.1 (d, J = 24 Hz), 94.0 (d, J = 180 Hz), 91.8 (d, J = 
22 Hz), 90.4 (d, J = 183 Hz), 75.2, 73.2 (d, J = 17 Hz), 72.0 (d, J = 8 Hz), 





BODIPY 2-fluoro galactoside (49): Deprotected 6-
azido-2-deoxy-2-fluoro galactoside 48 (33.6 mg, 0.16 
mmol) was dissolved in DMF (12 mL) and the 
solution was purged with argon for 30 min. To the 
solution was added a 0.075M sodium ascorbate solution (aq.) (1.5 mL, 0.11 
mmol), a 0.05M CuSO4 (aq.) (1.5 mL, 0.075 mmol) and the reaction was 
stirred for 1h. The mixture was taken up in brine and the product was 
extracted with EtOAc (2x). The combined organic layers were washed with 
brine (3x) dried over MgSO4, filtered and concentrated in vacuo. Purification 
by column chromatography yielded BODIPY 2-deoxy-2-fluoro galactoside 
49 as an orange solid (85.3 mg, 0.16 mmol, 98%). 
1
H NMR (400 MHz, 
CDCl3): δ 7.71 (s, 1H), 7.69 (s, 1H), 6.07 (s, 4H), 5.26 (d, J = 3.6 Hz, 1H-α), 
4.42-4.68 (m, 6H), 4.40 (t, J = 6.8 Hz, 1H-β), 4.30 (ddd, J = 52, 9.2, 8.0 Hz, 
1H-β), 3.96-4.06 (m, 2H), 3.90 (t, J = 3.0 Hz, 1H-α), 3.83 (t, J = 2.8 Hz, 1H-
β), 3.71-3.77 (m, 1H), 2.80-2.84 (m, 4H), 2.68 (t, J = 7.4 Hz, 2H), 2.41 (s, 
12H), 2.28 (s, 12H), 1.81 (p, J = 7.5 Hz, 4H), 1.52-1.60 (m, 4H); 
13
C NMR 
(100 MHz, CDCl3): δ 154.8, 148.4, 147.9, 142.3, 132.6, 124.3, 124.2, 122.6, 
96.0 (d, J = 23 Hz), 93.8 (d, J = 179 Hz), 91.8 (d, J = 22 Hz), 90.3 (d, J = 
183 Hz), 74.8, 72.9 (d, J = 17 Hz), 71.9 (d, J = 8 Hz), 71.3 (d, J = 9 Hz), 
70.2, 68.9 (d, J = 18 Hz), 52.1, 52.0, 32.1, 30.8, 28.9, 25.8, 16.4, 14.5. 
 
α/β-6-Azido-2-fluoro-glucosyl imidate (17): To a 0 °C 
cooled solution of 6-azido-2-deoxy-2-fluoro glucosyl 31 
(26.2 mg, 126 µmol) in acetone (6 mL) was added 
trifluoro aniline imidate 51 (52.5 mg, 253 µmol) and Cs2CO3 (100 mg, 280 
µmol). The reaction was gradually warmed to rt and stirred overnight. The 
solids were filtered and the filtrate was concentrated in vacuo Purificaton by 
column chromatography yielded glucose aniline imidate 17 as a α/β mixture 
(α/β = 3:2, 1.08 mg, 2.86 µmol, 2%). Spectroscopic data for the α-anomer 
17-α:
 1
H NMR (CD3CN, 600 MHz): δ 7.31 (t, 2H, J = 7.8 Hz), 7.12 (t, 1H, J 
= 7.2 Hz), 6.85 (d, 2H, J = 7.2 Hz), 6.41 (bs, 1H), 4.50 (d, 1H, J = 48.0 Hz), 
3.77-3.82 (m, 2H), 3.51-3.58 (m, 1H), 3.36-3.41 (m, 2H); LC-MS: Rt 7.68 
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min (C18 column, linear gradient 10  90% B in 15 min); FT-IR: vmax 
(neat)/cm
-1
 3352, 2104, 1720, 1312, 1211, 1155, 1116, 1031, 117, 695.  
Spectroscopic data for the β-anomer 17-β:
 1
H NMR (CD3CN, 850 MHz): δ 
7.31 (t, 2H, J = 7.7 Hz), 7.13 (t, 1H, J = 7.2 Hz), 6.87 (bs, 2H), 5.92 (bs, 
1H), 4.31(d, 1H, J = 50.2 Hz), 3.50-3.75 (m, 2H), 3.41-3.44 (m, 2H), 3.33-
3.39 (m, 1H); LC-MS: Rt 8.18 min (C18 column, linear gradient 10  90% 
B in 15 min); FT-IR: vmax (neat)/cm
-1
 3356, 2103, 1721, 1316, 1212, 1163, 
1001, 695. 
 
α/β-2-Fluoro-BODIPY-glucosyl imidate (18): To a 0 
°C cooled solution of BODIPY 2-deoxy-2-fluoro 
glucosyl 32 (51.1 mg, 95.4 µmol) in acetone (6 mL) 
was added trifluoro aniline imidate 51 (39.6 mg, 191 µmol) and Cs2CO3 
(47.0 mg, 140 µmol). The reaction was gradually warmed to rt and stirred 
overnight. The solids were filtered and the filtrate was concentrated in vacuo 
Purificaton by column chromatography yielded glucose aniline imidate 18 as 
a α/β mixture (α/β = 1:2, 22.3 mg, 31.6 µmol, 33%) . Purification by RP-
HPLC followed by lyophilisation yielded α-2-deoxy-2-fluoro-BODIPY-
glucosyl-aniline-imidate 18-α (1.63 mg, 2.30 µmol, 2%) and β-2-deoxy-2-
fluoro-BODIPY-glucosyl-aniline imidate 18-β (97 µg, 0.14 µmol, 0.1%) 
both as an orange powder. Spectroscopic data for the α-anomer 18-α:
 1
H 
NMR (CD3CN, 600 MHz): δ 7.50 (s, 1H, CHarom triazole), 7.27 (t, 2H, J = 
8.1 Hz, CHarom phenyl), 7.09 (t, 1H, J = 7.5 Hz, CHarom phenyl), 6.55 (d, 2H, 
J = 7.2 Hz, CHarom phenyl), 6.26 (bs, 1H, H-1), 6.14 (s, 2H, CHarom pyrrole), 
4.72 (d, 1H, J = 13.8 Hz, H-6), 4.40-4.48 (m, 2H, H-2, H-6), 3.87-4.01 (m, 
4H, H-3, H-5, OH), 3.26 (bs, 1H, H-4), 2.97 (t, 2H, J = 8.7 Hz, CH2), 2.67-
2.77 (m, 2H, CH2), 2.43 (s, 6H, CH3), 2.37 (s, 6H, CH3), 1.81-1.84 (m, 2H, 
CH2), 1.52-1.76 (m, 2H, CH2); LC-MS: Rt 9.80 min (C18 column, linear 
gradient 10  90% B in 15 min); FT-IR: vmax (neat)/cm
-1
 3383, 1719, 1550, 
1510, 1310, 1203, 1159, 1075, 986. HRMS [M + H]
+
 calculated for 




Spectroscopic data for the β-anomer 18-β: NMR (CD3CN, 600 MHz): δ 7.57 
(s, 1H, CHarom triazole), 7.26 (t, 2H, J = 7.8 Hz, CHarom phenyl), 7.08 (t, 1H, 
J = 7.5 Hz, CHarom phenyl), 6.70 (t, 2H, J = 7.2 Hz, CHarom phenyl), 6.15 (s, 
2H, CHarom pyrrole), 5.66 (bs, 1H, C-1), 4.79 (d, 1H, J = 14.4 Hz, H-6), 4.32-
4.36 (m, 2H, H-2, H-6), 4.06 (bs, 1H, OH), 3.96 (bs, 1H, OH), 3.71 (bs, 2H, 
H-3, H-5), 3.33 (bs, 1H, H-4), 2.92 (t, 2H, J = 8.4 Hz, CH2), 2.54-2.61 (m, 
2H, CH2), 2.44 (s, 6H, CH3), 2.34 (s, 6H, CH3), 1.70-1.75 (m, 2H, CH2), 
1.52-1.54 (m, 2H, CH2); HRMS [M + H]
+
 calculated for C33H37BF6N6O4: 
707.29463, found 707.29547. 
 
α/β-2-Flouro-BODIPY-glucosyl imidate (19): To a 
0 °C cooled solution of 2-deoxy-2-fluoro BODIPY 
glucose 32 (53.2 mg, 99.4 µmol) in acetone (6 mL) 
was added trifluoro pOMe-aniline imidate reagens 52 (47.2 mg, 199 µmol) 
and Cs2CO3 (48.9 mg, 150 µmol). The reaction was gradually warmed to rt 
and stirred overnight. The solids were filtered and the filtrate was 
concentrated in vacuo Purificaton by column chromatography yielded 
pOMe-aniline imidate glucosyl 19 as a α/β mixture (α/β = 1:2, 19.8 mg, 26.7 
µmol, 27%). Purification by RP- followed by lyophilisation yielded α-2-
fluoro-BODIPY-glucose-pOMe-aniline-imidate 19-α (0.374 mg, 0.51 µmol, 
0.5%) and β-2-fluoro-BODIPYglucose-pOMe-aniline imidate 19-b (1.03 
mg, 1.4 µmol, 1.4%) both as an orange powder. Spectroscopic data for the α-
anomer 19-α: 
1
H NMR (600 MHz, CD3CN): δ 7.49 (s, 1H), 6.82 (d, J = 9.0 
Hz, 2H), 6.60 (bs, 2H), 6.23 (bs, 1H), 6.14 (s, 2H), 4.71 (d, J = 14.4 Hz, 1H), 
4.37-4.46 (m, 2H), 3.88-3.95 (m, 4H), 3.71 (s, 3H), 3.26 (bs, 1H), 2.97 (t, J = 
8.7 Hz, 2H), 2.66-2.78 (m, 2H), 2.43 (s, 6H), 2.37 (s, 6H), 1.80-1.85 (m, 
2H), 1.52-1.59 (m, 2H); LC-MS: Rt 3.92 min (C18 column, linear gradient 
50  90% B in 15 min); FT-IR: vmax (neat)/cm
-1
 3356, 2925, 1551, 1508, 
1203, 1159, 1067; HRMS [M + H]
+
 calculated for C34H39BF6N6O5: 
737.30519, found 737.30615.  
Spectroscopic data for the β-anomer 19-β: NMR (600 MHz, CD3CN): δ 7.55 
(s, 1H,), 6.81 (d, J = 6.6 Hz, 2H), 6.67 (bs, 2H), 6.15 (s, 2H), 5.65 (bs, 1H), 
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4.79 (d, J = 14.4 Hz, 1H), 4.31-4.35 (m, 2H), 4.05 (bs, 1H), 3.94 (bs), 3.68 
(bs 5H), 3.32 (bs, 1H), 2.91 (t, J = 8.4 Hz, 2H), 2.54-2.59 (m, 2H), 2.44 (s, 
6H), 2.34 (s, 6H), 1.74 (bs, 2H), 1.51-1.54 (m, 2H); LC-MS: Rt 4.14 min 
(C18 column, linear gradient 50  90% B in 15 min); LC-MS: Rt 9.73 min 
(C18 column, linear gradient 10  90% B in 15 min); FT-IR: vmax (neat)/cm
-
1
 3356, 2971, 1551, 1508, 1409, 1310, 1203, 1160, 1080, 986, 836; HRMS 
[M + H]
+
 calculated for C34H39BF6N6O5: 737.30519, found 737.30613. 
 
α/β-2-Fluoro-BODIPY-glucosyl imidate (20): To a 
0 °C cooled solution of 2-deoxy-2-fluoro BODIPY 
glucose 32 (75.1 mg, 140 µmol) in acetone (6 mL) 
was added trifluoro pNO2 aniline imidate 53 (70.7 mg, 240 µmol) and 
Cs2CO3 (68.2 mg, 210 µmol). The reaction was gradually warmed to rt and 
stirred overnight. The solids were filtered and the filtrate was concentrated in 
vacuo. Purification by column chromatography yielded glucosyl pOMe-
aniline imidate 20 as an α/β mixture (α/β = 2:3, 47.5 mg, 63.2 µmol, 45%) . 
Purification by RP-HPLC followed by lyophilisation yielded α-2-deoxy-2-
fluoro-BODIPY-glucosyl-pNO2-aniline-imidate 20-α (2.52 mg, 3.35 µmol, 
2%) and β-2-deoxy-2-fluoro-BODIPY-glucosyl-pNO2-aniline imidate 20-β 
(3.03 mg, 4.03 µmol, 2.9%) both as an orange powder. Spectroscopic data 
for the α-anomer 20-α: NMR (CD3CN, 600 MHz): δ 8.06 (dd, 2H, J = 6.9, 
2.1 Hz), 7.50 (s, 1H), 6.73 (dd, 2H, J = 6.9, 2.1 Hz), 6.15 (s, 1H), 6.12 (s, 
2H), 4.75 (dd, 1H, J = 14.4, 2.4 Hz), 4.49 (ddd, 1H, J = 48 Hz), 4.39 (dd, 
1H, J = 14.4, 3.0 Hz), 4.10 (dt, 1H, J = 9.6, 2.4 Hz), 3.40 (bs, 1H), 3.90-3.93 
(m, 1H) 3.31-3.33 (m, 1H), 2.87-2.90 (m, 2H), 2.68-2.80 (m, 2H), 2.43 (s, 
6H), 2.32 (s, 6H), 1.80-1.83 (m, 2H), 1.45-1.47 (m, 2H); LC-MS: Rt 3.57 
min (C18 column, linear gradient 50  90% B in 15 min); LC-MS: Rt 9.36 
min (C18 column, linear gradient 10  90% B in 15 min); FT-IR: vmax 
(neat)/cm
-1
 3360, 2972, 1551, 1511, 1408, 1343, 1311, 1203, 1161, 1066, 
986; HRMS [M + H]
+





Spectroscopic data for the β-anomer 20-β: NMR (CD3CN, 600 MHz): δ 8.09 
(dt, 2H, J = 9.0, 2.7 Hz), 7.58 (s, 1H), 6.83 (dt, 2H, J = 9.0, 2.4 Hz), 6.14 (s, 
2H), 5.59 (bs, 1H), 4.80 (dd, 1H, J = 14.7, 1.5 Hz), 4.30-4.43 (m, 2H), 4.08 
(bs, 1H), 4.00 (bs, 1H), 3.62-3.76 (m, 2H), H-52.84-2.88 (m, 2H), 2.52-2.69 
(m, 2H), 2.43 (s, 6H), 2.29 (s, 6H), 1.85-1.98 (m, 2H), 1.63-1.80 (m, 2H); 
LC-MS: Rt 3.95 min (C18 column, linear gradient 50  90% B in 15 min); 
LC-MS: Rt 9.55 min (C18 column, linear gradient 10  90% B in 15 min); 
FT-IR: vmax (neat)/cm
-1
 3360, 2972, 1551, 1511, 1408, 1311, 1202, 1161, 
1079, 986. HRMS [M + H]
+
 calculated for C33H36BF6N7O6: 752.27971, 
found 752.28052. 
 
α-6-Azido-2-Flouro-mannosyl imidate (21): To a 0 °C 
cooled solution of 2-deoxy-2-fluoro azido mannose 39 
(27.5 mg, 133 µmol) in acetone (6 mL) was added 
trifluoro aniline imidate 51 (55.0 mg, 265 µmol) and 
Cs2CO3 (67.0 mg, 0.2 mmol). The reaction was gradually warmed to rt and 
stirred overnight. The solids were filtered and the filtrate was concentrated in 
vacuo. Purificaton by column chromatography yielded α-glucose aniline 
imidate 21 (α/β = 1:0, 18.0 mg, 47.5 µmol, 36%). Purification by RP-HPLC 
followed by lyophilisation yielded α-6-azido-2-deoxy-2-fluoro-mannosyl-
aniline-imidate 21 as an orange powder (5.25 mg, 13.9 µmol, 10%). LC-MS: 
Rt 7.64 min (C18 column, linear gradient 10  90% B in 15 min); 
Spectroscopic data for the α-anomer 21-α: 
1
H NMR (CD3CN, 600 MHz): δ 
7.36-7.30 (m, 2H), 7.12 (t, 1H, J = 7.5 Hz), 6.86 (d, 2H, J = 7.2 Hz), 6.25 
(bs, 1H), 4.82 (d, 1H, J = 46.2 Hz), 3.73-3.83 (m, 2H), 3.60-3.65 (m, 1H), 
3.51-3.56 (m, 2H), 3.36-3.45 (m, 2H); Rt 7.64 min (C18 column, linear 
gradient 10  90% B in 15 min); FT-IR: vmax (neat)/cm
-1
 3369, 2103, 1717, 
1307, 1211, 1165, 1111, 951, 755, 694; HRMS [M + H]
+
 calculated for 
C14H14F4N4O4: 455.14225, found 455.15176. 
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α-2-Flouro-BODIPY-mannosyl imidate (22): To a 0 
°C cooled solution of 2-deoxy-2-fluoro BODIPY 
mannose 40 (59.6 mg, 111 µmol) in acetone (6 mL) was 
added trifluoro aniline imidate 51 (46.2 mg, 223 µmol) and Cs2CO3 (55.9 
mg, 0.167 mmol). The reaction was gradually warmed to rt and stirred 
overnight. The solids were filtered and the filtrate was concentrated in vacuo 
Purificaton by column chromatography yielded α-mannose-BODIPY aniline 
imidate 22-α (α/β = 1:0, 16.8 mg, 23.8 µmol, 21%). Purification by RP-
HPLC (linear gradient 50 → 90 % MeCN in 12min) followed by 
lyophilisation yielded α-2-deoxy-2-fluoro-BODIPY-mannose-aniline-
imidate 22-α as an orange powder (4.33 mg, 6.13 µmol, 5.5%).
 1
H NMR 
(600 MHz, CD3CN): δ 7.53 (s, 1H), 7.27 (t, J = 8.1 Hz, 2H), 7.10 (t, J = 7.5 
Hz, 1H), 6.68 (d, J = 7.2 Hz, 2H), 6.15 (bs, 1H), 6.14 (s, 2H), 4.80 (d, J = 
48.0 Hz, 1H), 4.4.74 (d, J = 14.4 Hz, 1H), 4.48 (dd, J = 14.4, 7.8 Hz, 1H), 
4.00 (bs, 1H), 3.70-3.84 (m, 3H), 2.97 (t, J = 8.7 Hz, 2H), 2.68-2.77 (m, 2H), 
2.43 (s, 6H), 2.38 (s, 6H), 1.80-1.85 (m, 2H), 1.54-1.66 (m, 2H); Rt 9.96 min 
(C18 column, linear gradient 10  90% B in 15 min); FT-IR: vmax (neat)/cm-
1 3368, 2972, 1550, 1510, 1409, 1309, 1202, 1161, 1117, 1079, 985.; HRMS 
[M + H]
+
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Glycoconjugates are involved in numerous fundamental biological processes 
and are the subject of many studies. Glycoconjugates can bind on the basis 
of their specific carbohydrate structures to lectin receptors. Lectin receptors 
can be either membrane bound or soluble and play a key role in a wide 
variety of cellular recognition and communication processes. Many of the 
lectins, in particular those found on cells of the immune system are members 
of the C-type lectin family and these include the mannose receptor (MR), 
Dectin-1 and 2 as well as DC-SIGN. These carbohydrate-binding receptors 
have been exploited in immunological studies and targeting strategies. 
Significant attention has been directed to the design and synthesis of 
artificial glycoconjugates for binding to specific lectins. The research in this 
thesis is mainly focussed on glycoconjugates that carry oligomannosides and 
artificial mannose clusters that can be recognized by the mannose receptor 
(MR) or other mannose binding lectins.  
In Chapter 1 a selection of different mannose binding lectin-targeting 
strategies is described. Although carbohydrate protein interactions vary 
depending on the lectin of interest, the majority is considered to be 




multivalent mannosyl conjugates is discussed. In addition examples of the 
synthesis of high mannose N-glycan conjugates are described.  
Chapter 2 describes the design, synthesis and evaluation of three conjugates 
comprising the irreversible cathepsin inhibitor DCG-04, a BODIPY dye and 
a mono-, tri- or heptamannoside, featuring natural O-glycosidic linkages (1, 
2, 3, Figure 1). In a modular synthesis approach the oligomannosides were 
introduced via a Cu(I)-catalyzed “click” reaction in these conjugates. It was 
shown that the heptamannoside conjugate showed the least effective 
cathepsin labelling in cell lysates, whereas the uptake of the tri- and 
heptamannoside conjugates outcompeted the monomannoside conjugate in 
living cells. Also in live cells the trisaccharide proved to be a more effective 
inhibitor than its heptasaccharide counterpart. This outcome could be related 
to the resistance of the conjugates to the endo/lysosomal removal of the 
mannose residues by mannosidases and further research is needed to clarify 
this finding. For example the naturally occurring nonamannoside conjugate 4 
can be probed. On the basis of the existence mannose-6-phosphate receptors 
and the targeting study of Hoogendoorn et al.
1
 it is proposed to synthesize 
and evaluate structurally related conjugates of which the 6-hydroxyl groups 
in the oligomannosides is provided with a phosphate monoesters (5, Figure 
1) The potential hydrolysis of the phosphate functions by phosphatases can 
be prevented by replacement of the 6-phosphate groups by 6-C-
phosphonates (6, Figure 1).  
 




Figure 1: The structures of the conjugates 1, 2 and 3 presented in Chapter 2 and the structures 
of the proposed high mannose-N-glycan- (4), mannose 6-O-phosphate- (5) and mannose-6-C-
phosphonate-DCG-04 (6) conjugates.  
 
In Chapter 3 the synthesis and evaluation of Man1-BODIPY-cyclophellitol 
7 and Man3-BODIPY-cyclophellitol 8 as “caged” activity based probes for 
glucocerebrosidase, the key enzyme in Gaucher disease, is described (Figure 
2). The mannosides in these probes should function as homing device to 
target the fluorescent cyclophellitol inhibitor via the mannose receptor to 
Gaucher cells. The self-immolative linker system was installed between the 
mannoside and the cyclophellitol to allow liberation of the probe in the 






Figure 2: The structures of the conjugates presented in Chapter 3.  
 
In a convergent approach the mono- and trimannosides were prepared and 
the self-immolative linker was introduced at the reducing end of the 
mannosides by nucleophilic aromatic substitution. An alternative and high 
yielding route of synthesis to a partially protected azido-cyclophellitol was 
developed in which the stereoselective introduction of the epoxide was 
followed by the introduction of the azide. Having the mannosylated linker 
systems and the partially protected azido-cyclophellitol and BODIPY-alkyne 
in hand the assembly of the probes went uneventful. Biological evaluation of 
the probes showed that they were significantly less effective inhibititors of 
the target enzyme than their BODIPY-cyclophellitol counterparts without 
the targeting device. This indicates ineffective cleavage of the mannosyl 
residues from the probes by intracellular mannosidases.  
Guided by the successful uptake of the probes with the aid of the 
(oligo)mannosides as targeting device it is proposed to apply a disulfide 
based sulfhydryl-assisted self- immodulative linker.
2
 As depicted in Figure 
3, after internalization of the probe by Gaucher cells, cyclophellitol can be 





or γ-interferon-inducible lysosomal thiol reductase and 








Figure 3: Proposed mechanism of a disulfide based sulfhydryl-assisted self immodulative 
linker. 
 
The first biodegradable disulfide based conjugate, which is proposed, 
contains the same oligomannose homing device as described in Chapter 3 
(Scheme 1). 
 
Scheme 1: Proposed synthesis of disulfide bridged mannose-cyclophellitol construct 7. 
 
Reagents and conditions: (a) Disulfide 13, TfOH, DCM; (b) TBAF, DCM/MeOH; (c) 14, 
TEA, DMF, rt.; d) NaOMe/MeOH; e) Alkyne-BODIPY, CuSO4, sodium ascorbate 
DMF/H2O. 
 
Based on the work of Bhuniya et al.
2
 the partially protected TBDMS-2-
hydroxyethyl disulphide linker 13
7
 is condensed with trimannoside (N-
phenyl)trifluoroimidate 8 to give disulfide trimer 9. Removal of the TBDMS 
group in 9 allows coupling with 4-nitrophenyloxycarbonate 
azidocyclophellitol derivative 14 to give compound 11. Further processing 
by global deacetylation
8
 and conjugation of alkyne-BODIPY with Cu(I)-cat. 
“click” chemistry leads to the proposed conjugate 7.  
In the same vein other mannose based targeting devices can be used. For 




reported by Chen et al.
9
 with the synthetic mannose cluster, capable for 
lysosomal targeting of a cathepsin inhibitor, as developed by Hillaert et al.
10 
A potential route of synthesis to this conjugate 15 is presented in Scheme 2. 
Azido-cyclophellitol derivative 18 can be coupled with TIPS-protected 
disulfide linker 17
11
. Protective group manipulations followed by conversion 
of the carboxylic acid into the OSu-ester 21 allows the installation of 
mannose cluster 16
10
. In the final event the BODIPY tag is introduced by 
“click” chemistry affording the proposed conjugate 15. 
 
Scheme 2: Proposed synthesis of disulfide bridged mannose cluster-cyclophellitol construct 
15. 
 
Reagents and conditions: (a) 18, DIC, DMAP, THF, 0 °C to rt.; (b) i. HF/pyr, 
pyridine/MeCN, 0 °C to rt; ii. NaOMe/MeOH; (c) DIC, HOSu, 0 °C to rt.; (d) 8, DMSO, rt.; 
(e) Alkyne-BODIPY, CuSO4, sodium ascorbate DMF/H2O.  
 
Chapter 4 describes the synthesis and preliminary immunological 
evaluation of twenty mannosylated peptide conjugates. One, two, three and 
six copies of a mono-mannoside, three different dimannosides and a 
trimannoside, were conjugated to a peptide containing the MHC-class-I 
epitope SIINFEKL. The respective target peptides were provided with the 
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required number of azidolysines, while all (oligo)mannosides were equipped 
with an alkyne allowing an efficient Cu(I) catalyzed “click” mediated 
synthesis of the twenty mannosylated peptide conjugates. Worth noting is 
the increase in overall yield of the conjugates by the use of CupriSorb
®
 resin 
to remove copper from the reaction mixture after the Cu(I) catalyzed “click” 
reaction. Preliminary immunological evaluation showed an increase in T cell 
response of almost all mannosylated conjugates in comparison with the non-
mannosylated parent peptide. In addition, the uptake of the conjugates was 
likely mannose receptor mediated. Surprisingly, the monomannoside 
conjugates with one or two monomannosides showed the highest T cell 
response compared to the other constructs and no clear correlation between 
the type and number of (oligo)mannosides in the conjugates and the T cell 
response was apparent. A possible explanation for this finding is the reduced 
proteolytic susceptibility and processability of the mannosylated epitope 
conjugates. It is also unclear at present which lectins are involved in binding 
and or transporting the conjugates. It is proposed to introduce biodegradable 
linkers between the (oligo)mannose clusters and the epitope using the same 
chemistry as proposed for the modified cyclophellitol conjugates (vide 
supra, Scheme 1 and 2) to influence the processing the conjugates. 
As discussed above, mannose-6-phosphate conjugates are promising devices 
for receptor-mediated uptake. To study the relation between mannose-6-
phosphate-receptor mediated uptake and antigen presentation, multivalent 









Chapter 5 describes the synthesis of mannose configured α- and β-
cyclophellitol 22, and their aziridine counterparts 23. The chiral 
cyclohexene, the common intermediate for both epoxides and aziridines, was 
obtained by adaptation of the procedure of the group of Madsen for the 
synthesis of cylcophellitol.
12
 Using the procedure of Li et al.
13
 for the 
conversion of the -epoxide to the β-aziridine, the manno-configured β-
aziridine cyclophellitol was generated. The synthesis of the α-aziridine 
started with the β-epoxide, the minor product of the cyclohexene epoxidation 
reaction. Opening of the epoxide with sodium azide and mesylation of the 
formed hydroxyl was followed by reduction of the azide with LiAlH4 to 
produce the α-aziridine cyclophellitol. The absolute configurations of the α- 
and β benzyl-protected epoxides compounds were elucidated by NMR 
spectroscopy. Both the α- and β-epoxide adopt a 
4
H3 conformation as 
corroborated by DFT calculations.  
Both aziridine α-23 and β-23 can be converted into two-step labelling 
activity based probes 24 and 26 by introduction of an azide ligation handle 
via either acylation or alkylation of the aziridine nitrogen (Scheme 3).
14
 
These two-step probes can be further converted into direct activity based 
probes 25 and 27 by introduction of a BODIPY reporter group, using a Cu(I) 
catalyzed “click” reaction.  
 
Scheme 3: Proposed functionalization of mannose configured aziridine cyclophellitol 23. 
 
Reagents and conditions: a) acid 28 or 29, EEDQ, DMF, 0 °C; b) iodide 30 or 31, K2CO3, 
DMF, 90 °C. 
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Chapter 6 deals with the synthetic accessibility of differently configured 2-
deoxy-2-fluoro glycosides with various (substituted) N-
phenyltrifluoroacetimidate leaving groups at the anomeric centre as potential 
glycosidase inhibitors. The research in this chapter is based on the work of 
Walvoort et al.
15
 who showed that 2-deoxy-2-fluoro-β-glucose bearing an 
anomeric N-phenyltrifluoroacetimidate has an improved inhibitory profile 
towards the enzyme glucocerebrosidase in comparison with commonly used 
inhibitors featuring other leaving groups such as fluoride, 2,4-dinitrophenyl 
and diphenylphosphate. Various naturally occurring glycosidases are known 
that hydrolyze different epimeric glycans using the Koshland double-
replacement mechanism and therefore glucose- mannose- and galactose 
configured probes were targeted in this chapter. Unfortunately it turned out 
that all the 2-deoxy-2-fluoroglycosyl imidates were highly unstable and 
degraded partly or completely during HPLC purification. Only α-2-deoxy-2-
fluoro-mannosyl N-phenyltrifluoroacetimidate and a few α- and β-2-deoxy-
2-fluoroglucosyl N-phenyltrifluoroacetimidate derivatives could be prepared 
in low yields. All 2-fluoro-galactose configured imidates were too instable 
and could not be isolated.  
It is proposed to use thioimidates as more stable leaving groups in the 2-
deoxy-2-fluoro glycosides probes. Several possible routes of synthesis to 2-





Scheme 4: Proposed synthesis of thioimidate glycosidase probes 32-37.  
 
Reagents and conditions: (a) Piperidine/DMF; (b) Dioxane, Lawesson’s reagent, 80 °C; (c) 
MMTrtCl, pyridine; (d) NaOMe/MeOH; (e) TFA, TES-H, DCM; (f) ClC(=NPh)CF3, K2CO3, 
acetone; (g) Alkyn-BODIPY, CuSO4, sodium ascorbate, DMF/H2O; (h) i. thiourea; 
ii.Na2S2O5, DCM/H2O; (i) TsCl, pyridine; (j) NaN3, DMF; (k) i. TsCl, pyridine; ii. 3N NaOH 
(aq.); (l) Ac2O, pyridine; (m) i. (TMS)2S, DCM, TMSOTf; ii. Ac2O, pyridine iii 
KSAc/MeOH.  
 
In the first route 2,6-dideoxy-2-fluoro-6-azido-glucose derivative 38 is 
converted to the corresponding thiol 40 with the aid of the Lawesson’s 
reagents.
16
 Protection of the thiol function with an monomethoxytrityl 
(MMTrt) group can give the individual α- and β-anomers α-41 and β-41.
17
 
Deacetylation and deprotection of the MMTrt-group is followed by reaction 
with N-phenyl trifluoroacetimidoyl chloride under basic conditions
18
 to give 
the individual α- and β-anomers of the potential thio-imidate probe 32. A 
BODIPY fluorophore can be introduced at the azide of compound 32 with 
alkyn-BODIPY using “click” chemistry giving probe 33. 
In the second approach 2-deoxy-2-fluoro-glucose derivatives 44 and 49 are 
used as starting compounds, thereby postponing the introduction of the azide 
to a later stage of the synthesis (Scheme 4). Treatment of anomeric bromide 
44 with potassium thioacetate followed by selective deacetylation of the 
Summary and future prospects 
209 
 
thioester gives -45. Ensuing, protection of the thiol with a MMTrt group 
and deacetylation of the remaining acetyl groups sets the stage for the 
successive introduction of the azide at the 6-position and the thio-imidate at 
the anomeric centre to furnish -probe 43. The corresponding α-probe is 





 followed by global acetylation and selective deacetylation of the 
anomeric thioester to give α-45. Using the procedure described above, α-45 
can be transformed into the α-thio-imidate probe 32.  
The proposed 2-deoxy-2-fluoro-glucosyl thioimidate inhibitors can be 
evaluated as pharmacological chaperones of the enzyme GBA for the 
treatment of the Gaucher’s disease.
20
 It is also proposed to evaluate 
lipophilic thio-imidate 53, 54 and 55 as a closer mimic of the natural 
substrate glucosylceramide (52, Figure 5).  
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Glycoconjugaten zijn betrokken bij een groot aantal biologische processen 
en onderwerp van vele studies. Glycoconjugaten kunnen aan lectine 
receptoren binden op basis van hun specifieke suiker structuur. Veel van 
deze lectines, en voornamelijk diegene aanwezig op cellen van het 
immuunsysteem. zijn lid van de C-type lectin familie. De mannose receptor, 
Dectrin-1 en 2 maar ook DC-SIGN vallen hieronder. Binnen 
immunologische studies en “targeting” strategien zijn deze suiker-bindende 
receptoren interessante doelen om gebruik van te maken. Veel aandacht is 
besteed aan het ontwerp en synthese van artificiële glycocnjugaten om 
specifieke lectines te binden. Het onderzoek beschreven in dit proefschrift 
richt zich voornamelijk op glycoconjugaten bestaande uit oligomannosides 
en kunstmatige mannose clusters die herkend worden door de mannose 
receptor of andere mannose bindende lectines. 
Hoofdstuk 1 geeft een overzicht van verschillende mannose lectine-
binding strategieën. Ondanks dat suiker eiwit interactie verschilt per lectine, 
worden de meeste beschouwd als multivalent. Enkele geselecteerde 
voorbeelden van lineaire en dendritische multivalente mannosyl conjugaten 
worden verder toegelicht toegelicht waarbij de toepassing, synthese en 
biologische evaluatie in detail wordt behandeld. Tot slot wordt de synthese 
van de natuurlijke mannose N-glycaan conjugaten beschreven.   
Hoofdstuk 2 beschrijft de synthese en biologische evaluatie van drie 
(oligo)mannosyl-DCG-04-conjugaten. Om de invloed van mannose op de cel 
opname te onderzoeken zijn verschillende mannoses variërend in grootte 
gekoppeld aan de irreversibele cathepsine remmer DCG-04 met een 




de natuurlijke O-glycosidische band in tact gehouden is. Middels een koper 
gecatalyseerde “click” reactie is deze verbonden met BODIPY-DCG-04. 
Behandeling van de constructen met cel lysaat toonde aan dat de 
hexamannoside conjugaat het slechts bond met cathepsines in cel lysaat.  
Echter, hexamannoside en trimannoside conjugaten vertoonde een hoge 
opname door levende cellen, in tegenstelling tot de monomannose conjugaat 
wat nauwelijks opname vertoonde. Verder was de trimannoside conjugaat 
een betere inhibitor in levende cellen dan de heptameermannoside variant.  
In Hoofdstuk 3 wordt de synthese van een mono- en tri-mannosyl-
BODIPY-cyclophellitol construct beschreven. Deze constructen zijn 
ontworpen om selectief herkend en opgenomen te worden door Gacher 
cellen (macrophagen) door middel van mannose suiker herkenning. Het 
construct wordt opgenomen waarna het getransporteerd wordt naar het 
lysosoom. Door de aanwezigheid van α-mannosidase wordt het construct 
afgebroken waarna BODIPY-cyclophellitol, een “retaining β-glucosidase” 
probe vrij komt en bindt aan het enzym Glucocerebrosidase aanwezig in het 
lysosoom. De synthese kan verdeeld worden in vier onderdelen. 1) Mannose 
suiker synthese; 2) linker synthese aan de suikers; 3) de synthese van 
gedeeltelijk bescherm cyclophellitol en tot slot het assembleren van het 
constructen. Een nieuwe synthese route naar azidocyclophellitol wordt 
beschreven  waarbij de azine pas in een laat stadium wordt geïntroduceerd. 
Biologische evaluatie toonde een opname van beide probes aan door de cel 
echter een lage binding was geobserveerd. De lage binding efficiëntie komt 
vermoedelijk door een ineffectieve hydrolyse van de mannose residuen.   
Hoofdstuk 4 beschrijft de synthese en eerste immunologische resultaten 
van twintig gemannosyleerde peptiden conjugaten. Hierbij is gekeken naar 
de invloed van verschillende mannose clusters op de opname en antigeen 
presentatie van levende cellen. De peptide, SIINFEKLDEVA5K, een MHC-I 
epitope, wordt opgenomen via de mannose receptoren waarna het epitope via 
de MHC-II route gepresenteerd wordt aan de T cel. Dit wordt ook wel 
“cross-presentation” genoemd. Aan het peptiden zijn mannose residuen 




grootte (mono- di- en tri-mannosiden). Door een strategie toe te passen 
waarbij eerst het volledige peptide gesynthetiseerd wordt, kan zo het 
gewenste  mannose residuen erop gekoppeld. Door deze strategie toe te 
passen kan uit één enkel peptide eenvoudig verschillende conjugaten 
verkregen worden. Cluster vorming van het product met het aanwezige Cu(I) 
zorgde voor product verlies tijdens het eerste zuiveringsproces. Dit is 
opgelost door gebruik te maken van de ionenwisselaar CupriSorb
®
 waarna 
de opbrengst aanmerkelijk is verhoogd. Verrassend genoeg vertoonde de 
conjugaten met één of twee mono mannose residuen het hoogste T cel 
response. Echter een duidelijke trend tussen aantal mannose residuen en 
mannose grootte is niet zichtbaar. 
Hoofdstuk 5 beschrijft de synthese van mannose geconfigureerd α- en β-
cyclophellitol en de corresponderende aziridine derivaat. Deze verbindingen 
kunnen gebruikt worden als selectieve probes om retaining α- en β-
mannosidase te remmen. Voor de synthese is een beschreven route gevolgd 
waarna de absolute conformatie van benzyl ether beschermd α- en β-
aziridine cyclophellitol is gemeten met behulp van NMR spectroscopie. 
Zowel α- en β-aziridine cyclophellitol begaven zich in een 
4
H3 conformatie 
wat bevestigd is met DFT berekeningen. 
Het werk beschreven in Hoofdstuk 6 is gebaseerd op voorgaand 
onderzoek van Walvoort die aantoonde dat 2-deoxy-fluoro-β-glucose met 
een  N- phenyltrifluoroacetimidate gesubstitueerde groep op het anomere 
centrum een verbeterde binding gaf met het enzym glucocerebrosidase dan 
zijn voorgangers. Dit hoofdstuk beschrijft de synthetische toegankelijkheid 
van verschillende geconfigureerde 2-deoxy-fluoro suikers met verschillende 
N-phenyltrifluoroacetimidate substituenten als vertrekkende groep op de 
anomere positie. Helaas blijken de 2-deoxy-fluoro imidaat suikers zeer 
instabiel te zijn en gedeeltelijke tot volledige degradatie van het product 
tijdens HPLC zuiveringen kon niet worden voorkomen. Enkel α-2-deoxy-2-
fluoro-mannosyl N-phenyltrifluoroacetimidate en enkele α- en β-2-deoxy-2-
fluoro-glucosyl gesubstitueerde N-phenyltrifluoroacetimidate derivaten 




galactose geconfigureerde imidaten bleken te instabiel waardoor er geen 
product geïsoleerd is.  
Tot slot wordt in Hoofdstuk 7 een samenvatting gegeven van de 
voorgaande hoofdstukken en worden een aantal toekomstperspectieven 
behandeld, waaronder de introductie van een dithiol linker om afgifte van 
BODIPY-cyclophellitol te bevorderen en de conjugatie van het natuurlijke 
mannose N-glycaan oligomeer aan de cathepsine remmer DCG-04. Verder 
wordt het gebruik van mannose-6-fosfaten voorgesteld om opname van de 
SIINFEKLDEVA5K te verhogen en worden er alternatieve synthese routes 
voorgesteld naar de productie van thioimidaat suikers als potentiële 
glucocerebrosidase remmers.   
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